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AbstrAct
Prostate cancer is the most common cancer among males in finland. familial ag-
gregation of prostate cancer was first observed in the 1950s, though age and ethnic 
background are now recognised as additional risk factors. five to ten percent of 
prostate cancer cases can be attributed to inherited defects. The aim of this study was 
to further investigate familial prostate cancer in finland using epidemiological and 
molecular genetic methods.  
In this thesis, I aimed to further investigate the mode of familial aggregation of 
prostate cancer, whether there are other cancers present in these families and how 
these familial cancers act as a clinical disease. I performed segregation analyses for two 
population-based cohorts of 557 early onset and 989 late onset familial prostate cancer 
cases. This analysis confirmed the existence of hereditary prostate cancer in the finnish 
population under a complex model that included a major susceptibility locus with 
Mendelian recessive inheritance as well as a polygenic/multifactorial component.  
I collected detailed clinical and histopathological data for 617 males affected by 
prostate cancer from 202 families in finland. I confirmed observations suggesting that 
familial prostate cancers show a higher grade, a higher amount of metastases and a 
trend toward higher PSA levels as compared to sporadic cancers. however, there was 
no difference in the cancer-specific survival between the cohorts.
The incidence of other cancers was investigated among familial prostate cancer 
patients and their relatives to define the association of prostate cancer with a cancer 
syndrome or second-site cancers. I found that the incidence of non-prostate cancer is 
not increased in either clinically aggressive or nonaggressive familial prostate cancer 
cases in finland, with the exception of stomach cancer among female relatives. 
I also investigated the role of PALB2 variants in hereditary and unselected finnish 
prostate cancer cases. A total of six variants in PALB2 were identified. Though none 
of the detected PALB2 variants were associated with prostate cancer at the population 
8 – Sanna Pakkanen
level in finland, it is still possible that some of these variants contribute to cancer 
susceptibility at the individual level. 
In summary, this thesis confirms previous observations of familial aggregation of 
prostate cancer for the finnish population and indicates that the inheritance of this 
disease is best explained by a recessive mode. In addition, the clinical and histopatho-
logical characteristics of familial prostate cancer are described, and the incidence of 
other cancers in these families are investigated. I also determined that PALB2 variants 
are not associated with prostate cancer at the population level in finland. 
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tiivisteLmä
eturauhassyöpä on miesten yleisin syöpä Suomessa. eturauhassyövän seulonnasta 
johtuen viimeiset 20 vuotta eturauhassyövän ilmaantuvuus oli voimakkaassa kasvussa, 
mutta saavutti huippunsa vuonna 2006 (115/100 000). vuonna 2008 Suomessa oli 
4235 uutta eturauhassyöpätapausta. huolimatta eturauhassyövän nopeasta lisäänty-
misestä ja suuresta kansanterveydellisestä merkityksestä, sen etiologia ja riskitekijät ovat 
hyvin huonosti tunnettuja. eturauhassyövän perheitäinen esiintyminen on havaittu 
jo 1950-luvulla. Tämänhetkinen konsensus on että perinnöllisen eturauhassyövän 
osuus on noin 5-10%. Tämän väitöskirjatyön tavoitteena oli tutkia perheittäin esi-
intyvää eturauhassyöpää Suomessa käyttäen epidemiologisia ja molekyyligeneettisiä 
tutkimusmenetelmiä. 
eturauhassyövän perheittäistä esiintymistä ja periytymismallia selvitettiin tässä 
väitöskirjatyössä kahdessa laajassa väestöpohjaisessa aineistoissa, joiden koot olivat 8008 
ja 12196 henkilöä. Segregaatioanalyysin tuloksena sain, että perheittäinen eturauhas-
syöpä periytyy resessiivisen mendeliaalisen periytymismallin mukaan ja että tässä on 
havaittavissa merkittävä polygeeninen/monitekijäinen vaikutus. Tutkimustulos tukee 
havaintoa, että eturauhassyövän periytymistä säädellään geenitasolla. Tämä julkaisu on 
ensimmäinen missä resessiivinen periytymismalli sopii sekä nuorena, että vanhempana 
sairastuneisiin eturauhassyöpä miehiin. 
Tässä väitöskirjatyössä on kuvattu perheittäin esiintyvän eturauhassyövän kliiniset 
ja histopatologiset ominaisuudet Suomessa. havaitsin, että eturauhassyöpään sairas-
tuneilla miehillä, joiden perheessä esiintyi eturauhassyöpää, on korkeampi kasvaimen 
erilaistumisaste, useammin alueellisia imusolmukemetastaaseja, korkeampi primaari 
PSA arvo kuin miehillä, joilla oli sporadinen syöpä. Mutta syöpäspesifisessä elinajassa 
ei ollut eroa. 
on todettu, että eturauhassyöpä on melko itsenäinen sairaus ja ettei muita pahan-
laatuisia syöpätauteja esiinny eturauhassyöpäperheissä normaalia enempää. Myöhem-
min on havaittu, että Suomessa eturauhasyöpää sairastavien potilaiden sukulaisilla 
olevan lisääntynyt riski eturauhas- ja mahasyöpiin. Tässä väitöskirjatutkimuksessa 
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selvitettiin 202 eturauhassyöpäperheen muita syöpiä ja tuloksena saimme, ettei yleinen 
syöpäilmaantuvuus ole korkeampi kuin verrokkiväestössä, paitsi eturauhassyöpä per-
heiden naisilla, joilla oli suurempi sairastuvuus mahasyöpään. 
hiljattain on tunnistettu uusi proteiini, PALB2, joka sitoutuu BrcA2:een. 
väitöskirjatyössä selvitettiin PALB2 muutosten esiintyminen suomalaisilla eturauhas-
syöpäpotilailla.  Tuloksena sain, etteivät havaitut PALB2 variantit selitä eturauhassyövän 
ilmaantumista populaatiotasolla Suomessa, mutta todennäköisesti osa varianteista 
saattaa altistaa syövälle yksilötasolla.  
yhteenvetona tämä väitöskirja tukee aikaisempia havaintoja siitä, että eturau-
hassyöpä on geneettinen tauti ja omaa väestökohtaisia erityispiirteitä. Perheittäinen 
esiintyminen Suomessa selittyy parhaiten resessiivisellä periytymismallilla ja periytymis-
alttius johtunee monen eri tekijän yhteisvaikutuksesta. Tässä väitöskirjatutkimuksessa 
on kuvattu perheittäisen eturauhasyövän kliiniset ja histopatologiset ominaisuudet 
sekä muiden syöpien esiintyminen. Perheittäin esiintyvä syöpä saattaa olla kliinisenä 
tautina aggressiivisempi, kuin sporadinen syöpä. 
Profiling of High-risk Prostate Cancer Families in Finland – 11
introduction
Prostate cancer is the most frequently diagnosed cancer among caucasian men and 
the second most common cause of cancer-related deaths, after lung cancer (finnish 
cancer registry, 2008). The incidence of prostate cancer has increased rapidly in the 
last few decades, especially in the early 1990s, due to the widespread use of serum 
prostate-specific antigen (PSA) as a diagnostic tool. despite the high incidence and 
mortality of this malignancy, the underlying aetiology of prostate cancer remains 
poorly understood. 
Besides age and ethnicity, the strongest risk factor for prostate cancer is family 
history. Through numerous epidemiological and molecular biological studies, consider-
able evidence has accumulated in favour of a significant but heterogeneous hereditary 
component in prostate cancer susceptibility. Twin studies provide the most straight-
forward tool for evaluating the significance of genetic and environmental aetiological 
factors. Several twin studies (Grönberg et al. 1994, Page et al. 1997, Lichtenstein et 
al. 2000) have suggested that shared genetic factors cause the accumulation of prostate 
cancer cases within single specific families. In linkage analyses, several loci have been 
found to show evidence of linkage, but only three genes, with an estimated collective 
contribution of about 5%, have been identified in hereditary prostate cancer patients 
to date (Grönberg et al. 1994, Page et al. 1997, rebbeck et al. 2000a, Tavtigian et al. 
2001, carpten et al. 2002, Xu et al. 2002, Schaid 2004). Because of the heterogene-
ous nature of the disease, the genes that promote prostate cancer have been extremely 
hard to identify; no high-risk genes underlying hereditary prostate cancer have yet 
been discovered. 
Prostate cancer is likely caused by multiple relatively common interacting loci. 
Many questions need to be answered before the genetic susceptibility of prostate cancer 
is fully understood, but there is still clinical importance within the present genetic 
knowledge. on average, hereditary prostate cancer is diagnosed six to seven years earlier 
than sporadic cancer, but does not otherwise clinically differ from the sporadic form. 
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however, a greater proportion of men with the hereditary form die of the disease than 
those with non-hereditary prostate cancer. currently, PSA screening is the only avail-
able clinical tool to reduce prostate cancer mortality (Matikainen et al. 1999, neal and 
donavan 2000) and detect the disease when it is still at a curable stage.
In this thesis, I have focused on familial prostate cancer in finland. I have used 
unique prostate cancer family data collected across finland in addition to the finnish 
cancer registry, Population registry and parish records. 
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review oF tHe LiterAture
1. epidemiology of prostate cancer
1.1 incidence and mortality
Prostate cancer is the most commonly diagnosed cancer in men in the uSA, account-
ing for an estimated 186 320 cases in 2008 and 25% of all cancer diagnoses in men. 
The incidence of prostate cancer has changed notably over the last 20 years, rapidly 
increasing from 1988-1992, declining sharply from 1992-1995 and levelling off after 
1995 (American cancer Society, 2009). In finland, there were 4235 diagnosed prostate 
cancer cases in 2008, accounting for 31% of all cancer cases (finnish cancer registry, 
2008). figure 1 shows the most common cancers among men in finland in 2008. 
Figure 1. The most common cancers among men (all ages, 13647 cases in total) in Finland 
in 2008.  
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cancer incidence rates in finland have changed in a similar manner as the rates in the 
uSA, but the rapid increase and decrease became apparent five to ten years after the 
corresponding changes in the uSA. An exceptionally irregular trend in prostate cancer 
incidence has been observed in recent years due to the increased frequency of PSA 
testing. The large-scale european prostate cancer screening study (erSPc) showed 
a 3.2-fold increase in the diagnosis of prostate cancer for men undergoing systematic 
PSA screening (Schröder et al. 2009). however, after a rapid increase prior to 2005, 
there has been an even sharper decrease. The decrease in incidence is expected to level 
off (as has been seen in the uSA), but the exact timing of this levelling off is difficult 
to predict (finnish cancer registry, 2008). 
Although the incidence of prostate cancer has increased substantially, the mor-
tality rate has stayed constant. In the uSA, prostate cancer was a leading cause of 
cancer death, with an estimated 28 660 deaths, in 2008. In finland, 817 men died of 
prostate cancer in 2008, indicating an age-adjusted mortality rate of 14.1 per 100 000 
men. The erSPc study, completed in 2008, included 162 000 men and presented 
the first mortality analysis (Schröder et al. 2009). during the nine years of follow-up, 
the erSPc showed an approximately 30% reduction of prostate cancer mortality in 
those who were actually screened. figure 2 compares prostate cancer incidence and 
mortality in finland, where the incidence was highest across europe in 2005 (finnish 
cancer registry, 2008).
Profiling of High-risk Prostate Cancer Families in Finland – 15
Figure 2. Annual age-standardised incidence and mortality rates for prostate cancer in Fin-
land, 1972-2008 (Rate per 100 000). Graph from NORDCAN (Engholm et al. 2010).
1.2 risk factors and aetiology
The aetiology of prostate cancer has evolved coincidentally with our deepening under-
standing of the complex interplay between the human genome and the environment. 
Genetic determinants, the endocrine milieu and environmental exposures all need to 
be considered when resolving the aetiology of prostate cancer. The well-established 
risk factors for prostate cancer are age, ethnicity and family history of the disease.
1.2.1 Age of onset
As typical for all cancers, the risk of developing prostate cancer increases with age. 
In the uSA, the median age at diagnosis of prostate cancer was 67 years of age  2003-
2007, and more than 65% of all prostate cancers are diagnosed in men over the age 
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of 65 (Altekruse et al. 2009). In finland, the age-specific highest annual number of 
new cancer cases was 871 prostate cancers in men aged 70-74 years, and the highest 
age-specific and age-adjusted incidence rate is 1154 per 100 000 in 80- to 84-year-old 
men in finland (finnish cancer registry, 2008). figure 3 shows the incidence rates 
across age groups from 1972 to 2006 in finland. 
1.2.2 ethnic origin
 
The incidence of prostate cancer varies among different countries and is highest in 
Australia/new Zealand (104.2 per 100 000 person-years), western and northern 
europe and north America. The lowest age-standardised incidence rate was calculated 
for South-central Asia (4.1 cases per 100 000 person-years) (International Agency for 
research on cancer, 2008). As shown in figure 4, there are substantial ethnic differ-
ences in both prostate cancer incidence and mortality in the uSA. African Americans 
have the highest incidence and mortality rates, whereas the lowest is found in Alaskan 
natives. An interesting issue is that Inuit have low rates of prostate cancer (dewailly 
et al. 2003). figure 5 shows regional incidence rates in nordic countries, illustrating 
the variability present even in homogenous countries like finland. 
Figure 3. Age-standardised prostate cancer incidence rates in Finland. Graph from NOR-
DCAN (Engholm et al. 2010).
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Figure 4. Age-adjusted incidence and mortality rates of prostate cancer in SEER areas 
(San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta) 
arranged by year and race in the USA. Data modifi ed from the U.S. National Cancer Insti-
tute (Altekruse et al. 2009). 
Figure 5. Age-standardised prostate cancer incidence rates in Nordic countries.  Graph 
from NORDCAN (Engholm, 2010).
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1.2.3 Family history
A positive family history is the most consistently identifi ed risk factor for prostate cancer. 
familial clustering of prostate cancer was fi rst observed in the 1950s (Morganti et al. 
1956), and there is a clear positive family history of the disease in about 5-10% of all 
cases. Subsequent studies have shown that a high risk of prostate cancer is associated 
with having multiple affected relatives: there is a two- to ten-fold increase in the risk of 
prostate cancer in brothers and sons of men with prostate cancer. Particularly high risk 
has been associated with men having multiple affected relatives or relatives diagnosed 
at an early age, where the proportion of familial clustering is also much higher, up to 
40-50% (figure 6) (Grönberg et al. 1999, Bruner et al. 2003). This familial risk has 
been observed in all ethnic groups and populations studied (whittemore et al. 1995, 
hayes et al. 1995, ohtake et al. 1998, Glover et al. 1998). In a population-based 
study in finland, an approximately two-fold increased risk was observed for men with 
affected fi rst-degree relatives (Matikainen et al. 2001). The risk of developing prostate 
cancer increases as the age of probands decreases, as the closeness and number of af-
fected members in the family increases, or when both factors are considered together 
(eeles 1999).
Figure 6. Relative risk of prostate cancer with respect to affected family members (Eeles 
1999, Matikainen et al. 2001). The relative risks are approximations based on a synthesis 
of published epidemiological studies. 
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1.2.4 Aetiology 
The observed differences in prostate cancer risk exhibited by different ethnic groups 
suggest that genetic factors are at least partially responsible. The changes in incidence 
rates over time also imply that differences in environment or lifestyle are important. 
Indeed, the observations that prostate cancer risk increases when Japanese migrate to 
hawaii (Maskarinec and noh 2004) or to Los Angeles (Shimizu et al. 1991) suggest 
that diet and environmental factors also play a major role. despite extensive research, 
the environmental risk factors for prostate cancer are not well understood. 
Hormonal influences
It is clear that male sex hormones play an important role in the development and growth 
of prostate cancer. They are needed for prostate growth, development, function and 
maintenance. In 1941, huggins and hodges demonstrated that prostatic cancers are 
androgen dependent (huggins 1941). Testosterone diffuses into the prostate gland, 
where it is converted to the more metabolically active dihydrotestosterone (dhT) by 
the enzyme 5α-reductase. Both dhT and testosterone bind to the androgen receptor, 
which then translocates to the nucleus, binds to deoxyribonucleic acid (dnA) and 
transactivates genes that, for example, control cell division. Prostate cancer does not 
develop in men who are castrated at an early age (Smith et al. 1991). Men who have 
higher levels of dhT appear to have a higher risk of developing prostate cancer (eaton 
et al. 1999). Accordingly, reduction of dhT formation by 5α-reductase inhibitors 
decreases the incidence of prostate cancer (Andriole et al. 2010). 
Diet and nutrition
diet and nutrition are interesting issues with respect to prostate cancer risk. A wide 
variety of dietary factors have been implicated in the development of prostate cancer in 
prospective intervention. however, a true consensus has not been reached. Selenium, 
vitamin e and lycopene seem to have protective effects against prostate cancer in 
epidemiological studies (Giovannucci et al. 1995, clark et al. 1998, yoshizawa et al. 
1998, heinonen et al. 1998, Schuurman et al. 2002, van den Brandt et al. 2003). Many 
studies have reported a positive association between milk consumption and prostate 
cancer risk (Bostwick et al. 2004). The present view states that low fibre consump-
tion, intake of red meat and an imbalance of omega-3 and omega-6 fatty acids may all 
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increase the risk of prostate cancer. on the other hand, the consumption of fruit and 
vegetables may lower the risk. A healthy lifestyle and diet drawn up according to the 
proposed guidelines could decrease the incidence of this disease (divisi et al. 2006). 
Inflammation
The complex relationship between inflammation and cancer has been well described 
since the late 1800s (Balkwill and Mantovani 2001).  epidemiological studies have 
convincingly demonstrated that inflammatory diseases increase the risk of developing 
cancer. for example, gastric infection with Helicobacter pylori (Parsonnet et al. 1991), 
inflammatory bowel disease (rhodes and campbell 2002) and chronic hepatitis (Impe-
rial 1999) have been linked to malignancies of the affected organs.  numerous reports 
have revealed a potential link between chronic prostatic inflammation and prostate 
cancer (dennis and dawson 2002, nelson et al. 2004).  chronic inflammation of the 
prostate is common, and epidemiological data suggest that 2-10% of adult men suffer 
symptoms from prostatitis at some point in their life (Krieger and riley 2004). An 
increase in prostate cancer incidence has been correlated with symptoms of prostatitis 
and with sexually transmitted infections, independent of the specific pathogen (dennis 
and dawson 2002). further studies are needed to establish a definitive epidemiological 
link between prostatitis and prostate cancer. 
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2. natural history of cancer
cancer comprises a class of diseases in which a group of cells show uncontrolled growth. 
usually, the timing of cell division is strictly controlled by complex signalling mecha-
nisms. Mutations in one or more genes in the nodes of this network can trigger cancer 
through genetic predisposition and/or exposure to certain environmental factors (e.g. 
tobacco and radiation). Therefore, cancers are caused by abnormalities in the genetic 
material of the transformed cells. Besides environmental factors, cancer-promoting 
genetic abnormalities can randomly occur through errors in dnA replication or may 
be inherited and thus present in all cells of the body. The inheritance of cancer pre-
disposition is usually affected by complex interactions between carcinogens and the 
host’s genome (Stratton et al. 2009). 
Genetic abnormalities found in cancer typically affect two general classes of genes. 
cancer-promoting oncogenes are often activated in cancer cells, whereas tumour sup-
pressor genes are inactivated.  Briefly, the predominant mechanisms underlying the 
development of cancer include 1) impairment of dnA repair pathways, 2) transforma-
tion of a normal gene into an oncogene, 3) the malfunction of a tumour suppressor 
gene or 4) changes in gene regulation (e.g. epigenetic changes or non-coding-rnA 
regulation) (Kirby et al. 2006). 
2.1 Knudson’s cancer development model 
Almost forty years ago, Knudson proposed a two-hit hypothesis of cancer develop-
ment, showing that tumour formation requires recessive loss of function mutations in 
certain genes called tumour suppressor genes (Knudson 1971). According to Knudson’s 
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hypothesis, inherited susceptibility to cancer can be traced to germline mutations that 
lead to malfunctions in one of the copies of these genes. he studied a rare eye tumour, 
retinoblastoma, and proposed the existence of regulatory genes (tumour suppressor 
genes) that control the cell cycle, apoptosis and proliferation. normal human cells 
have two copies of each gene, one inherited from each parent. Knudson’s model sug-
gests that two hits are required to inactivate both alleles of a tumour suppressor gene, 
leading the cell to undergo malignant transformation (figure 7). Knudson’s hypothesis 
was verifi ed 20 years later when germline mutations in the retinoblastoma gene were 
detected in patients with hereditary retinoblastoma (hogg et al. 1993). 
Figure 7. Knudson’s model for inactivation of a tumour suppressor gene. The fi rst hit is usu-
ally a rare mutation in the primary DNA sequence of the gene (red star). This mutation can 
be transmitted through the germline, giving rise to an inherited form of cancer. The second 
hit leads to physical loss of genetic material in the gene region (Knudson 1971).   
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2.2 cancer syndromes and association with other cancers
2.2.1 cancer syndromes
Most forms of cancers are sporadic, meaning that there is no obvious inherited cause. 
however, researchers have identified more than 20 inherited cancer syndromes in 
which there is an inherited predisposition for cancer, often due to a defect in a gene 
that protects against tumour formation. finding evidence for hereditary cancer is more 
likely when the cancer has an early age of onset, when there is a range of cancer types 
and when there are multiple cases in a family, affecting several generations. Several 
hereditary cancer syndromes have been identified; most of them are rare, affecting 
only about 1% of all cancer patients (fearon 1997). The known cancer syndromes are 
listed in Table 1, as previously reviewed by Garber and offit (2005).
Table 1. Syndromes of inherited cancer predispositions as reviewed by Garber and Offif 
(2005).
Syndrome Component tumours Mode of inheritance Genes
Hereditary prostate 
cancer prostate cancer Dominant 
HPC1, HPCX, 
HPC2, PCAP, 
PCBC, PRCA, 
GPC3
Hereditary breast and 
ovarian cancer breast, ovarian, prostate and pancreatic cancers Dominant BRCA1, BRCA2
Li-Fraumeni Syndrome
soft tissue sarcoma, breast cancer, 
osteosarcoma, leukaemia, brain tumours, 
adrenocortical carcinoma
Dominant p53, CHECK2
Cowen Syndrome breast, thyroid and endometrial cancer Dominant PTEN
Bannayan-Riley-Ruval-
caba syndrome
breast cancer, meningioma, thyroid follicular cell 
tumours Dominant PTEN
Ataxia teleangiectasia leukaemia, lymphoma Recessive ATM
Hereditary non 
polyposis colorectal 
cancer (HNPCC) Lynch 
syndrome
colon, endometrial, ovarian, renal pelvis, urethral, 
pancreatic, stomach and small bowel cancers Dominant
MLH1, MSH2, 
MSH6
Familial polyposis colon cancer Dominant APC
Hereditary gastric cancer stomach cancers Dominant CDH1
Juvenile polyposis gastrointestinal and pancreatic cancers Dominant SMAD4/DPC4, BMPR1A
Peutz-Jeghers syndrome colon, small bowel, breast, ovarian and pancreatic cancers Dominant STK11
Hereditary melanoma 
pancreatic cancer pancreatic cancer, melanoma Dominant CDKN2A/p16
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Hereditary pancreatitis pancreatic cancer Dominant PRSS1
Turcot syndrome colon and basal cell cancer and ependymoma, medulloblastoma, glioblastoma Dominant
APC, MLH1, 
PMS2
Familial gastrointestinal 
stromal tumour gastrointestinal stromal tumours Dominant KIT
Melanoma syndromes malignant melanoma Dominant CDKN2, CDK4, CMM
Basal cell cancers, Gorlin 
syndrome basal cell cancers, brain tumours Dominant PTCH, PTEN
Neurofibromatosis 1 
and 2 
neurofibrosarcomas, phaeochromocytomas, optic 
gliomas, meningiomas Dominant NF1, NF2
Tuberous sclerosis myocardial rhabdomyoma, bilateral renal angiomyolipoma, ependymoma Dominant TSC1, TSC2
Carney complex myxoid subcutaneous tumours, adrenocortical nodular hyperplasia, testicular Sertoli cell tumour Dominant PRKAR1A
Rothmund Thomson 
syndrome
basal cell carcinoma, squamous cell carcinoma, 
osteogenic sarcoma Recessive RECQL4
Bloom syndrome leukaemia, carcinoma of the tongue, squamous cancers, Wilm’s tumour, colon cancer Recessive BLM
Fanconi Anaemia leukaemia, squamous cancers, skin carcinoma, hepatoma Recessive FANCA-F 
Shwachman-Diamond 
syndrome myelodysplasia, acute myelogenous leukaemia Recessive SBDS
Nijmegan breakage 
syndrome
lymphoma, glioma, medulloblastoma, 
rhabdomyosarcoma Recessive NBS1
Canale-Smith syndrome lymphoma Dominant FAS, FASL
Wiskott-Aldrich hematopoietic malignancies X-linked recessive WAS
Severe combined im-
mune deficiency B-cell lymphoma
X-linked 
recessive IL2RG
X-linked lymphoprolifera-
tive syndrome lymphoma
X-linked 
recessive SH2D1A
Simpson-Golabi-Behmel 
syndrome embryonal tumours, Wilm’s tumour
X-linked reces-
sive GPC3
von Hippel-Lindau 
syndrome
hemangioblastomas of retina and central nervous 
system Dominant VHL
Beckwith-Wiedeman 
syndrome
Wilm’s tumour, hepatoblastoma, adrenal 
carcinoma, gonadoblastoma Dominant CDKN1C, NSD1
Wilm’s tumour syndrome Wilm’s tumour Dominant WT1
Birt-Hogg-Dube syn-
drome renal tumours Dominant FLCL
Papillary renal cancer 
syndrome papillary renal cancer Dominant MET, PRCC
Rhabdoid predisposition 
syndrome rhabdoid tumours Dominant SNF5/INI1
Hereditary 
paraganglioma paraganglioma, phaeocromocytoma Dominant
SDHD, SDHC, 
SDHB
Retinoblastoma retinoblastoma, osteosarcoma Dominant RB1
Multiple exostoses chondrosarcoma Dominant EXT1, EXT2
Leiomyoma/renal cancer 
syndrome
papillary renal cell carcinoma, uterine 
leiomyosarcomas Dominant FH
Werner syndrome sarcoma/osteosarcoma, meningioma Recessive WRN
MEN1 pancreatic islet cell tumours, pituitary adenomas, parathyroid adenomas Dominant MEN1
MEN2 medullary thyroid cancers, phaeochromocytoma, parathyroid hyperplasia Dominant RET 
Familial papillary thyroid 
cancer papillary thyroid cancer Dominant Multiple loci
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2.2.2 Prostate cancer syndromes
extensive efforts have been made to reveal the genetics behind prostate cancer sus-
ceptibility, but our knowledge of crucial genes and variations predisposing to prostate 
cancer is still insufficient. To date, only three putative susceptibility genes have been 
identified. The first, elac E. coli homolog 2 (HPC2/ELAC2) at 17p11, was identified 
from extended high-risk hPc families studied in utah (Tavtigian et al. 2001). The 
second reported prostate cancer gene, ribonuclease L (HPC1/RNASEL) at the 1q24-
25 locus, was identified among prostate cancer families at Johns hopkins hospital 
(carpten et al. 2002). Macrophage scavenger receptor 1 (MSR1) is the third reported 
prostate cancer gene and is positioned at 8p22-23 (Xu et al. 2002). The evidence that 
these genes underlie prostate cancer predisposition in finnish prostate cancer-prone 
families and patients is weak (rökman 2002 et al. 2002, rökman et al. 2001, Seppälä 
et al. 2003). This is likely because of the heterogeneous nature of this disease. Genetic 
risk factors seem to vary between populations and ethnic groups. It remains a significant 
challenge to find genetic variations in prostate cancer that could distinguish between 
different types of the disease, from marginal clinical relevance to lethal prostate cancer, 
in different populations.
other susceptibility genes with an associated risk for prostate cancer include 
BRCA1 and BRCA2 (easton et al. 1997, friedenson et al. 2005). The estimated relative 
risk of developing prostate cancer was calculated to be 3.3 for male carriers of BRCA1 
mutations compared with the general population (ford et al. 2004). Alarmingly, 
mutations in BRCA2 are associated with a 23-fold increased risk of prostate cancer 
(edwards et al. 2003, friedenson 2005).  
2.2.3. Prostate cancer and other cancers 
In epidemiological studies, an increased risk of prostate cancer has been observed and 
confirmed among the first-degree relatives of men with the disease.  nonetheless, studies 
of associations between prostate cancer and cancers at other sites are conflicting. Some 
studies have indicated that hereditary prostate cancer is site-specific and that no other 
malignancy occurs at a higher than expected rate (Isaacs et al. 1995). however, there 
seems to be a connection between susceptibility to prostate cancer and brain tumours 
(Isaacs et al. 1995, Gibbs et al. 1999), gastric cancer (Grönberg et al. 2000, Matikainen 
et al. 2001) and breast cancer (valeri et al. 2000, Grönberg et al. 2001).  
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In population-based studies, associations have been reported to exist between 
prostate cancer and gastric, colon, rectal, kidney, breast, ovarian, bladder, thyroid and 
brain cancers as well as melanoma and non-hodgkin’s lymphoma, but such findings 
have been inconsistent between studies, and only a few of these neoplasms have been 
reported even twice (Goldgar et al. 1994, Matikainen et al. 2001, Grönberg et al. 2001, 
eldon et al. 2003, verhage et al. 2004, Amundadottir et al. 2004, negri et al. 2005). 
A study by hemminki et al. (2005), performed with 170 000 men with prostate can-
cer, revealed an excess of breast, ovarian and liver cancers as well as hodgkin’s disease, 
leukaemia and melanoma (hemminki and chen 2005). Although differences in study 
populations (i.e. genetic heterogeneity) may account for these diverse findings, the 
available data suggest that the inherited susceptibility to prostate cancer is relatively 
“site-specific” and not part of an inherited cancer syndrome like the BRCA1-associ-
ated breast and ovary cancer syndrome or the mismatch repair gene-related hereditary 
non-polyposis colorectal cancer syndrome (hnPcc) (verhage et al. 2004). 
2.3 Familial clustering of prostate cancer
Based on family history, three prostate cancer patient groups can be identified: heredi-
tary, familial and sporadic. hereditary prostate cancer was first described by carter et 
al. (1993) and includes nuclear families with three or more prostate cancer cases, the 
occurrence of prostate cancer in each of three generations in the maternal or paternal 
lineage or a cluster of two first-degree relatives (father, brothers or sons) diagnosed 
with prostate cancer at the age of 55 or younger (carter et al. 1993). As no high-risk 
mutations causing hereditary prostate cancer have yet been identified, the definition 
of this disease is solely based on family history and pedigree. Approximately 3 to 5% 
of prostate cancer cases can be classified as hereditary based on these criteria (carter 
et al. 1992). however, because of the difficulties inherent in identifying three genera-
tions of disease carriers or the female carriers within the pedigree, these criteria has a 
poor sensitivity for detecting families with hereditary susceptibility to prostate cancer. 
The true proportion of prostate cancer caused by mutations in dominantly inherited 
susceptibility genes with high penetrance is more likely 5 to 10% (Bratt 2002). Among 
men with early onset prostate cancer, inherited susceptibility is much more common 
and may account for more than 40% of those diagnosed before the age of 55 (Bratt 
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et al. 1999). familial prostate cancer does not meet these strict criteria, but it repre-
sents families in which there are two first-degree or one first-degree and two or more 
second-degree relatives with prostate cancer. familial prostate cancer is estimated to 
account for 10 to 20% of all prostate cancer cases (carter et al. 1993, Stanford and 
ostrander. 2001). Sporadic prostate cancer signifies that only one man in a family has 
been diagnosed with prostate cancer, with no known affected relatives. however, as 
prostate cancer is a late onset disease, it is important to determine the disease status of 
the index parents, brothers and children to be sure that the patient indeed represents 
a sporadic case of prostate cancer. 
2.4 Histology and histopathology of prostate cancer
Prostate cancer develops from the secretory epithelial cells, most often in the peripheral 
zone of the prostate. Prostatic intraepithelial neoplasia (PIn) is also often found in 
the peripheral zone and is believed to be a premalignant stage of prostate carcinoma 
(de Marzo et al. 2003).  
Prostate cancer progression is a multistep process in which an organ-confined 
tumour eventually invades though the capsule of the prostate into the surrounding 
environment and metastasises to local lymph nodes and distant organs, mainly bones. 
Growth of the vast majority of prostate cancers is androgen dependent. however, 
during androgen withdrawal, a hormone-refractory tumour clone eventually emerges. 
Like PIn, commonly observed latent microscopic prostate cancer may also represent 
a preliminary stage of clinical cancer. however, the potential of the latent cancer to 
progress into a theoretically life-threatening clinical cancer is not definitively known. 
Microscopic cancer lesions have been found in autopsies of more than 50% of men 
between 70 and 80 years old (Sheldon et al. 1980). Like PIn, these common latent 
microscopic prostate cancers may also represent a preliminary stage of clinical cancer. 
Most often, only a minority of these lesions would develop into clinical cancer (Gittes 
1991). however, it is unclear whether these incidental small carcinomas represent 
the same disease as clinically relevant life-threatening tumours (Selman 2000). Most 
clinically detected prostate carcinomas are adenocarcinomas and can be further clas-
sified by the Gleason grading system introduced over 40 years ago. Gleason grading 
remains one of the most powerful prognostic factors for prostate cancer and defines 
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five histological patterns or grades with decreasing differentiation (Gleason 1966). 
In addition to Gleason grading, histological staging can be used to classify prostate 
cancers. Three different characteristics are considered: primary tumour (T), regional 
lymph nodes (n) and distant metastases (M) (eble et al. 2004).
2.5 diagnosis of prostate cancer
even before the PSA test came into common usage twenty years ago, most prostate 
cancers were asymptomatic and detected by digital rectal examination. The diagnosis 
is typically established by histopathologic examination of needle biopsy tissue. clinical 
symptoms are usually a manifestation of more advanced disease. only 8% of prostate 
cancers cause bladder outlet obstruction, and only rarely does urinary obstruction 
result from large-volume periurethral tumours (Mai et al. 2000). Locally extensive 
tumours may present with pelvic pain, rectal bleeding or obstruction (Scott et al. 
1969). Metastatic prostatic adenocarcinomas can present as bone pain (huddart et 
al. 1997). Stamey and coworkers reported that serum PSA levels were proportional to 
the size of the palpable cancer; subsequently, the PSA test and the Gleason histologic 
grading system for tumour samples were recognised as the key diagnostic tools for 
prostate cancer (Stamey et al. 1987). Because the clinical phenotype of prostate can-
cer is complex and heterogeneous, the arrival of the PSA era has further complicated 
analysis of prostate cancer by allowing the early diagnosis of a disease that might remain 
latent or clinically unimportant. In addition, other prostatic diseases, like hyperplasia 
or inflammation, can cause increases in PSA levels, making it important to exclude 
cancer in certain patients. 
The use of PSA as a screening test has been studied in two large randomised trials: 
erSPc and the uS-based Prostate, Lung, colorectal and ovarian cancer screening 
(PLco) (Grubb et al. 2008, Schröder et al. 2009). The erSPc study showed that 
PSA screening led to a significant but relatively small decline in mortality rate, but 
pointed out the associated risk of overdiagnosis and overtreatment. In addition, quality 
of life issues need to be further studied before conclusions from PSA screening can be 
made (eckersberger et al. 2009).  
Serum PSA is widely used in the diagnosis and surveillance of prostate cancer, 
although its non-specificity limits its usefulness.  other novel markers have been 
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studied (e.g. the prostate cancer gene 3), but they have not overtaken PSA in specificity 
and sensitivity of diagnosis (Teahan et al. 2010). 
2.6 treatment of prostate cancer
when choosing a treatment plan for a patient diagnosed with prostate cancer, the 
selection strategy depends upon the risk posed by the newly diagnosed cancer. There 
is no universally accepted definition of clinically significant or insignificant disease, but 
studies have clearly shown that cancer volume, clinical stage and tumour histology are 
important predictors of long-term outcomes (epstein 1994). Tumour size and stage are 
estimated by serum PSA levels and digital rectal examination, and tumour histology is 
assessed by the Gleason scoring system. In addition, the patient’s age, general condition 
and presence of other diseases must be considered when selecting a treatment (epstein 
1994). Treatment options can be divided into two categories according to whether the 
disease appears to be local or of an advanced type (Kirby et al. 2006). 
2.7 clinical characteristics of hereditary prostate cancer 
Several studies have noted the earlier age of onset observed in familial prostate cancer as 
compared to sporadic prostate cancer (carter et al. 1993, Keetch et al. 1996, Grönberg 
et al. 1997b, norrish et al. 1999, Bratt et al. 1999, valeri et al. 2000, Ahaghotu et 
al. 2004). In a nationwide Swedish study of 201 patients from 62 Swedish hereditary 
prostate cancer families and 402 matched controls, the age of onset was six years earlier 
in hereditary prostate cancer, with a median age at diagnosis of 68 years. Studies that 
did not find support for an earlier age of onset in hereditary prostate cancer most often 
used prostatectomy patients as their selected study populations. roehl et al. (2006) 
found an age of onset of 61-63 years among the various groups studied, but the low 
age can be explained by the study setting in which only patients who underwent radical 
prostatectomy were included. The small difference in age at onset between hereditary 
and sporadic prostate cancer (six to seven years compared with 20 years for breast, 
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ovarian and colorectal cancers) implies that environmental factors may be important 
in many families with hereditary prostate cancer. however, a greater proportion of 
men with hereditary prostate cancer die of the disease than those with nonhereditary 
prostate cancer (Grönberg et al. 1997). currently, PSA screening is the only available 
clinical tool to reduce prostate cancer mortality and detect the disease when it is still 
at a curable stage in hereditary prostate cancer families. 
An increased number of precursor lesions and tumour multifocality are commonly 
associated with hereditary cancers. however, multifocality and multiple precursor 
lesions are not specifically associated with familial types of prostate cancer (Bastacky 
et al. 1995). Tumour grade and pathological stage at diagnosis do not differ between 
patients with hereditary prostate cancer and those with sporadic prostate cancer 
(Bastacky et al. 1995, valeri et al. 2000, Bratt 2002). 
Many studies have reported that BRCA1-associated breast cancers show particular 
tumour characteristics such as a basal-like phenotype and high histological grade (Phil-
lips 2000, narod and foulkes 2004). In hnPcc, tumours are usually located in the 
proximal colon, but in sporadic colon cancer they are instead found in the distal colon 
(Lindblom 2001). however, differences in the histological characteristics of hereditary 
prostate cancer and sporadic prostate cancer have not been found (Bratt 2007).
In a study by norrish et al. (1999), familial prostate cancer appeared to be diag-
nosed at an earlier stage of disease progression, possibly as a result of higher socio-eco-
nomic status or greater use of screening and investigative procedures among patients 
reporting positive family history (norrish et al. 1999). This could partly explain the 
high proportion of low-grade tumours also observed in the studies by Bastacky et al. 
(1995) and Keetckh et al. (1996).   
overall, no substantial clinical or pathological differences seem to exist between 
clinically defined hereditary, familial or sporadic prostate cancer cases. however, this 
does not exclude the possibility that certain hereditary prostate cancer genes are as-
sociated with specific biological characteristics. Indeed, given the unique features of 
other hereditary cancers (hnPcc, BrcA), it is surprising that differences between 
sporadic and hereditary prostate cancer have not been found. PSA screening allows 
the detection of latent prostate cancers that would not have been found otherwise. 
In addition, this screening may eventually reveal distinct types of prostate cancer and 
alter the established clinical paradigm of prostate cancer. 
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3. Genetic epidemiology of prostate cancer
Accumulating evidence has shown that prostate cancer results from interactions be-
tween genes, hormones and environmental factors (ross and henderson 1994, Kolonel 
1996, Bosland 2000). Through numerous epidemiological and molecular biological 
studies, a considerable amount of data has been gathered in favour of a significant but 
heterogeneous genetic component in prostate cancer susceptibility. The field of genetic 
epidemiology studies the genetic contribution to disease along with the environmental 
factors affecting families and inherited causes of disease in populations (Morton and 
chung 1978, Thomas 2004). Traditionally, genetic epidemiology study designs have 
included familial aggregation, segregation, linkage and association studies. familial 
aggregation studies investigate whether the disease clusters in families. Segregation 
studies determine the mode of inheritance of the disease. Linkage studies resolve the 
chromosomal locus where the disease gene is located, and association studies deter-
mine the particular allele related to the disease (Khoury et al. 1993, Mccarthy et al. 
2008). 
Twin studies provide the most straightforward tool for evaluating the significance 
of genetic and environmental aetiological factors. Twin studies compare disease con-
cordance rates for a given disease for identical (monozygotic) versus non-identical 
(dizygotic) twins and allow researchers to test for evidence of genetic aetiology. Several 
twin studies of human prostate cancer have been published   (Grönberg et al. 1994, 
Page et al. 1997, Ahlbom et al. 1997, verkasalo et al. 1999, Lichtenstein et al. 2000). 
In these studies, concordance rates for prostate cancer have been substantially higher 
among monozygotic twin pairs than among dizygotic twin pairs, indicating the impor-
tance of genetic factors in the development of prostate cancer. In the largest of these 
studies, using data for 44,788 pairs of nordic twins, Lichtenstein et al. (2000) reported 
a heritability of 42% for prostate cancer, which was the highest ever reported for a 
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common malignancy. Interestingly, this fraction was even higher than that estimated 
for either breast or colon cancers, which have been clearly linked to high-penetrance 
risk genes. figure 9 illustrates the interacting effects of high and low as well as rare and 
common allele frequencies in common diseases such as prostate cancer. 
 
Figure 9. A graph describing different allele frequencies and penetrance levels. Linkage 
analyses mainly identify rare alleles with high penetrance. Genome-wide association stud-
ies identify common variants. With DNA sequencing, low-frequency variants can be de-
tected. Picture modifi ed from McCarthy et al. (2010). 
3.1 mode of inheritance, segregation analysis
Segregation analysis is a statistical method used to test compatibility with Mendelian 
expectations by estimating the parameters of a given model of inheritance from family 
data. The results of these analyses are diffi cult to interpret for complex diseases that 
are likely to be caused by multiple predisposing genes. however, such estimates are 
required for carrying out parametric linkage analyses for cancer. 
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when testing for genetic control, three types of individuals are considered: AA, AB 
and BB, where the disease allele is A and B represents the unaffected allele(s). figure 8 
explains the differences between dominant and recessive inheritance models. Previous 
segregation analyses in diverse populations have suggested that familial aggregation 
of prostate cancer follows autosomal dominance, multifactorial, recessive or X-linked 
inheritance, but remain inconclusive. Six reports suggested a dominant inheritance 
mode (Table 2) (carter et al. 1992, Grönberg et al. 1997a, Schaid et al. 1998, verhage 
et al. 2001, valeri et al. 2003, conlon et al. 2003). cui (2001) reported a mixture 
of models, including autosomal dominant inheritance in younger onset families and 
recessive or X-linked inheritance in older-onset families (cui et al. 2001). A multi-
factorial model has been suggested by Gong et al. (2002). 
Figure 8. The disease locus is assumed to have a gene with two forms, A and B.  A causes 
disease, but B does not. Each child has two alleles, one from the father and one from the 
mother.  In dominant inheritance, those who receive A from the father have the disease. 
People with the BB genotype do not have the disease. If the disease is recessive, a child 
also has to receive A from the mother because the homozygous AA genotype is required 
to inherit the disease. In the recessive case, the AB and BB genotypes are not affected. 
However, the AB genotype is a disease carrier. 
In a recent study by MacInnis et al. (2009), genetic susceptibility to prostate cancer 
was proposed to be mostly explained by one or more genes having a strong recessively 
inherited risk as well as a number of genes with variants having small, multiplicative 
risks (MacInnis et al. 2010). 
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Table 2. Main characteristics of previous segregation analyses for prostate cancer
Study Publication year
Study 
period Population
No. of 
families
Suggested 
inheritance model
Carter et al. 1992 1982-1989 American 691 rare dominant gene with high lifetime risk
Grönberg et al. 1997 1959-1963 Swedish 2857 relatively frequent dominant gene with moderate lifetime risk
Schaid et al. 1998 1966-1995 American 4288 rare dominant gene with high lifetime risk
Verhage et al. 2001 1991-1993 American 1199 rare dominant gene with high lifetime risk
Cui et al. 2001 1994-1997 Australian 1476 
relatively frequent dominant 
component with intermediate life-
time risk and recessive or X-linked 
component with high lifetime risk
Gong et al. 2002 1989-1995 American, Canadian 1719 multifactorial
Baffoe-Bonnie et al. 2002 _ Icelandic 389 codominant
Valeri et al. 2003 1994-1997 French 691 
rare dominant gene with high 
lifetime risk and residual 
brother-brother dependence
Conlon et al 2003 – American 263 autosomal dominant
MacInnis et al. 2009 1960-2004 Australian and UK 4390 mixed recessive model
3.2 Linkage studies 
results of segregation analyses have strongly indicated that a subset of prostate cancers 
can likely be attributed to the action of one or more major genes. These findings have 
led to large efforts worldwide to identify and carry out linkage studies on families 
with multiple prostate cancer cases. This method aims to map markers and diseases 
on chromosomes to identify the genetic basis of disease. neighbouring genes have a 
tendency to stick together during meiotic recombination, enabling the localisation of 
cancer genes by their close proximity to a specific marker gene (Altshuler et al. 2008). 
Linkage analyses mainly identify tumour suppressor genes. In hereditary cancer syn-
dromes, one abnormal copy of the tumour suppressor gene is inherited in the germline 
from one parent, whereas the other copy of the gene is normal. To develop cancer, the 
normal allele needs to acquire a mutation in somatic cells. These inherited mutated 
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tumour suppressor genes are associated with a high risk of cancer, but they are usually 
relatively rare (hofstra et al. 2008). 
Prostate cancer linkage studies have been used to localise rare and highly penetrant 
susceptibility genes. The linkage approach has been successful in identifying major 
susceptibility genes for other common cancers, such as those of the breast (BRCA1 
and BRCA2) and colon (APC, MLH1, MSH2, MSH6, PMS2, MYH, LKB1, SMAD4, 
ALK3, PTEN) (Miki et al. 1994, wooster et al. 1995). The International consortium 
for Prostate cancer Genetics (IcPcG) was founded to improve the mapping of pros-
tate cancer genes and has emphasised that one of the major difficulties in studying 
prostate cancer is genetic heterogeneity, possibly due to multiple genes with incomplete 
penetrance (Xu et al. 2005). over a dozen linkage analyses have been performed, but 
despite the strong evidence for genetic predisposition to prostate cancer, the findings 
from these studies have been inconclusive Several susceptibility loci, including 1p36 
(CABP), 1q24-25 (HPC1), 1q42.2-43 (PCAP), 8p22-23, 8q24, 16q23, 17p11, 19q13, 
20q13 (HPC20) and Xq27-28 (HPCX) have been reported, but most of these findings 
could not be confirmed in other independent studies. Because of the heterogeneous 
nature of the disease, the genes that promote prostate cancer have been extremely 
hard to identify; no high-risk genes underlying hereditary prostate cancer have yet 
been discovered.
In finland, the HPC1/RNASEL, HPC2/ELAC2 and MSR1 loci have been shown 
to explain only a small fraction of prostate cancer cases (rökman et al. 2001, rökman 
et al. 2002, Seppälä et al. 2003a). Instead, four additional major susceptibility loci 
have been identified in finnish families, including the HPCX (Xq27-28), 3p25-26, 
11q14 (Xu et al. 2005, chang et al. 2006) and 17q21 regions (cropp et al. submit-
ted). Linkage to loci on 3p, 11q and 17q has been found in other populations as well 
(Lange et al. 2003, Xu et al. 2005, chang et al. 2006). The HPCX locus on Xq27-28 
seems to explain a particularly large fraction of finnish hereditary prostate cancer 
cases, especially among families with no male-to-male transmission and late age of 
diagnosis. In contrast, we found no evidence for the involvement of the HPC1 locus 
at 1q24-q25 in finnish families. A recent genome-wide linkage analysis of 69 finnish 
families confirmed the presence of a signal at 17q21-22 (unpublished data). even so, 
a large proportion of finnish hereditary prostate cancer cases remain unexplained. 
overall, confirmation of the involvement of these genes has been inconsistent 
across different study populations (Schaid 2004, Kirby et al. 2006). despite extensive 
efforts using linkage analysis, no genes that reproducibly account for more than a small 
percentage of familial prostate cancer cases have been found. when one considers 
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the heterogeneity of prostate cancer, this is perhaps not unexpected, but does suggest 
that new strategies, such as meta-analyses, pooled analyses and larger sample sizes, are 
needed and that the patients being analysed should be more strictly defined according 
to, for example, a clinical outcome such as aggressive disease. 
3.3 Association studies
After the aforementioned linkage analyses indicated that major genes are unlikely to 
underlie prostate cancer susceptibility, more interest has been given to association 
studies seeking to identify genes that may have more common, albeit weaker, risk 
alleles. These studies are performed with case-control approaches and typically detect 
more common, lower-risk variants with lower penetrance compared to linkage analyses 
(Mccarthy et al. 2008). with respect to prostate cancer, these studies are typically 
performed in study populations of men with and without prostate cancer, often 
without regard to family history (houlston and Peto 2004, Kirby et al. 2006). The 
selection and validation of the control group is essential, otherwise false associations 
may be drawn. These case-control studies have been greatly aided by the increased 
understanding of the variability within the human genome sequence among differ-
ent individuals and the concept that common diseases can be attributed to common, 
possibly population-specific, genetic variants (Lohmueller et al. 2003).  for example, 
CHECK2 variants have been shown to associate with sporadic prostate cancer in the 
uSA, but in analyses done in finland and Poland, the association was with hereditary 
prostate cancer (Seppälä et al. 2003b, cybulski et al. 2004). These associations between 
genes and disease risk can be rapidly assessed by simply examining the frequency of 
polymorphic alleles, typically single nucleotide polymorphisms (SnPs), among cases 
and controls. A large number of genes involved in the critical processes of prostate 
cancer, e.g. androgen action and metabolism, growth factor signalling, carcinogen 
detoxification, dnA repair and inflammation, have been systematically evaluated in 
this fashion (Simard et al. 2002, rennert et al. 2005, Kirby et al. 2006). Addition-
ally, genome-wide association studies (GwAS) of prostate cancer involving hundreds 
of thousands of genetic markers have been conducted; these studies implicate a large 
number of genes in prostate cancer risk (Gudmundsson et al. 2008, eeles et al. 2008, 
Thomas et al. 2008).
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A recent example of the power of GwASs can be found in the discovery that 
common genetic variations in 8q24 influence the risk of developing prostate cancer. 
Interestingly, none of the prostate cancer risk variants align to a known gene or alter 
the coding sequence of an encoded protein (freedman et al. 2006, Gudmundsson et 
al. 2007, haiman et al. 2007). In light of this new information, prostate cancer may 
not be caused by mutations in genes but instead by mutations in regulatory regions. 
The original reports did not divide material into familial versus sporadic cases. how-
ever, in a study by wang et al. (2007), a stronger association with 8q24 was found in 
familial cases of prostate cancer (wang et al. 2007). In a study by Suuriniemi et al. 
(2007), a genetic variant at locus 8q24 is a strong risk factor for aggressive prostate 
cancer (Suuriniemi et al. 2007). In addition, a meta-analysis by cheng et al. (2008) 
suggested that 10 tested SnPs in 8q24 would increase the risk of prostate cancer up to 
50% (cheng et al. 2008). The 8q24 association has been recently verified in a meta-
analysis of genome-wide and replication association studies (Liu et al. 2010).  
3.4 candidate gene studies in prostate cancer
The candidate gene approach can be used to confirm prostate cancer susceptibility 
genes. In general, these studies rely on previous evidence obtained from other stud-
ies. candidate gene studies may include genes that have been linked to other cancers 
or cancer syndromes or even genes involved in oestrogen or androgen metabolism, 
inflammation or dnA repair pathways. Analyses of dnA repair pathway genes are 
based on the assumption that cancer arises from problems in a cell’s ability to repair 
dnA damage. examples of such genes previously investigated in finnish prostate 
cancer patients are MSR1, CHECK2, KLF6 and ARLTS1 (Seppälä et al. 2003a, Sep-
pälä et al. 2003b, Seppälä et al. 2007, Siltanen et al. 2008). 
3.4.1 PALb2 partner and localiser of brcA2
dnA repair pathway genes play an undisputed role in cancer progression, and inherited 
mutations in these genes have been strongly associated with different cancers. dnA 
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repair mechanisms are critical to prevent accumulation of dnA damage and maintain 
stability (Agalliu et al. 2007). BRCA1 and BRCA2 are both tumour suppressor genes 
involved in dnA repair. Mutations in these genes predominantly predispose carriers 
to breast and ovarian cancers, though potential links to prostate cancer have also been 
studied for both genes. Multiple studies have shown that mutations in BRCA2 lead to 
an increased risk of developing prostate cancer (friedenson et al. 2005, Sigurdsson et 
al. 1997).  however, finnish BRCA1 and BRCA2 founder mutations are not associated 
with prostate cancer predisposition among finnish prostate cancer patients (Ikonen et 
al. 2003), but an increased risk of prostate cancer has been observed in finnish breast 
cancer families carrying BRCA2 mutations (eerola et al. 2001).
 PALB2 is a recently discovered BrcA2-binding protein. The BrcA2-PALB2 
interaction is essential for BrcA2-mediated dnA repair.  Two independent stud-
ies have recently reported that biallelic truncating mutations in PALB2 cause a new 
type of fanconi anaemia (Xia et al. 2006, reid et al. 2007).  fanconi anaemia is an 
autosomal or X-linked recessive genetic disorder characterised by developmental 
defects, susceptibility to cancer at young age, bone marrow failure and early mortal-
ity.  family histories of fanconi anaemia patients also indicate an increased risk for 
adulthood cancers among monoallelic mutation carriers.  This observation has been 
confirmed in several studies showing that truncating monoallelic PALB2 mutations 
are associated with an increased risk of breast cancer (erkko et al. 2007, Xia et al. 
2007, rahman et al. 2007, foulkes et al. 2007, Tischkowitz et al. 2007).  however, 
incomplete segregation of PALB2 mutations among affected relatives is an indication 
of a low-risk susceptibility allele, and the risk association is clearly more modest than 
that of BRCA2 monoallelic mutations (rahman et al. 2007). 
In the finnish study by erkko and colleagues (erkko et al. 2009), a novel PALB2 
founder mutation (1592delT) was identified among finnish breast cancer families. 
In addition, a truncation mutation was detected in one family with multiple cases of 
prostate cancer, indicating that it could also contribute to prostate cancer develop-
ment in the finnish population. functional studies revealed decreased dnA repair 
function in all of the cell lines where the mutation was introduced.  however, in the 
original study by erkko and colleagues (erkko et al. 2007), the prostate cancer cases 
were only screened for the c.1592delT mutation, and involvement of other cancer-
related mutations in PALB2 was not ruled out.  
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 Aims oF tHe study
The aim of the study was to investigate the genetic epidemiology of prostate cancer 
in finland. The specific aims were:
I. To determine the most parsimonious model that explains the familial segregation 
of prostate cancer in the finnish population (I).
II. To investigate clinical and histopathological characteristics in finnish familial 
prostate cancer (II). 
III. To assess whether primary non-prostate cancer tumours are associated with finn-
ish families with either clinically aggressive or nonaggressive prostate cancer (III). 
Iv. To assess whether any other PALB2 variants besides the 1592delT mutation are 
associated with increased risk of prostate cancer and provide a clinical description 
of patients with the PALB2 delT mutation (Iv).
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mAteriALs And metHods 
1. data sources
The data for this thesis were ascertained from the following sources: the finnish can-
cer registry, the Population register centre and local population registries. clinical 
information was collected from the regional hospitals where patients had undergone 
treatment and follow-up. 
Population registries have a long history in finland, where population information 
has been registered since the 1530s. currently, the finnish population information 
system is a computerised national register that contains accurate information about 
finnish citizens based on electronic personal identity codes. This database is maintained 
by the Population register centre and local register offices. finland’s population data 
registry is internationally considered to be of high quality. 
The population-based finnish cancer registry was founded in 1952 and covers 
virtually all histologically confirmed cancer diagnoses made in the past six decades. 
cancer notification to the finnish cancer registry was made obligatory by law in 
1961. reports to the cancer registry are made by three independent sources: physicians, 
hospitals and pathology laboratories. In addition, cancer-related information from death 
certificates is sent to the finnish cancer registry. The coverage of the cancer registry 
is considered to be of excellent quality, over 99% in finland (Teppo et al. 1994). 
The finnish population of five million inhabitants represents a genetically homog-
enous population with a unique gene pool useful for the study of genetic susceptibility 
to cancer and other complex diseases (de la chapelle 1993, Peltonen 1997). however, 
even among homogenous finns, substantial differences can be seen between the eastern 
and western parts of the country (Jakkula et al. 2008, Palo et al. 2009). 
Another advantage to studying the finnish population is that information from 
different registries can be linked to unique personal identity codes. Moreover, the public 
has a favourable attitude towards medical research, and registries of the national health 
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care system are well organised and reliable. In addition, the training of clinicians is 
considered excellent, and the quality of medicine is similar throughout all of finland. 
Therefore, clinical information on diseases is comparable nationwide. 
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2. study subjects 
2.1 Probands and relatives for segregation analysis (study i)
I identified 9142 men who were newly diagnosed with prostate cancer between 1 
January 1988 and 31 december 1993, before the PSA test became available. Two non-
overlapping cohorts were established according to the age of onset of prostate cancer. 
A group of 557 men diagnosed before the age of 61 were chosen as index patients and 
designated as the early onset cohort (cohort 1). In addition, 989 men diagnosed at or 
after the age of 61 (cohort 2) were collected from three hospital regions in Mid-finland 
(Pirkanmaa) and eastern finland (north-Karelia and Kainuu).  details regarding the 
collection of population-based prostate cancer families and cancers analyses among 
first-degree relatives were published previously (Matikainen et al. 2001). Briefly, in-
formation on the birthplaces of probands was obtained from the central Population 
registry. The local registries (church parishes and local authorities) were contacted 
to obtain the names and birthplaces of their parents, siblings, spouses and children. 
The parents and siblings were followed up from parish records until death or until 
they obtained personal identification codes in 1967. Tracing of family members was 
successful for 94% of the index patients. Altogether, 10650 first-degree relatives were 
identified from the registries. Table 3 summarises the analysed cohorts. 
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Table 3. Descriptive statistics for prostate cancer cohorts in Finland. More detailed descrip-
tions of the data can be found in the original publication (I). 
Description Cohort 1 Cohort 2 Combined cohort
Probands 557 989 1546
Non-probands 3631 7019 10650
Number of affected individuals 608 1098 1706
Individuals in cohort 4188 8008 12196
Number of males 2418 (58%) 4664 (53%) 7082 (58%)
Number of females 1770 (42%) 3344 (47%) 5114 (42%)
Mean age of probands (years) 56.6 ± 3.4 74.4 ± 7.4 68.2 ±10.7
Range of age at diagnosis (years) 42 to 60.9 61 to 96 42 to 96
Mean age of affected non-probands 
(years) 70 ± 8.0 72 ± 7.8 71 ±7.9
2.2 Finnish prostate cancer families (studies ii, iii, iv)
Since January 1995, data on prostate cancer families with two or more affected cases 
have been collected in the Laboratory of cancer Genetics at Tampere university and 
Tampere university hospital, finland. Methods for collecting data on such families 
included referrals to physicians, family questionnaires sent to patients, a nationwide 
registry-based search and advertisements in newspapers, radio and television. A detailed 
description of the finnish prostate cancer family collection process was previously 
described (Matikainen et al. 2000, Matikainen et al. 2001). Since then, additional 
families were found between 1999 and 2008 and integrated into the database using 
the same methods. for studies II and III, the relatives of 202 families with prostate 
cancer were collected in the following manner: parents of the index patients, siblings of 
the index person, children of the siblings and children of the index person. follow-up 
for relatives was done from parish records and local authorities. Altogether, there were 
617 affected males in these families. Genealogical information on family members was 
confirmed from records kept by the finnish Population registry centre, parish records 
and local authorities. Medical information regarding prostate cancer was obtained 
from regional hospital records where the patient received treatment and follow-up. 
The following information was gathered: date at diagnosis, age at diagnosis, the rea-
son for diagnosis, primary PSA value, follow-up PSA values, PSA progression date, 
clinical progression, histology, who grading of tumour samples (biopsy, TurP, 
prostatectomy), Gleason grading of tumour samples, clinical and pathological TnM 
stage, primary treatment and follow-up.
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for study III, families were sorted into two groups according to the following 
clinical characteristics: age of diagnosis, primary PSA value, who grade, Gleason 
score and TnM stage at diagnosis. 
for study Iv, we utilised a group of 178 families with two or more affected 
first-degree relatives. A blood sample was analysed from the youngest affected male 
in each family. 
2.3 Pirkanmaa hospital control group (studies ii and iv)
Beginning in 1995, detailed clinical information has been collected for a population-
based group of prostate cancer patients at the department of urology at Tampere 
university hospital, the Tampere city hospital and the valkeakoski district hospital. 
for study II, a control group of 3011 men from 1996-2009 was used (1995 was left 
out because the data were not extensive). 
from 1999 onwards, a blood sample has been taken from each patient in this 
group. Patients visiting the clinic give informed consent, fill out a family questionnaire 
and donate blood samples for dnA extraction. Altogether, the coverage is over 85% 
of all prostate cancer patients treated in the Pirkanmaa hospital district since 1996. 
for study Iv, we used 285 unselected patients. Potentially interesting variants were 
verified in an additional set of 463 unselected cases. 
2.4 control samples
The population controls were blood donors from the finnish red cross in the cit-
ies of Tampere, Turku and Kuopio. Blood donors in finland are 18- to 65-year-old 
healthy volunteers. The number of controls used in this study (Iv) was 470, whereas 
760 were assessed for potentially interesting variants. 
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3. methods
3.1 dividing families into clinically aggressive and nonaggressive 
prostate cancer groups (study iii)
Prostate cancer is a common disease. even the strict criteria for identifying hereditary 
cancer families are carefully followed, a family with sporadic disease aggregation can be 
falsely classified as a hereditary prostate cancer family. Therefore, we wanted to divide 
families into two cohorts according to the clinical characteristics of the prostate cancer 
cases in each family. we collected detailed clinical characteristics from hospital records, 
including age at diagnosis, primary PSA value, who grade and tumour-node-metas-
tasis stage at diagnosis. In addition, we calculated the proportion of prostate cancer 
cases in the family by dividing the number of prostate cancer cases by the number of 
males in the family. using the collected clinical data, patients were sorted with cluster 
analysis into two groups: group 1 (clinically nonaggressive prostate cancer) and group 
2 (clinically aggressive prostate cancer). from a total of 202 families, 59 were classified 
as clinically aggressive and 143 as clinically nonaggressive.
hierarchical cluster analysis by the agglomerative method and average distance 
was used to classify families with clinically aggressive disease into a separate cohort. 
diagnostic age, primary PSA and the proportion of prostate cancer cases in the family 
were standardised to equalise variables.  
3.2 mutation analysis of PALb2 (study iv)
dnA samples from the youngest man in each family (n = 178), 285 unselected cases 
and 470 control samples were initially used for direct sequencing of the entire coding 
region and splice sites of PALB2. The gene was screened using the ABI PrISM Bigdye 
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Terminator cycle Sequencing ready reaction kit (Applied Biosystems) from unselected 
cases with Gleason scores over seven and an early age of onset. for five variants showing 
a trend toward prostate cancer association, additional direct sequencing was performed 
(PALB2 1592delT, 1674A>G, 2993G>A and 3300T>G and BRCA2 353A>G).  This 
additional analysis was done for 95 early onset aggressive cases and 368 nonaggressive 
cases with an average age of onset of 67 years. Mutation detection and loss of hetero-
zygosity analysis are described in detail in the original publication (Iv). 
The associations of different variants with prostate cancer were calculated using 
odds ratios and 95% confidence intervals, and association analyses were made using 
fisher’s exact test. Pairwise linkage disequilibrium between the three most frequently 
detected variants (1674A>G, 2293G>A and 3300T>G) in PALB2 were analysed with 
haploview 4.1. 
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4. data analysis and statistical methods
4.1 segregation analysis (study i)
complex segregation analysis was used to specifically test Mendelian inheritance of 
prostate cancer in finnish pedigrees. The reGTL program refers to the logistic version 
of the regressive module in the Statistical Analysis for Genetic epidemiology (release 
3.1). reGTL is used for segregation analysis of a censored trait such as age of onset 
of a disease. censoring means that not all individuals have experienced the disease. 
The basis of reGTL is a regressive model described by Bonney (Bonney 1986). This 
model assumes that similarity between siblings is a consequence of having the same 
parents. for our analysis, the phenotype for prostate cancer is the age of onset. for 
those with known age, the phenotype is a continuous variable that follows a logistic 
distribution probability density function, possibly after log transformation. for prostate 
cancer, only a proportion of the population are susceptible, i.e. males, and therefore 
are the only individuals to show an age of onset. The disease is binary with variable 
age of onset. reGTL makes the assumption that log-transformed age of onset follows 
a logistic distribution, as genetic and non-genetic causes are possible. 
reGTL uses five hypotheses of disease transmission (no major gene, dominant, 
recessive, codominant and environmental model) and a general model for comparison. 
Altogether, six models are estimated. The general model has no restrictions, and all 
nine parameters are estimated. for the ‘no major gene’ model, three parameters are 
estimated, and for the dominant and recessive models, five parameters are estimated 
(see original publication (I), Tables 2-4, for details). 
All models are compared to the general model. The null hypothesis states that 
there is no difference between the best model of transmission and the general model 
except those arising by chance alone. The difference with the smallest chi-squared 
value and largest p-value is closest to the general model and the most parsimonious 
48 – Sanna Pakkanen
model for disease segregation. If the p value is < 0.0001, then we reject the hypothesis 
because the model is too different from the general model. 
Maximum likelihood segregation analysis was performed on the log-transformed 
age at diagnosis of prostate cancer data, expressed as a censored trait using the reGTL 
program SAGe 3.1 (SAGe3.1. 1997). 
4.2 estimated standardised incidence risk ratio (study iii)
The follow-up analysis of cancer incidence in relatives of prostate cancer patients was 
done using the files of the finnish cancer registry. The follow-up period extended 
from January 1, 1967, to december 31, 2004. More specifically, the follow-up for 
index patients began at their first prostate cancer diagnosis. for parents of the index 
patients, follow-up began at the birth of the index patient. for the other cohort mem-
bers, follow-up began at their date of birth if it this was later than January 1, 1967. 
If the person had emigrated or died before december 31, 2004, the calculation of 
person-years ended at the earlier date. 
In an ideal situation, when using family data, we would designate the first man 
to be diagnosed with prostate cancer as the index person in any given family recruited 
to the study. otherwise, we might induce bias in defining a prostate cancer family. 
however, because the source information was occasionally incomplete and showed a 
large amount of variability, we calculated familial standardised incidence ratios (SIrs) 
in two ways. In the single-index data method (method 1), the follow-up from the date 
of prostate cancer diagnosis was excluded for one prostate case, but all other family 
members were followed-up as described above. In the multiple-index data method 
(method 2), all known prostate cancer cases were considered index patients, and fol-
low-up data prior to prostate cancer diagnosis were excluded from the analysis. The 
SIrs calculated by these two methods provide the lowest and highest possible estimates 
of the true relative risk for prostate cancer. 
The expected number o f malignancies is based on person-years at risk, gender, 
age and calendar period of the specific incidence rates in the general population. SIrs 
were calculated by dividing the observed numbers of malignancies by the expected 
numbers. exact 95% confidence intervals were defined, assuming that the number of 
observed cases followed a Poisson distribution. 
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4.3 statistical analysis
comparisons between clinical information were calculated using Student’s t-test, the 
Mann-whitney u test and the Pearson’s chi-squared test. 
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5. ethical considerations
Permission to utilise finnish cancer registry data in the studies of this thesis was 
granted by the Ministry of health and Social Affairs (dnro 59/08/95) and ethics com-
mittee of Tampere university hospital (95062). Prostate cancer family data collection 
was approved by the Ministry of health and Social Affairs local ethics committees 
of regional hospitals. written informed consent was obtained from all patients and 
relatives who gave blood samples for study Iv. 
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resuLts
1. segregation model for prostate cancer in Finland
1.1 cohort 1: 557 early onset prostate cancer families
In the early onset prostate cancer cohort, the ‘no major gene’ model gave a poor fit to 
the data. It was rejected against the general unrestricted model in which all parameters 
were estimated based on the likelihood ratio test (p < 0.005). In addition, the dominant 
(p = 0.0014), codominant (p = 0.036) and environmental (p = 0.0082) models were all 
rejected compared to the general model. The final general model reported was almost 
identical to the recessive Mendelian model (p = 0.83). Akaike’s information criteria, 
which take into account the number of parameters estimated, also confirmed that the 
recessive model was the most parsimonious. The predicted mean age at diagnosis for the 
high-risk homozygous carriers of the putative risk allele (AA individuals) was 60 years, 
whereas the age at diagnosis for heterozygous AB and BB non-carriers was estimated 
to be 65 years. under this Mendelian recessive model, the cumulative probability that 
a male in finland would be affected by prostate cancer by age 70 was 0.92 for carriers 
and 0.79 for non-carriers. This result implies that if carriers and non-carriers did not 
die from competing causes, the estimated risk of being diagnosed with prostate cancer 
at age 70 for homozygous carriers of the deleterious allele (q = 0.054) would be 2.7 
per 1000 among a hypothetical cohort of 100 000 men. 
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1.2  cohort 2: 989 late onset prostate cancer families
for the late onset prostate cancer family cohort, the unrestricted general model, the 
‘no major gene model’, the Mendelian dominant model and the environmental model 
did not fit the data and were rejected at p < 0.001. The Mendelian codominant model 
was also rejected by a p-value of 0.006. The recessive model was the most parsimonious 
model according to the likelihood ratio test (p < 0.15 for 4df ), and it also had the lowest 
Akaike’s information criteria value (1331.10). under this recessive model, inheritance 
of a putative high-risk allele A with an allele frequency (± Se) of 0.086 (± 0.006) gave 
predicted mean ages of onset of 66 years for men with the AA genotype and 72 years 
for AB/BB males.  The lifetime risk of being diagnosed with prostate cancer under this 
model was 5.0 per 1 000 among a hypothetical cohort of 100 000 men.
1.3 combined cohort 1 and cohort 2: 1 546 prostate cancer 
families
The combined cohort gave similar parameters as those obtained from cohort 2. All 
models except the Mendelian recessive model were rejected when compared with the 
unrestricted general model. The recessive model was the most parsimonious model 
according to the likelihood ratio test (p <0.07 for 4df ), and it also had the lowest 
Akaike’s information criteria value (1795.12). under this recessive model, inheritance 
of a putative high-risk allele A with an allele frequency (± Se) of 0.0903 (± 0.005) gave 
predicted mean ages of onset of 64 years for men with the AA genotype and 71 years 
for men with the AB/BB genotypes. with a cumulative risk of 0.80 for homozygous 
carriers of the A allele at age 70 years, the estimated risk of being diagnosed with 
prostate cancer in the absence of competing causes of death was 6.5 per 1 000 among 
a hypothetical cohort of 100 000 men.
Profiling of High-risk Prostate Cancer Families in Finland – 53
2. clinical characteristics of Finnish familial 
prostate cancer
The mean age at diagnosis of prostate cancer was 68 years (Sd 9.0, range 43-98), 
and the mean year of diagnosis was 1992 (Sd 9.3, range 1962-2006). The primary 
median PSA value was 16 (Quartile deviation (Qd) 17; range 0.8-11000), and the 
mean year in which PSA levels were measured was 1997 (Sd 4.2, range 1988-2006). 
histologically, 95% (n = 537) of the males had adenocarcinoma, 4.9% (n = 28) had 
unclassified carcinoma and the histology was unknown in 8.4% (n = 54) of the cases. 
Table 4 summarises the clinical and histopathological parameters of finnish familial 
prostate cancer. 
Table 4. Clinical and histopathological characteristics of 617 Finnish familial prostate can-
cer cases. n = the number of data points available for different variables. * = transurethral 
resection of the prostate. 
Year of Diagnosis (n = 617)
Mean, median (range) 1992, 1994 (1962-2006) 
Standard deviation 9.3 
Age at Diagnosis (n = 617)
Mean, median (range) 68, 68 (43-98) 
Standard deviation 9.0
Primary PSA value (n = 416)
Mean, median (range) 134, 16 (0.8-11000)
Standard deviation 672
Year when primary PSA was taken (n = 416)
Mean, median (range) 1997, 1997 (1988-2006)
Standard deviation 4.2
Reason for diagnosis (n = 533) 
Symptoms 313 (51%)
Elevated PSA 173 (28%)
TURP* 47 (8%)
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First treatment (n = 531) Surgical castration 167 (27%)
 
Prostatectomy 149 (24%)
Chemical castration 68 (11%)
Radiation therapy 60 (10%)
Active surveillance 41 (7%)
Antiandrogen treatment 16 (3%)
Brachytherapy 8 (1%)
PSA Progression
Yes 106 (17%)
No 299 (48%)
Unknown 212 (34%)
Clinical progression
Distant progression 77(12%)
Local progression 66 (11%)
WHO grading in biopsy samples 
(n = 477)
Well differentiated 158 (33%)
Moderately differentiated 53 (11%)
Poorly differentiated 53 (11%)
Gleason grading in biopsy sample (n = 202)
Gleason score 2-5 86 (42%)
Gleason score 6-7 98 (48%)
Gleason score 8-10 3 (10%)
WHO grading in prostatectomy samples (n 
= 135)
Well differentiated 32 (24%)
Moderately differentiated 94 (70%)
Poorly differentiated 9 (7%)
Gleason grading in prostatectomy samples 
(n = 101) 
Gleason score 2-5 55 (54%)
Gleason score 6-7 41 (41%)
Gleason score 8-10 5 (5%)
TNM stage for prostatectomy patients (n = 
142)
Clinically unapparent (T1) 3 (2%)
Within prostate confined (T2) 96 (68%)
Over prostate extending (T3) 42 (30%)
No lymph node metastasis N0 130 (92%)
Lymph node metastasis N1 6 (4%) 
TNM stage provided by the urologist (n = 546)
Clinically unapparent (T1) 158 (29%)
Within prostate confined (T2) 145 (27%)
Over prostate extending (T3) 193 (35%)
Fixed tumour (T4) 50 (9%)
Metastasis (M1) 103 (17%)
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Altogether, 52% (323/617) of the biopsy samples were recollected and reclassifi ed. The 
reasons for missing information included missing samples (75%, n = 227), diagnosis 
made from a TurP sample (17%, n = 44), diagnosis made from a cytological sample 
(5%, n = 15), diagnosis made from a prostatectomy sample (2%, n = 5), diagnosis made 
from metastasis (1%, n = 2) and diagnosis made during an autopsy (0.4%, n = 1)). 
we reanalysed 301 original samples with who grading and 160 original samples 
with Gleason scores. when comparing the old and new biopsy samples, similar trends 
in who and Gleason grading patterns were seen, though the older grading was less 
aggressive. Statistical analyses were done using the paired T-test. The newly graded 
who values were signifi cantly different from the original graded values, with p = 
0.000 (correlation coeffi cient of 0.74; the difference between original and regraded 
samples was 0.26, with a 95% confi dence interval of 0.31-0.21)). Similarly, the Gleason 
grading pattern showed a remarkable change, with p = 0.000 (correlation coeffi cient 
of 0.90; the difference in mean score was 0.87, with a 95% confi dence interval of 
0.77-0.97). figures 11a and b show how the biopsy sample grading pattern shifted 
to more aggressive values. 
Figure 11a. Original and regraded WHO grades from 323 men in Finnish prostate cancer 
families.  
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Figure 11b. Original and regraded Gleason scores from 160 men in Finnish prostate can-
cer families. 
when comparing the regraded who and Gleason scores to the population-based 
Pirkanmaa hospital cohort of 3011 prostate cancer patients (excluding the males 
belonging to prostate cancer families), the family samples showed a lower grade in 
diagnostic biopsy samples. This difference was statistically signifi cant, with a p-value 
of 0.007 for the who grade and 1.0 X 10-5 for the Gleason score.  figures 12 a and 
b show the differences in who and Gleason grades between these two groups. 
Figure 12a. Distribution of WHO grades between cases of familial prostate cancer and the 
population-based Pirkanmaa hospital cohort of 3011 men. 
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Figure 12b. Distribution of Gleason scores between cases of familial prostate cancer and 
the population-based Pirkanmaa hospital cohort of 3011 men. 
Men with familial prostate cancer had a signifi cantly higher PSA level, with a p-value 
of 9.9 x 10-6 (Student’s t-test). In addition, the tumour (T) and nodal (n) stages of 
men who underwent radical prostatectomy were compared between men with famil-
ial prostate cancer (n = 139) and the population-based Pirkanmaa hospital cohort 
(n = 1133). Tumour stage was compared using combined groups of T1, T2 and T3. 
familial samples had a larger proportion of T2-stage diseases (familial 69% vs. PIr 
65%), whereas the population-based Pirkanmaa cohort had more T3-stage diseases 
(familial 29% vs. PIr 34%) (figure 12c). differences in T or n stages between these 
two groups were not statistically signifi cant (Mann-whitney u test).  There was no 
difference in cancer-specifi c survival rates between the two cohorts.
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Figure 12c. Tumour stages in men with familial prostate cancer and men in the Pirkanmaan 
hospital control group. 
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3. cancer risks in clinically aggressive and   
nonaggressive prostate cancer families
There were a total of 497 malignancies among the 3,902 members of the clinically 
nonaggressive prostate cancer families and the 1,621 members of the 59 clinically ag-
gressive families. Table 5 describes the numbers of observed and expected cancer cases 
obtained using methods 1 and 2. 
Table 5. Numbers of observed and expected cancer cases with methods 1 and 2 in clini-
cally nonaggressive and aggressive prostate cancer families. 
Clinically nonaggressive prostate cancer families
 observed cancer cases expected cancer cases SIR 95% CI
Men, method 1 364 211 1.7 1.6-1.9
Men, method 2 151 180 0.8 0.7-1.0
Women 133 140 1.0 0.8-1.1
Clinically aggressive prostate cancer families
 observed cancer cases expected cancer cases SIR 95% CI
Men, method 1 188 97 1.9 1.7-2.2
Men, method 2 83 79 1.1 0.8-1.3
Women 72 96 1.1 0.8-1.3
we observed a significantly increased risk of gastric cancer among women in clinically 
nonaggressive prostate cancer families (SIr 1.9, cI 1.0-3.2). Among men, there was less 
lung cancer than expected (SIr 0.4, 0.2-0.6, method 1 and SIr 0.5, 0.4-1.1, method 
2). when analysing males and females separately, males presented more cases of gall 
bladder cancer (obs 3, SIr 4.1, cI 0.8-11.8 method 1, obs 3, SIr 5.1, cI 1.0-14.9), 
while females had more cases of liver cancer (obs 3, SIr 4.8, cI 1.0-14.0).  
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Altogether, there were 479 cases of cancer in the 202 families. Some people had 
more than one malignancy. Sixty individuals had two malignancies, and six individuals 
had three. forty-one individuals had prostate cancer as one of the cancers. 
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4. PALb2 variants in hereditary and unselected 
Finnish prostate cancer cases
Probands from 178 finnish hereditary prostate cancer families and 285 unselected 
cases were screened for PALB2 mutations. Six variants were found among the coding 
regions and exon-intron boundaries of PALB2. All of the variants have been previ-
ously described (erkko 2007), and only the truncating mutation (c.1592delT) has 
been shown to have functional consequences for the dnA damage response. The as-
sociation of four detected variants (c.1592delT, 1674A>G, 2993G>A and 3300T>G) 
with prostate cancer was assessed in more detail in a larger set of unselected cases (n = 
463). The truncating c.1592delT mutation was detected in one control sample and 
two sporadic cases in addition to the previously described family number 310.  Inter-
estingly, family 310 has lately been found to also harbour predispositions to stomach 
and skin cancer in addition to earlier described breast cancer predisposition. Three 
of the detected variants, 1674A>G in exon 4, 2993G>A in exon 9 and 3300T>G in 
exon 12, co-existed in 6/178 familial samples (or 1.52 cI 95% 0.6-3.9), 20/748 
unselected cases (or 1.20 cI 95% 0.6-2.3) and in 17/760 of the controls, showing 
no statistically significant difference between the sample sets. 
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discussion
Prostate cancer is a major health problem in the western world, and the economic 
burden of the disease is substantial and growing. The number of newly diagnosed cases 
has been increasing since 1990. demographic trends in the next 20 years will exacerbate 
the effects of the disease epidemiology by increasing the population of older men at risk 
for prostate cancer. new diagnostics and therapeutic procedures are needed, though 
these will put additional demands on our research and health care resources. 
This thesis studied the mode of inheritance of prostate cancer and the clinical and 
histopathological characteristics of familial prostate cancer in finland.  The special 
characteristics that made this study possible relate to the fairly homogenous finnish 
population, the standardised health care system and various comprehensive registries. 
These features have made it possible to collect family history data that are registry-based 
and genealogically confirmed. In addition, the excellent health care services in finland 
provide detailed patient registries, enabling the use of clinical and histopathological 
information on diseases and a registry-based approach rather than needing to rely on 
solely patient interviews.  
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1. the mode of inheritance
The familial clustering of prostate cancer has been well documented (Morganti et al. 
1956). Previous segregation analyses suggested different inheritance patterns, from 
Mendelian inheritance (dominant, recessive with X-linked components, codominant) 
to multifactorial inheritance (carter et al. 1992, Grönberg et al. 1997, cui et al. 2001, 
cong et al. 2002). In most of the previous studies, probands have been selected from 
hospital-based radical prostatectomy patients presenting with primarily localised dis-
ease. This has led to a subgroup of patients not representative of all prostate cancer 
cases in the population.  The aim of our study was to assess the basis for the observed 
familial aggregation of histologically confirmed familial prostate cancer in a large 
population-based cohort in finland. 
In our population-based segregation analysis (Study I), the inheritance of prostate 
cancer in the finnish population was best explained by a Mendelian recessive model 
with a significant paternal regressive coefficient indicative of a polygenic multifacto-
rial component. These results suggest that prostate cancer inheritance in multiplex 
families is controlled by major genes. This is the first time a recessive model has been 
suggested to fit all of the data, even when divided into early and late onset cohorts. This 
is in line with our previous genetic epidemiological analyses, where X-linked recessive 
inheritance was shown to be an important contributor to hereditary prostate cancer, 
especially in finland (Schleutker et al. 2000). however, the results of the segregation 
analysis need to be considered carefully because the analysis was performed with dif-
ferent data and the program can give variable results. 
A recent study by MacInnis et al. (2010) investigated genetic models of susceptibil-
ity to prostate cancer using segregation analyses of occurrence in families ascertained 
through a population-based series totalling 4390 cases. Their analyses indicated that 
one or more genes have a strong recessively inherited effect of risk and that a number 
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of other genes have variants with small multiplicative effects of risk, confirming our 
previous results (MacInnis et al. 2010). 
Because multiple different modes of inheritance of prostate cancer have been pro-
posed, prostate cancer is most likely caused by a number of genes, each with different 
modes of inheritance, population frequencies and penetrance. reliable estimates of 
gene frequencies and penetrance cannot be made until the genes have been identified 
and the frequencies of mutations have been screened at the population level.
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2. clinical and histopathological characteristics
Previous studies published on the clinical characteristics of familial prostate cancer 
have used variable selection criteria for selecting familial prostate cancer families. In 
addition, the collection of three generations is demanding due to the structure of the 
health care system and population registration methods. hereditary cancers are char-
acterised as having an earlier age of onset, a more aggressive form of the disease and 
aggregation of cancer across several generations in a family. The earlier age of onset of 
familial prostate cancer has been published in many studies (carter et al. 1993, Grön-
berg et al. 1997b, norrish et al. 1999, Bratt et al. 1999, valeri et al. 2000, Ahaghotu 
et al. 2004). More contradictory findings have been published for other clinical and 
histopathological characteristics. 
one challenge inherent in family studies is the long study period, which can exceed 
a hundred years in three-generation families. clinical practices have changed remarkably 
in the past century. The Gleason grading system was introduced over 40 years ago, but 
it remains one of the most powerful prognostic factors available (Gleason 1966). The 
system was updated in 2005 to address a trend in practice towards a grading shift that 
rarely used Gleason patterns 1 and 2 or Gleason scores of 2-4 (epstein. 2010). In our 
study (Study II), we wanted to overcome this problem of non-comparable samples. 
we collected all of the diagnostic biopsy samples and had them re-evaluated by the 
same experienced uropathologist. As hypothesised, the differences between the original 
and reanalysed who and Gleason grading scores of biopsy samples were large and 
statistically significant. 
however, the year of prostate cancer diagnosis in the control dataset (1996-2009) 
has a different range than that of the family data (1962-2006). This means that the 
control patients were more likely to have been exposed to PSA screening, and thus, 
their cancers were likely detected at an earlier stage of the disease. In addition, we 
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were not able to reanalyse the biopsy samples in control data; the histological scores 
for these samples were likely lower than they would have been if regraded. 
Prior studies investigating primary differences in PSA levels between familial 
and sporadic prostate cancer cases most often reported no difference between groups 
(Keetch et al. 1996, Grönberg et al. 1997b, Bauer et al. 1998, valeri et al. 2000, 
Ahaghotu et al. 2004, Spangler et al. 2005, roehl et al. 2006). however, Siddiqui 
et al. (2006) observed higher primary PSA levels in cases of familial prostate cancer 
(Siddiqui et al. 2006). Most of the previous studies were done on prostatectomy pa-
tients with more localised disease as opposed to population-based data. In our study 
(Study II), a significantly higher primary PSA level was observed among the familial 
prostate cancer patients. 
Previously published studies assessing differences between the grades of sporadic 
and familial prostate cancer cases usually reported no differences (Bastacky et al. 1995, 
Kupelian et al. 1997, Bauer et al. 1998, valeri et al. 2000, Bratt 2002, roehl et al. 
2006, Siddiqui et al. 2006). I found that the familial prostate cancers displayed a higher 
grade and were more likely to have metastasised to lymph nodes and bone compared 
to the unselected patient series, but there was no difference in cancer-specific survival 
(Study Iv). however, these findings have to be considered carefully due to the differ-
ences between the family and control data. The most valuable aspect of this study is 
the clinical and histopathological description of the finnish prostate cancer families. 
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3. other cancers in Finnish prostate cancer families
In our nationwide prostate cancer family study, the incidence of non-prostate cancer 
malignancies was not higher than that in the greater finnish population, with the 
exception of gastric cancer in women. we tested numerous associations and found 
increased risks of liver cancer in women and gallbladder cancer in men from clinically 
aggressive prostate cancer families. 
Previously, Isaacs et al. (1995) reported prostate cancer to be relatively site-specific 
and that prostate cancer families only show an increased risk of developing cancers 
of the central nervous system (Isaacs et al. 1995). Subsequent studies have published 
contradictory results, finding aggregation of breast, gastric, colon, rectum, gallbladder 
or kidney cancer in addition to multiple myeloma, non-hodgkin’s lymphoma and 
melanoma (Grönberg et al. 2000, valeri et al. 2000, Albright et al. 2005, hemminki 
at al. 2005). however, only the Swedish and utah studies were performed in a popula-
tion-based manner (Isaacs et al. 1995). 
we observed an increase in gastric cancers among female members of prostate 
cancer families (Study III). In a previous finnish population-based study, an increased 
risk of gastric cancer was detected among male relatives of early onset prostate cancer 
patients (Matikainen et al. 2001). e-cadherin (CDH1) has been suggested as a poten-
tial gene underlying prostate and gastric cancer aggregation (Ikonen et al. 2001), but 
further studies are needed to explain the association between these two cancers. 
Previous epidemiological identified a coaggregation of prostate and breast cancers 
(Thiessen 1974, Tulinius et al. 1992). In our analysis of clinically aggressive prostate 
cancer families, female relatives under 40 years of age had increased risks of breast and 
ovarian cancer. This association can be partially explained by the presence of recog-
nised cancer-predisposing genes; for example, BRCA2 has been implicated in prostate 
cancer predisposition in some populations (Baffoe-Bonnie et al. 2002, edwards et al. 
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2003). It is likely that mutations in BRCA1/2 pathway genes can cause malignancies 
at multiple cancer sites (Breast cancer linkage consortium 1999). 
Some of the differences between the aforementioned publications can be explained 
by the difficulty of identifying hereditary prostate cancer populations and all malignan-
cies exhibited by relatives. In addition, differences in cancer aggregation and clinical 
phenotypes among the populations studied might reflect different genetic backgrounds 
and heterogeneity of germline mutations among populations. 
In summary, we did not detect a general elevation in malignancies in prostate 
cancer families in finland. furthermore, the risk of developing other cancers did not 
appear to be related to the clinical and histopathological characteristics of familial 
prostate cancer cases. In addition, the profile of related cancers and risk genes for 
hereditary prostate cancer families may differ between populations. 
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4. Genetic loci predisposing to prostate cancer 
in Finland 
Prompted by the previous observation that the truncating founder mutation PALB2 
1592delT segregated in a finnish family (family 310) with four prostate cancer cases, 
we wanted to determine whether other possible PALB2 mutations contributed to 
prostate cancer susceptibility. Six previously described variants were identified in 
the coding region and exon-intron boundaries of PALB2, none of which induced a 
truncation. In addition to its previously described link with breast cancer, family 310 
was also found to be predisposed to stomach and skin cancers. Interestingly, three 
of the detected PALB2 variants co-existed in six patients. A haplotype analysis was 
performed to assess whether these three variants had a stronger combined effect, but 
no association with prostate cancer was observed. 
The mitomycin c sensitivity test was previously performed for the c.1592delT 
homozygous mutation. we wanted to test whether this mutation has functional con-
sequences in a heterozygous form, as was the case in all of our patients. we exposed 
two heterozygous lymphoplastoid cell lines with c.1592delT to mitomycin c. In both 
cell lines, mitomycin c-induced growth inhibition was observed, suggesting PALB2 
haploinsufficiency. 
our findings suggest that no other deleterious PALB2 variants, except the 1592delT 
mutation, contribute even marginally to prostate cancer risk in finland. variant 
2993G>A is now reported for the first time in the finnish population.  As reported 
by rahman and colleagues (rahman et al. 2007), the 2993G>A variant might damage 
protein function, based on SIfT (sorting intolerant from tolerant) analysis. eleven 
variants in PALB2 were found, but none were truncating mutations, and no associa-
tion with the disease was observed. The small amount of variation seen among finns 
likely reflects the known genetic homogeneity and founder effect of the population, 
though substantial differences between eastern and western finland do exist (de la 
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chapelle 1993, Palo et al. 2009). Although PALB2 variation does not explain familial 
aggregation of prostate cancer at a population level, it may still be important at an 
individual level. It is also possible that other genes from the BRCA1-PALB2-BRCA2 
pathway have prostate cancer-predisposing alleles. PALB2 has been found to predispose 
individuals to breast and pancreatic cancer and could thus be considered a common 
cancer-predisposing gene (eerola et al. 2001, Slater et al. 2010).  
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5. special characteristics of studying hereditary 
prostate cancer
There are a number of factors that complicate the study of prostate cancer. first, pros-
tate cancer is a common disease in the population. Autopsy studies suggest that most 
ageing men develop lesions that if detected clinically would be diagnosed as prostate 
cancer (Xu et al. 2010). due to the high frequency of prostate cancer, it is likely that 
some cases considered to be hereditary in pedigree analyses actually represent sporadic 
cases (phenocopies). Phenocopies are most likely also present in families that segregate 
a disease-predisposing mutation. 
Second, prostate cancer grows relatively slowly, with a doubling time of three to 
four years (friberg and Mattson 1997). It takes about 20-25 years for prostate cancer 
to grow from initiation to the stage at which the phenotype can be clinically detected 
(Griffiths et al. 2007). however, there is substantial variation in the spectrum of the 
clinical disease phenotype. In addition, prostate cancer is multifocal, meaning that 
the cancer might grow in several locations within the gland. finally, the wide use of 
the PSA test leads to overdiagnosis of this disease.
Third, prostate cancer has a late age of onset. The mean age of onset in finland is 
71 years. Because of this, the identification of more than two generations for molecular 
studies is difficult. More than one hundred years need to be covered to complete a 
three-generation pedigree. 
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6. Future prospects
why is the study of familial prostate cancer and prostate cancer susceptibility important? 
we hope that by extensive study of prostate cancer pedigrees and in-depth analysis and 
appreciation of other cancers and diseases that co-occur in prostate cancer families, we 
can more effectively optimise the predictive information of family history. This will 
be important for providing more clinical detail regarding the prostate cancers present 
throughout the family history. In addition, defining genes that affect prostate cancer 
risk can potentially provide otherwise unattainable insight into the mechanisms of 
prostate cancer carcinogenesis and support the identification of novel therapeutic tar-
gets. Moreover, future family studies will make use of new high-throughput sequencing 
methods and thus become more accurate and useful for gene hunting attempts. 
while progress has been made in identifying genes associated with both sporadic 
and familial cancer, there is still much to be learned. Many findings in this field have 
been difficult to replicate, possibly because prostate cancer is heterogeneous disease 
with a complex aetiology involving genetic as well as strong environmental influences 
and, inevitably, interactions between the two. It is noteworthy that the APC gene, 
which is inactivated in the majority of both familial and sporadic forms of colon cancer, 
was originally identified via studies of families with familial adenomatous polyposis 
(fAP), a syndrome that accounts for only a small fraction of colon cancers or familial 
colorectal cancer (Kinzler and vogelstein. 1996). 
As we foresaw, the genetic mechanisms that promote prostate cancer are likely to 
be complex, and it is probable that different genes are important in different popula-
tions. despite extensive efforts and a number of promising leads, no major gene that 
can be used to identify individuals at high risk for prostate cancer has been identified. 
In the light of the current data, a multigenic model provides a more likely explana-
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tion. however, once population-specific and the most relevant prognostic genes have 
been identified, it will be possible to determine the status of multiple genes in a single 
assay. It may be worthwhile to screen high-risk families for a particular susceptibility 
mutation (e.g. BRCA1 and BRCA2), but for prostate cancer, such screening may not be 
effective at a larger scale. however, a more focused analysis of clinically distinct subsets 
of prostate cancer might lend important insight into this question. once patients can 
be diagnosed at the molecular level, those patients at high risk could be identified 
earlier and provided with individual treatment and follow-up plans. 
different populations may have their own risk genes, and all nations should 
determine the impact of these genes in their populations. for example, in Poland, 
CHEK2 mutations are associated with a moderate risk for prostate cancer, larger 
than in any other population analysed (cybulski et al. 2004, cybulski et al. 2006). 
Moreover, in Iceland, a specific BRCA2 mutation accounts for most of the familial 
prostate cancer cases observed in families with excess numbers of breast cancer cases 
(Tulinius et al. 2002). 
future studies will systematically screen regulatory regions and introns as well as 
exons to determine the genetic code of common diseases. Successful interpretation 
and application of the data for public health purposes will require close cooperation 
between different experts, e.g. statisticians, geneticists and basic researchers. Though 
each malignancy harbours its own genetic structure, the mutations underlying com-
mon malignancies should be unravelled in the near future. we hope that this will 
improve the diagnostics and prognostics of cancer and lead to the development of novel 
pharmaceutical molecules. The mutation profiles in different malignancies appear to 
be extensive, thus posing challenges for the development of curative medications. In 
the future, people will know their own genetic risk profile, how to attend follow-up 
and how their diseases should be treated (personalised medicine). In addition, the 
frequency of overdiagnosis caused by excessive use of the PSA test signals the need to 
distinguish clinically mild from aggressive diseases and decrease unnecessary burdens 
on patients’ quality of life and national economics. 
despite the challenges inherent in studying cancer, the puzzle will be resolved, 
piece by piece. 
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concLusions
The present study was conducted to provide new information on the mode of inher-
itance of prostate cancer and clinical and histopathological characteristics of familial 
prostate cancer. 
The major findings of this study were:
1.  A recessive mode of inheritance is likely involved in familial prostate cancer in 
finland. 
2. Patients from finnish prostate cancer families have been clinically and histopatho-
logically described and do not significantly differ from sporadic cancers. 
3.  The overall incidence of cancer is not increased in clinically aggressive or non-ag-
gressive prostate cancer families in finland, with the exception of stomach cancer 
among female relatives.  
4.  The detected PALB2 variants do not explain the aggregation of prostate cancer at 
the population level, but some of these variants may contribute to cancer suscep-
tibility at the individual level. 
Profiling of High-risk Prostate Cancer Families in Finland – 75
AcKnowLedGements
This study was carried out at the Laboratory of cancer Genetics, Institute of Medical 
Technology, university of Tampere and Tampere university hospital during the years 
2005-2010. I wish to thank Professor olli Silvennoinen, M.d., Ph.d., head of the 
Institute of Medical Technology, and docent erkki Seppälä, M.d., Ph.d., chairman, 
department of clinical chemistry, for providing outstanding research facilities. The 
Tampere Graduate School for Biomedicine and Biotechnology (TGSBB) is acknowl-
edged for its excellent courses and travel grants. 
I want to express my deepest gratitude to my supervisors Professor Teuvo L.J. 
Tammela, M.d., Ph.d., and Professor Johanna Schleutker, Ph.d. I thank Johanna 
for the opportunity to join the research group and for introducing me to the world of 
prostate cancer genetics. Teuvo has astonished me with his devotion to urology and 
his broad knowledge on the subject. 
I wish to thank my dissertation committee members, docent Mika Matikainen, 
M.d., Ph.d., and Professor Pasi Koivisto, M.d., Ph.d., for guidance, criticism and 
help with this project. 
The official reviewers, Professor Jaakko Kaprio, M.d., Phd and Associate Profes-
sor ola Bratt, M.d., Phd are thanked for their valuable comments. 
I wish to thank my co-authors for their professional help and editing the publica-
tions. In particular, I want to thank Professor eero Pukkala, Ph.d., for persistently 
guiding me through the statistical and epidemiological challenges of studying cancer. 
I also want to thank Tiina wahlfors, Ph.d., for guidance and co-work, especially in 
the PALB2 project; we learned a great deal about science and ourselves. I also thank 
Mika Matikainen, M.d., Ph.d., who initiated the research project that I was fortunate 
enough to continue, and Professor Pasi Koivisto M.d., Ph.d., who has taught me 
that there is life outside work, and Paula Kujala, M.d., Ph.d., for warm guidance in 
pathology.
76 – Sanna Pakkanen
Special thanks also to co-authors ha nati, M.Sc., and heidi Kainulainen for their 
support with the statistical analyses, and to Sanna Siltanen and Mimmi Patrikainen 
for their contributions to these projects. 
Special thanks also to our collaborators at the national Institutes of health, Joan 
Bailey wilson, Ph.d., Agnes Baffoe Bonnie, M.d., Ph.d., Shenal deshmukh and 
Liang ou. 
I am very grateful to friends at the lab of cancer Genetics, present and past 
members of PIGs, Tarja Ikonen, Ph.d., eija Seppälä, Ph.d., henna Mattila, Ph.d., 
Sanna Siltanen, M.Sc., nina Mononen, Ph.d., Annika rökman, Ph.d., Ms. Linda 
enroth, Ms. Minna Sjöblom, Kirsi Kuusisto, M.Sc., riikka nurminen, M.Sc., , 
Kimmo Ivori, M.Sc., Martin Schindler, Ph.d., Jarkko Isotalo, Ph.d., and daniel 
fischer, M.Sc. warmest thanks go to Mrs. riitta vaalavuo for great conversations 
and for looking after me. 
I wish to thank all of my great friends, especially noora, eriika and “the Gourmee 
girls” in addition to drs. Mari uotila, riikka Tähtinen and Irina rimon. I am grateful 
for drs. Kari Tikkinen and Teemu Murtola for conversations and great company at 
scientific meetings.  I want to also thank my employer, Attendo Medone, for being 
flexible during the years of my thesis project, and especially my work friends eveliina 
huurre, hanna Polso, Terhi Solasaari and Merja Inkinen. 
My deepest thanks go to my family, my mother Pirkko, father veijo and sister 
Satu and her family. Life has its turning points, and I want to thank you for always 
being there for me. without you, I would not stand on my own feet. I love you all 
very much. 
finally, I want to thank Johan for bringing love into my life and proving that 
fairy tale princes do exist in real life. 
I also wish to express my sincere gratitude to all of the patients and their family 
members who volunteered to participate in the study. 
The primary financial supporter of this study was the Lindell foundation. In 
addition, the Pirkanmaa cancer Society, the finnish cancer Society, the Medical 
research foundation of Tampere university hospital and the university of Tampere, 
the Maud Kuistila foundation, the Päivikki and Sakari Sohlberg foundation and the 
finnish Medical Society duodecim are thanked for their financial support. 
Profiling of High-risk Prostate Cancer Families in Finland – 77
references
Adriole GL, Bostwick dG, Brawley ow, Gomella LG, Marberger M, Montorsi f, Pettaway 
cA, Tammela TL, Teloken c, Tindall dJ, Somerville Mc, wilson Th, fowler IL, 
rittmaster rS. (2010): effect of dutasteride on the risk of prostate cancer. n engl J 
Med. 362:1192-202
Agalliu I, Kwon eM, Zadory d, McIntosh L, Thompson J, Stanford JL and ostrander eA 
(2007): Germline mutations in the BrcA2 gene and susceptibility to hereditary 
prostate cancer. clin.cancer res. 13:839-843
Ahaghotu c, Baffoe-Bonnie A, Kittles r, Pettaway c, Powell I, royal c, wang h, vijayaku-
mar S, Bennett J, hoke G, Mason T, Bailey-wilson J, Boykin w, Berg K, carpten 
J, weinrich S, Trent J, dunston G and collins f (2004): clinical characteristics of 
African-American men with hereditary prostate cancer: the AAhPc Study Prostate 
cancer. Prostatic dis. 7:165-169
Ahlbom A, Lichtenstein P, Malmstrom h, feychting M, hemminki K and Pedersen nL 
(1997): cancer in twins: genetic and nongenetic familial risk factors. J.natl.cancer 
Inst. 89:287-293
Albright LA, Schwab A, camp nJ, farnham JS and Thomas A (2005): Population-based risk 
assessment for other cancers in relatives of hereditary prostate cancer (hPc) cases. 
Prostate 64:347-355
Altshuler d, daly MJ and Lander eS (2008): Genetic mapping in human disease. Science 
322:881-888
Altekruse Sf, Kosary cL, Krapcho M, neyman n, Aminou r, waldron w, ruhl J, how-
lader n, Tatalovich Z, cho h, Mariotto A, eisner MP, Lewis dr, cronin K, chen 
hS, feuer eJ, Stinchcomb dG, edwards BK (2009):  Seer cancer Statistics re-
view, 1975-2007, national cancer Institute. Bethesda, Md, at http://seer.cancer.
gov/csr/1975_2007/
American cancer Society (2009): cancer facts and figures at www.cancer.org
Amundadottir LT, Thorvaldsson S, Gudbjartsson df, Sulem P, Kristjansson K, Arnason S, 
Gulcher Jr, Bjornsson J, Kong A, Thorsteinsdottir u and Stefansson K (2004): 
cancer as a complex phenotype: pattern of cancer distribution within and beyond 
the nuclear family. PLoS Med. 1:e65
Baffoe-Bonnie AB, Kiemeney LA, Beaty Th, Bailey-wilson Je, Schnell Ah, Sigvaldason h, 
olafsdottir G, Tryggvadottir L and Tulinius h (2002): Segregation analysis of 389 
Icelandic pedigrees with Breast and prostate cancer. Genet.epidemiol. 23:349-363
Balkwill f and Mantovani A (2001): Inflammation and cancer: back to virchow? Lancet 
357:539-545
Bastacky SI, wojno KJ, walsh Pc, carmichael MJ and epstein JI (1995): Pathological fea-
tures of hereditary prostate cancer. J.urol. 153:987-992
Bauer JJ, Srivastava S, connelly rr, Sesterhenn IA, Preston dM, McLeod dG and Moul Jw 
(1998): Significance of familial history of prostate cancer to traditional prognostic 
variables, genetic biomarkers, and recurrence after radical prostatectomy. urology 
51:970-976
Bonney Ge (1986): regressive logistic models for familial disease and other binary traits. 
Biometrics 42:611-625
78 – Sanna Pakkanen
Bosland Mc (2000): The role of steroid hormones in prostate carcinogenesis. J.natl.cancer.
Inst.Monogr. 27:39-66
Bostwick dG, Burke hB, djakiew d, euling S, ho SM, Landolph J, Morrison h, Sonawane 
B, Shifflett T, waters dJ and Timms B (2004): human prostate cancer risk factors. 
cancer 101:2371-2490
Bratt o (2007): what should a urologist know about hereditary predisposition to prostate 
cancer? BJu Int. 99:743-748
Bratt o (2002): hereditary prostate cancer: clinical aspects. J.urol. 168:906-913
Bratt o, Kristoffersson u, Lundgren r and olsson h (1999): familial and hereditary pros-
tate cancer in southern Sweden. A population-based case-control study. eur.J.cancer 
35:272-277
The Breast cancer Linkage consortium (1999): cancer risks in BrcA2 mutation carriers. 
J.natl.cancer Inst. 91:1310-1316
Bruner dw, Moore d, Parlanti A, dorgan J and engstrom P (2003): relative risk of pros-
tate cancer for men with affected relatives: systematic review and meta-analysis. Int.
J.cancer 107:797-803
carpten J, nupponen n, Isaacs S, Sood r, robbins c, Xu J, faruque M, Moses T, ewing c, 
Gillanders e, hu P, Bujnovszky P, Makalowska I, Baffoe-Bonnie A, faith d, Smith 
J, Stephan d, wiley K, Brownstein M, Gildea d, Kelly B, Jenkins r, hostetter G, 
Matikainen M, Schleutker J, Klinger K, connors T, Xiang y, wang Z, de Marzo 
A, Papadopoulos n, Kallioniemi oP, Burk r, Meyers d, Gronberg h, Meltzer P, 
Silverman r, Bailey-wilson J, walsh P, Isaacs w and Trent J (2002): Germline mu-
tations in the ribonuclease L gene in families showing linkage with hPc1. nat.
Genet. 30:181-184
carter BS, Beaty Th, Steinberg Gd, childs B and walsh Pc (1992): Mendelian inheritance 
of familial prostate cancer. Proc.natl.Acad.Sci.u.S.A. 89:3367-3371
carter BS, Bova GS, Beaty Th, Steinberg Gd, childs B, Isaacs wB and walsh Pc (1993): 
hereditary prostate cancer: epidemiologic and clinical features. J.urol. 150:797-
802
chang BL, Lange eM, dimitrov L, valis cJ, Gillanders eM, Lange LA, wiley Ke, Isaacs Sd, 
wiklund f, Baffoe-Bonnie A, Langefeld cd, Zheng SL, Matikainen MP, Ikonen T, 
fredriksson h, Tammela T, walsh Pc, Bailey-wilson Je, Schleutker J, Grönberg h, 
cooney KA, Isaacs wB, Suh e, Trent JM and Xu J (2006): Two-locus genome-wide 
linkage scan for prostate cancer susceptibility genes with an interaction effect. hum.
Genet. 118:716-724
cheng I, Plummer SJ, Jorgenson e, Liu X, rybicki BA, casey G and witte JS (2008): 8q24 
and Prostate cancer: Association with Advanced disease and Meta-Analysis. eur.
J.hum.Genet. 16:496-505
clark Lc, dalkin B, Krongrad A, combs Gf,Jr, Turnbull Bw, Slate eh, witherington r, 
herlong Jh, Janosko e, carpenter d, Borosso c, falk S and rounder J (1998): 
decreased incidence of prostate cancer with selenium supplementation: results of a 
double-blind cancer prevention trial. Br.J.urol. 81:730-734
conlon eM, Goode eL, Gibbs M, Stanford JL, Badzioch M, Janer M, Kolb S, hood L, os-
trander eA, Jarvik GP and wijsman eM (2003): oligogenic segregation analysis of 
hereditary prostate cancer pedigrees: evidence for multiple loci affecting age at onset. 
Int.J.cancer 105:630-635
cui J, Staples MP, hopper JL, english dr, Mccredie Mr and Giles GG (2001): Segregation 
analyses of 1,476 population-based Australian families affected by prostate cancer. 
Am.J.hum.Genet. 68:1207-1218
Profiling of High-risk Prostate Cancer Families in Finland – 79
cybulski c, Gorski B, huzarski T, Masojc B, Mierzejewski M, debniak T, Teodorczyk u, 
Byrski T, Gronwald J, Matyjasik J, Zlowocka e, Lenner M, Grabowska e, nej K, 
castaneda J, Medrek K, Szymanska A, Szymanska J, Kurzawski G, Suchy J, oszurek 
o, witek A, narod SA and Lubinski J (2004): cheK2 is a multiorgan cancer sus-
ceptibility gene. Am.J.hum.Genet. 75:1131-1135
cybulski c, wokolorczyk d, huzarski T, Byrski T, Gronwald J, Gorski B, debniak T, Masojc 
B, Jakubowska A, Gliniewicz B, Sikorski A, Stawicka M, Godlewski d, Kwias Z, 
Antczak A, Krajka K, Lauer w, Sosnowski M, Sikorska-radek P, Bar K, Klijer r, 
Zdrojowy r, Malkiewicz B, Borkowski A, Borkowski T, narod S and Lubinski J 
(2006): A large germline deletion in cheK2 is associated with an increased risk of 
prostate cancer. J.Med.Genet. 43:863-6
de la chapelle A (2004): Genetic predisposition to colorectal cancer. nat.rev.cancer. 4:769-
780
de la chapelle A (1993): disease gene mapping in isolated human populations: the example 
of finland. J.Med.Genet. 30:857-865
de Marzo AM, Meeker AK, Zha S, Luo J, nakayama M, Platz eA, Isaacs wB and nelson wG 
(2003): human prostate cancer precursors and pathobiology. urology 62:55-62
dennis LK and dawson dv (2002): Meta-analysis of measures of sexual activity and prostate 
cancer. epidemiology 13:72-79
dewailly e, Mulvad G, Sloth Pedersen h, hansen Jc, Behrendt n and hart hansen JP 
(2003): Inuit are protected against prostate cancer. cancer epidemiol.Biomarkers 
Prev. 12:926-927
divisi d, di Tommaso S, Salvemini S, Garramone M and crisci r (2006): diet and cancer. 
Acta Biomed. 77:118-123
eaton ne, reeves GK, Appleby Pn and Key TJ (1999): endogenous sex hormones and pros-
tate cancer: a quantitative review of prospective studies. Br.J.cancer 80:930-934
eble Jn, Sauter G, epstein JI and Sesterhenn IA (2004): Tumours of the urinary System and 
Male Genital organs. who Press. 159-214
eckersberger e, finkelstein J, Sadri h, Margreiter M, Taneja SS, Lepor h and djavan B 
(2009): Screening for Prostate cancer: A review of the erSPc and PLco Trials. 
rev.urol. 11:127-133
edwards SM, Kote-Jarai Z, Meitz J, hamoudi r, hope Q, osin P, Jackson r, Southgate 
c, Singh r, falconer A, dearnaley dP, Ardern-Jones A, Murkin A, dowe A, Kelly 
J, williams S, oram r, Stevens M, Teare dM, Ponder BA, Gayther SA, easton 
df, eeles rA, cancer research uK/Bristish Prostate Group uK familial Prostate 
cancer Study collaborators and British Association of urological Surgeons Section 
of oncology (2003): Two percent of men with early-onset prostate cancer harbor 
germline mutations in the BrcA2 gene. Am.J.hum.Genet. 72:1-12
eeles rA (1999): Genetic predisposition to prostate cancer. Prostatic dis. 2:9-15
eeles rA, Kote-Jarai Z, Giles GG, olama AA, Guy M, Jugurnauth SK, Mulholland S, Leon-
gamornlert dA, edwards SM, Morrison J, field hI, Southey Mc, Severi G, donovan 
JL, hamdy fc, dearnaley dP, Muir Kr, Smith c, Bagnato M, Ardern-Jones AT, hall 
AL, o’Brien LT, Gehr-Swain Bn, wilkinson rA, cox A, Lewis S, Brown PM, Jha-
var SG, Tymrakiewicz M, Lophatananon A, Bryant SL; uK Genetic Prostate cancer 
Study collaborators; British Association of urological Surgeons’ Section of oncology; 
uK ProtecT Study collaborators, horwich A, huddart rA, Khoo vS, Parker cc, 
woodhouse cJ, Thompson A, christmas T, ogden c, fisher c, Jamieson c, cooper 
cS, english dr, hopper JL, neal de, easton df (2008): Multiple newly identified 
loci associated with prostate cancer susceptibility. nat Genet. 40:316-21
80 – Sanna Pakkanen
eerola h, Pukkala e, Pyrhonen S, Blomqvist c, Sankila r and nevanlinna h (2001): risk of 
cancer in BrcA1 and BrcA2 mutation-positive and -negative breast cancer fami-
lies (finland). cancer causes control 12:739-746
eldon BJ, Jonsson e, Tomasson J, Tryggvadottir L and Tulinius h (2003): familial risk of 
prostate cancer in Iceland. BJu Int. 92:915-919
engholm G, ferlay J, christensen n, Bray f, Gjerstorff ML, Klint Å, Kotlum Je, olafsdórrir 
e, Pukkala e, Storm hh (2010): nordcAn: cancer incidence, mortality, preva-
lence, and prediction in the nordic countries, version 3.6. Association of nordic 
cancer registeries. danish cancer Society at http://www.ancr.nu.
epstein JI (2010): An update of the Gleason grading system. J.urol. 183:433-440
epstein JI (1994): Pathology of prostatic intraepithelial neoplasia and adenocarcinoma of the 
prostate: prognostic influences of stage, tumor volume, grade, and margins of resec-
tion. Semin.oncol. 21:527-541
erkko h, Xia B, nikkila J, Schleutker J, Syrjakoski K, Mannermaa A, Kallioniemi A, Pylkas 
K, Karppinen SM, rapakko K, Miron A, Sheng Q, Li G, Mattila h, Bell dw, hab-
er dA, Grip M, reiman M, Jukkola-vuorinen A, Mustonen A, Kere J, Aaltonen LA, 
Kosma vM, Kataja v, Soini y, drapkin rI, Livingston dM and winqvist r (2007): 
A recurrent mutation in PALB2 in finnish cancer families. nature 446:316-319
fearon er (1997): human cancer syndromes: clues to the origin and nature of cancer-
Science278:1043-1050
finnish cancer registry (2008): cancer incidence and mortality in finland. cancer Statistics 
at www.cancerregistry.fi
foulkes wd, Ghadirian P, Akbari Mr, hamel n, Giroux S, Sabbaghian n, darnel A, royer 
r, Poll A, fafard e, robidoux A, Martin G, Bismar TA, Tischkowitz M, rousseau 
f and narod SA (2007): Identification of a novel truncating PALB2 mutation and 
analysis of its contribution to early-onset breast cancer in french-canadian women. 
Breast cancer res. 9:r83
freedman ML, haiman cA, Patterson n, Mcdonald GJ, Tandon A, waliszewska A, Penney 
K, Steen rG, Ardlie K, John eM, oakley-Girvan I, whittemore AS, cooney KA, 
Ingles SA, Altshuler d, henderson Be and reich d (2006): Admixture mapping 
identifies 8q24 as a prostate cancer risk locus in African-American men. Proc.natl.
Acad.Sci.u.S.A. 103:14068-14073
friberg S and Mattson S (1997): on the growth rates of human malignant tumors: implica-
tions for medical decision making. J.Surg.oncol. 65:284-297
friedenson B (2005):BrcA1 and BrcA2 pathways and the risk of cancers other than breast 
or ovarian. MedGenMed 7:60
Garber Je and offit K (2005): hereditary cancer predisposition syndromes. J.clin.oncol. 
23:276-292
Gibbs M, Stanford JL, McIndoe rA, Jarvik GP, Kolb S, Goode eL, chakrabarti L, Schuster 
ef, Buckley vA, Miller eL, Brandzel S, Li S, hood L and ostrander eA (1999): 
evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. 
Am.J.hum.Genet. 64:776-787
Giovannucci e, Ascherio A, rimm eB, Stampfer MJ, colditz GA and willett wc (1995): 
Intake of carotenoids and retinol in relation to risk of prostate cancer. J.natl.cancer 
Inst. 87:1767-1776
Gittes rf (1991): carcinoma of the prostate. n.engl.J.Med. 324:236-245
Gleason df (1966): classification of prostatic carcinomas. cancer chemother.rep. 50:125-
128
Profiling of High-risk Prostate Cancer Families in Finland – 81
Glover fe,Jr, coffey dS, douglas LL, russell h, cadigan M, Tulloch T, wedderburn K, 
wan rL, Baker Td and walsh Pc (1998): familial study of prostate cancer in Ja-
maica. urology 52:441-443
Goldgar de, easton df, cannon-Albright LA and Skolnick Mh (1994): Systematic popu-
lation-based assessment of cancer risk in first-degree relatives of cancer probands. 
J.natl.cancer Inst. 86:1600-1608
Gong G, oakley-Girvan I, wu Ah, Kolonel Ln, John eM, west dw, felberg A, Gallagher 
rP and whittemore AS (2002): Segregation analysis of prostate cancer in 1,719 
white, African-American and Asian-American families in the united States and 
canada. cancer causes control 13:471-482
Griffiths K, Prezioso d, Turkes A and denis LJ (2007): The prevention of prostate cancer. 
recent results cancer res. 175:33-63
Grönberg h, Ahman AK, emanuelsson M, Bergh A, damber Je and Borg A (2001): BrcA2 
mutation in a family with hereditary prostate cancer. Genes chromosomes cancer 
30:299-301
Grönberg h, Bergh A, damber Je and emanuelsson M (2000): cancer risk in families with 
hereditary prostate carcinoma. cancer 89:1315-1321
Grönberg h, damber L, Jonsson h and damber Je (1997): Prostate cancer mortality in 
northern Sweden, with special reference to tumor grade and patient age. urology. 
49:374
Grönberg h, damber L, damber Je and Iselius L (1997a): Segregation analysis of prostate 
cancer in Sweden: support for dominant inheritance. Am.J.epidemiol. 146:552-557
Grönberg h, damber L and damber Je (1994): Studies of genetic factors in prostate cancer 
in a twin population. J.urol. 152:1484-9
Grönberg h, Isaacs Sd, Smith Jr, carpten Jd, Bova GS, freije d, Xu J, Meyers dA, collins 
fS, Trent JM, walsh Pc and Isaacs wB (1997b): characteristics of prostate can-
cer in families potentially linked to the hereditary prostate cancer 1 (hPc1) locus. 
JAMA 278:1251-1255
Grönberg h, wiklund f and damber Je (1999): Age specific risks of familial prostate car-
cinoma: a basis for screening recommendations in high risk populations. cancer 
86:477-483
Grubb rL,3rd, Pinsky Pf, Greenlee rT, Izmirlian G, Miller AB, hickey TP, riley TL, Mabie 
Je, Levin dL, chia d, Kramer BS, reding dJ, church Tr, yokochi LA, Kvale 
PA, weissfeld JL, urban dA, Buys SS, Gelmann eP, ragard Lr, crawford ed, 
Prorok Pc, Gohagan JK, Berg cd and Andriole GL (2008): Prostate cancer screen-
ing in the Prostate, Lung, colorectal and ovarian cancer screening trial: update on 
findings from the initial four rounds of screening in a randomized trial. BJu Int. 
102:1524-1530
Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson d, helgason A, 
rafnar T, Bergthorsson JT, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir 
Kr, Jakobsdottir M, Xu J, Blondal T, Kostic J, Sun J, Ghosh S, Stacey Sn, Mouy 
M, Saemundsdottir J, Backman vM, Kristjansson K, Tres A, Partin Aw, Albers-
Akkers MT, Godino-Ivan Marcos J, walsh Pc, Swinkels dw, navarrete S, Isaacs 
Sd, Aben KK, Graif T, cashy J, ruiz-echarri M, wiley Ke, Suarez BK, witjes JA, 
frigge M, ober c, Jonsson e, einarsson Gv, Mayordomo JI, Kiemeney LA, Isaacs 
wB, catalona wJ, Barkardottir rB, Gulcher Jr, Thorsteinsdottir u, Kong A and 
Stefansson K (2007): Genome-wide association study identifies a second prostate 
cancer susceptibility variant at 8q24. nat.Genet. 39:631-7
82 – Sanna Pakkanen
Gudmundsson J, Sulem P, rafnar T, Bergthorsson JT, Manolescu A, Gudbjartsson d, Agnars-
son BA, Sigurdsson A, Benediktsdottir Kr, Blondal T, Jakobsdottir M, Stacey Sn, 
Kostic J, Kristinsson KT, Birgisdottir B, Ghosh S, Magnusdottir dn, Thorlacius S, 
Thorleifsson G, Zheng SL, Sun J, chang BL, elmore JB, Breyer JP, Mcreynolds 
KM, Bradley KM, yaspan BL, wiklund f, Stattin P, Lindström S, Adami ho, Mc-
donnell SK, Schaid dJ, cunningham JM, wang L, cerhan Jr, St Sauver JL, Isaacs 
Sd, wiley Ke, Partin Aw, walsh Pc, Polo S, ruiz-echarri M, navarrete S, fuertes 
f, Saez B, Godino J, weijerman Pc, Swinkels dw, Aben KK, witjes JA, Suarez BK, 
helfand BT, frigge ML, Kristjansson K, ober c, Jonsson e, einarsson Gv, Xu J, 
Gronberg h, Smith Jr, Thibodeau Sn, Isaacs wB, catalona wJ, Mayordomo JI, 
Kiemeney LA, Barkardottir rB, Gulcher Jr, Thorsteinsdottir u, Kong A, Stefans-
son K. (2008) common sequence variants on 2p15 and Xp11.22 confer susceptibil-
ity to prostate cancer. nat Genet. 40: 281-3
haiman cA, Patterson n, freedman ML, Myers Sr, Pike Mc, waliszewska A, neubauer 
J, Tandon A, Schirmer c, Mcdonald GJ, Greenway Sc, Stram do, Le Marchand 
L, Kolonel Ln, frasco M, wong d, Pooler Lc, Ardlie K, oakley-Girvan I, whit-
temore AS, cooney KA, John eM, Ingles SA, Altshuler d, henderson Be and reich 
d (2007): Multiple regions within 8q24 independently affect risk for prostate can-
cer. nat.Genet. 39:638-44
hayes rB, Liff JM, Pottern LM, Greenberg rS, Schoenberg JB, Schwartz AG, Swanson GM, 
Silverman dT, Brown LM and hoover rn (1995): Prostate cancer risk in u.S. 
blacks and whites with a family history of cancer. Int.J.cancer 60:361-364
heinonen oP, Albanes d, virtamo J, Taylor Pr, huttunen JK, hartman AM, haapakoski J, 
Malila n, rautalahti M, ripatti S, Mäenpää h, Teerenhovi L, Koss L, virolainen M 
and edwards BK (1998): Prostate cancer and supplementation with alpha-tocophe-
rol and beta-carotene: incidence and mortality in a controlled trial. J.natl.cancer 
Inst. 90:440-446
hemminki K and chen B (2005): familial association of prostate cancer with other cancers 
in the Swedish family-cancer database. Prostate 65:188-194
hofstra rM, Spurdle AB, eccles d, foulkes wd, de wind n, hoogerbrugge n, hoger-
vorst fB and IArc unclassified Genetic variants working Group (2008): Tumor 
characteristics as an analytic tool for classifying genetic variants of uncertain clinical 
significance. hum.Mutat. 29:1292-1303
hogg A, Bia B, onadim Z and cowell JK (1993): Molecular mechanisms of oncogenic mu-
tations in tumors from patients with bilateral and unilateral retinoblastoma. Proc.
natl.Acad.Sci.u.S.A. 90:7351-7355
houlston rS and Peto J (2004): The search for low-penetrance cancer susceptibility alleles. 
oncogene 23:6471-6476
hsing Aw, Tsao L and devesa SS (2000): International trends and patterns of prostate cancer 
incidence and mortality. Int.J.cancer 85:60-67
huddart rA, rajan B, Law M, Meyer L and dearnaley dP (1997): Spinal cord compression 
in prostate cancer: treatment outcome and prognostic factors. radiother. oncol. 
44:229-236
huggins ML (1941): A new Society for X-ray and electron diffraction research workers. 
Science 93:489-490
Ikonen T, Matikainen M, Mononen n, hyytinen er, helin hJ, Tommola S, Tammela TL, 
Pukkala e, Schleutker J, Kallioniemi oP, Koivisto PA (2001) Association of e-cad-
herin gemline alterations with prostate cancer. clin cancer res.7:3465-71
Profiling of High-risk Prostate Cancer Families in Finland – 83
Ikonen T, Matikainen MP, Syrjäkoski K, Mononen n, Koivisto PA, rökman A, Seppälä 
eh, Kallioniemi oP, Tammela TL and Schleutker J (2003): BrcA1 and BrcA2 
mutations have no major role in predisposition to prostate cancer in finland. J.Med.
Genet. 40:e98
Imperial J (1999): Treatment of chronic hepatitis c virus infection: the end of an era. 
Am.J.Gastroenterol. 94:555-556
International Agency for research on cancer (2008): Prostate cancer incidence and mortality 
in finland. cancer statistics at www.iarc.fr
Isaacs Sd, Kiemeney LA, Baffoe-Bonnie A, Beaty Th and walsh Pc (1995): risk of cancer 
in relatives of prostate cancer probands. J.natl.cancer Inst. 87:991-996
Jakkula e, rehnström K, varilo T, Pietiläinen oP, Paunio T, Pedersen nL, defaire u, Järvelin 
Mr, Saharinen J, freimer n, ripatti S, Purcell S, collins A, daly MJ, Palotie A, 
Peltonen L (2008): The genome-wide patterns of variation expose significant sub-
structure in a founder population. Am J hum Genet. 83:787-94 
Keetch dw, humphrey PA, Smith dS, Stahl d and catalona wJ (1996): clinical and path-
ological features of hereditary prostate cancer. J.urol. 155:1841-1843
Khoury MJ, Beaty Th and cohen Bh (1993): fundamentals of Genetic epidemiology. 
oxford university Press, oxford. 
Kinzler Kw and vogelstein B (1996): Lessons from hereditary colorectal cancer. cell 87:159-
170
Kirby rS, Partin Aw, feneley M, Parsons JK (2006): Prostate cancer Principles and Practice. 
Taylor & francis, oxon the united Kingdom.
Knudson AG,Jr (1971): Mutation and cancer: statistical study of retinoblastoma. Proc.natl.
Acad.Sci.u.S.A. 68:820-823
Kolonel Ln (1996): nutrition and prostate cancer. cancer causes control 7:83-44
Krieger Jn and riley de (2004): chronic prostatitis: charlottesville to Seattle. J.urol. 
172:2557-2560
Kupelian PA, Kupelian vA, witte JS, Macklis r and Klein eA (1997): family history of 
prostate cancer in patients with localized prostate cancer: an independent predictor 
of treatment outcome. J.clin.oncol. 15:1478-1480
Lange eM, Gillanders eM, davis cc, Brown wM, campbell JK, Jones M, Gildea d, riede-
sel e, Albertus J, freas-Lutz d, Markey c, Giri v, dimmer JB, Montie Je, Trent 
JM, cooney KA (2003): Genome-wide scan for prostate cancer susceptibility genes 
using families from the university of Michigan prostate cancer genetics project finds 
evidence for linkage on chromosome 17 near BrcA1. Prostate 57:326-34.
Lichtenstein P, holm nv, verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala e, Skyt-
the A and hemminki K (2000): environmental and heritable factors in the causa-
tion of cancer--analyses of cohorts of twins from Sweden, denmark, and finland. 
n.engl.J.Med. 343:78-85
Lindblom A (2001): different mechanisms in the tumorigenesis of proximal and distal colon 
cancers. curr.opin.oncol. 13:63-69
Lohmueller Ke, Pearce cL, Pike M, Lander eS and hirschhorn Jn (2003): Meta-analysis of 
genetic association studies supports a contribution of common variants to suscepti-
bility to common disease. nat.Genet. 33:177-182
MacInnis rJ, Antoniou Ac, eeles rA, Severi G, Guy M, McGuffog L, hall AL, o’Brien LT, 
wilkinson rA, dearnaley dP, Ardern-Jones AT, horwich A, Khoo vS, Parker cc, 
huddart rA, Mccredie Mr, Smith c, Southey Mc, Staples MP, english dr, hop-
per JL, Giles GG and easton df (2010): Prostate cancer segregation analyses using 
4390 families from uK and Australian population-based studies. Genet.epidemiol. 
34:42-50
84 – Sanna Pakkanen
Mai KT, Isotalo PA, Green J, Perkins dG, Morash c and collins JP (2000): Incidental pro-
static adenocarcinomas and putative premalignant lesions in TurP specimens col-
lected before and after the introduction of prostate-specific antigen screening. Arch.
Pathol.Lab.Med. 124:1454-1456
Maskarinec G and noh JJ (2004): The effect of migration on cancer incidence among Japa-
nese in hawaii. ethn.dis. 14:431-439
Matikainen MP, Pukkala e, Schleutker J, Tammela TL, Koivisto P, Sankila r and Kallioniemi 
oP (2001): relatives of prostate cancer patients have an increased risk of prostate 
and stomach cancers: a population-based, cancer registry study in finland. cancer 
causes control 12:223-230
Matikainen MP, Sankila r, Schleutker J, Kallioniemi oP and Pukkala e (2000):nationwide 
cancer family ascertainment using finnish cancer registry data on family names 
and places of birth for 35,761 prostate cancer patients. Int.J.cancer 88:307-312
Matikainen MP, Schleutker J, Morsky P, Kallioniemi oP and Tammela TLJ (1999): detec-
tion of subclinical cancers by prostate-spesific antigen screening in asymptomatic 
men from high-risk prostate cancer families. clin. caner res. 5:1275-1279
Mccarthy MI, Abecasis cr, cardon Lr, Goldstein dB, Littele J, Ioannis JPA and hir-
schhorn Jn (2010): Genome-wide association studies for complex traits: consensus 
uncertainty and challenges. nat rev Genet 11:415-25
Miki y, Swensen J, Shattuck-eidens d, futreal PA, harshman K, Tavtigian S, Liu Q, co-
chran c, Bennett LM and ding w (1994): A strong candidate for the breast and 
ovarian cancer susceptibility gene BrcA1. Science 266:66-71
Morganti G, Gianferrari L, cresseri A, Arrigoni G and Lovati G (1956): clinico-statistical 
and genetic research on neoplasms of the prostate. Acta Genet.Stat.Med. 6:304-
305
Morton ne and chung cS (1978): In Genetic epidemiology. Academic Press, ny, uSA. 
narod SA and foulkes wd (2004): BrcA1 and BrcA2: 1994 and beyond. nat.rev.can-
cer. 4:665-676
neal de and donavan JL (2000): Prostate cancer: to screen or not to screen? Lancet oncol. 
1:17-24
negri e, Pelucchi c, Talamini r, Montella M, Gallus S, Bosetti c, franceschi S and La vec-
chia c (2005): family history of cancer and the risk of prostate cancer and benign 
prostatic hyperplasia. Int.J.cancer 114:648-652
nelson wG, de Marzo AM, deweese TL and Isaacs wB (2004): The role of inflammation 
in the pathogenesis of prostate cancer. J.urol.172:S6-11
norrish Ae, Mcrae cu, cohen rJ and Jackson rT (1999): A population-based study of 
clinical and pathological prognostic characteristics of men with familial and sporadic 
prostate cancer. BJu Int. 84:311-315
ohtake n, hatori M, yamanaka h, nakata S, Sada M and Tsuji T (1998): familial prostate 
cancer in Japan. Int.J.urol. 5:138-145
Page wf, Braun MM, Partin Aw, caporaso n and walsh P (1997): heredity and prostate 
cancer: a study of world war II veteran twins. Prostate 33:240-245
Palo J, ulmanen I, Lukka M, ellonen P and Sajantila P (2009): Genetic markers and popula-
tion history; finland revisited. eur J of hum Genet 17: 1336-1346
Parsonnet J, friedman Gd, vandersteen dP, chang y, vogelman Jh, orentreich n and 
Sibley rK (1991): helicobacter pylori infection and the risk of gastric carcinoma. 
n.engl.J.Med. 325:1127-1131
Peltonen L (1997): Molecular background of the finnish disease heritage. Ann.Med. 29:553-
556
Profiling of High-risk Prostate Cancer Families in Finland – 85
Phillips KA (2000): Immunophenotypic and pathologic differences between BrcA1 and 
BrcA2 hereditary breast cancers. J.clin.oncol. 18:107S-12S
rahman n, Seal S, Thompson d, Kelly P, renwick A, elliott A, reid S, Spanova K, Barfoot 
r, chagtai T, Jayatilake h, McGuffog L, hanks S, evans dG, eccles d, Breast can-
cer Susceptibility collaboration (uK), easton df and Stratton Mr (2007): PALB2, 
which encodes a BrcA2-interacting protein, is a breast cancer susceptibility gene. 
nat.Genet. 39:165-167
rebbeck Tr, walker Ah, Zeigler-Johnson c, weisburg S, Martin AM, nathanson KL, wein 
AJ and Malkowicz SB (2000a): Association of hPc2/eLAc2 genotypes and pros-
tate cancerAm.J.hum.Genet.67:1014-1019
rebbeck Tr, walker Ah, Zeigler-Johnson c, weisburg S, Martin AM, nathanson KL, wein 
AJ and Malkowicz SB (2000b):Association of hPc2/eLAc2 genotypes and pros-
tate cancer. Am.J.hum.Genet. 67:1014-1019
reid S, Schindler d, hanenberg h, Barker K, hanks S, Kalb r, neveling K, Kelly P, Seal S, 
freund M, wurm M, Batish Sd, Lach fP, yetgin S, neitzel h, Ariffin h, Tischkow-
itz M, Mathew cG, Auerbach Ad and rahman n (2007): Biallelic mutations in 
PALB2 cause fanconi anemia subtype fA-n and predispose to childhood cancer. 
nat.Genet. 39:162-164
rennert h, Zeigler-Johnson cM, Addya K, finley MJ, walker Ah, Spangler e, Leonard 
dG, wein A, Malkowicz SB and rebbeck Tr (2005): Association of susceptibility 
alleles in eLAc2/hPc2, rnASeL/hPc1, and MSr1 with prostate cancer severity 
in european American and African American men. cancer epidemiol.Biomarkers 
Prev. 14:949-957
rhodes JM and campbell BJ (2002): Inflammation and colorectal cancer: IBd-associated 
and sporadic cancer compared. Trends Mol.Med. 8:10-16
roehl KA, Loeb S, Antenor JA, corbin n and catalona wJ (2006): characteristics of patients 
with familial versus sporadic prostate cancer. J.urol. 176:2438-42; discussion 2442
rökman A, Ikonen T, Mononen n, Autio v, Matikainen MP, Koivisto PA, Tammela TL, 
Kallioniemi oP and Schleutker J (2001): eLAc2/hPc2 involvement in hereditary 
and sporadic prostate cancer. cancer res. 61:6038-6041
rökman A, Ikonen T, Seppälä eh, nupponen n, Autio v, Mononen n, Bailey-wilson J, 
Trent J, carpten J, Matikainen MP, Koivisto PA, Tammela TL, Kallioniemi oP and 
Schleutker J (2002): Germline alterations of the rnASeL gene, a candidate hPc1 
gene at 1q25, in patients and families with prostate cancer. Am.J.hum.Genet. 
70:1299-1304
ross rK and henderson Be (1994): do diet and androgens alter prostate cancer risk via a 
common etiologic pathway? J.natl.cancer Inst. 86:252-254
SAGe3.1 (1997): Statistical analysis for genetic epidemiology, release 3.1. computer pro-
gram package available from the department of epidemiology and Biostatistics. 
rammelcamp centre for education and research,  Metro health campus, case 
western reserve university, cleveland, ohio.
Schaid dJ (2004): The complex genetic epidemiology of prostate cancer. hum.Mol.Genet. 
13 Spec no 1:r103-21
Schaid dJ, Mcdonnell SK, Blute ML and Thibodeau Sn (1998): evidence for autosomal 
dominant inheritance of prostate cancer. Am.J.hum.Genet. 62:1425-1438
Schleutker J, Matikainen M, Smith J, Koivisto P, Baffoe-Bonnie A, Kainu T, Gillanders e, 
Sankila r, Pukkala e, carpten J, Stephan d, Tammela T, Brownstein M, Bailey-
wilson J, Trent J and Kallioniemi oP (2000): A genetic epidemiological study of 
hereditary prostate cancer (hPc) in finland: frequent hPcX linkage in families 
with late-onset disease. clin.cancer res. 6:4810-4815
86 – Sanna Pakkanen
Schroder fh, hugosson J, roobol MJ, Tammela TL, ciatto S, nelen v, Kwiatkowski M, Lu-
jan M, Lilja h, Zappa M, denis LJ, recker f, Berenguer A, Määttänen L, Bangma 
ch, Aus G, villers A, rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de 
Koning hJ, Auvinen A and erSPc Investigators (2009): Screening and prostate-
cancer mortality in a randomized european study. n.engl.J.Med. 360:1320-1328
Schuurman AG, Goldbohm rA, Brants hA and van den Brandt PA (2002): A prospective 
cohort study on intake of retinol, vitamins c and e, and carotenoids and prostate 
cancer risk (netherlands). cancer causes control 13:573-582
Scott r,Jr, Mutchnik dL, Laskowski TZ and Schmalhorst wr (1969): carcinoma of the 
prostate in elderly men: incidence, growth characteristics and clinical significance. 
J.urol. 101:602-607
Selman Sh (2000): “Latent” carcinoma of the prostate: a medical misnomer? urology 
56:708-711
Seppälä eh, Ikonen T, Autio v, rökman A, Mononen n, Matikainen MP, Tammela TLJ and 
Schleutker J (2003a): Germ-line alterations in MSr1 gene and prostate cancer risk. 
clin.cancer res. 9:5252-5256
Seppälä eh, Ikonen T, Mononen n, Autio v, rökman A, Matikainen MP, Tammela TLJ and 
Schleutker J (2003b): cheK2 variants associate with hereditary prostate cancer. 
Br.J.cancer 89:1966-1970
Seppälä eh, Autio v, Suggai P, Ikonen T, Stenman uh, Auvinen A, Bailey-wilson Je, Tam-
mela TL, Schleutker J (2007) eur urol. 52:1076-81
Sheldon cA, williams rd and fraley ee (1980): Incidental carcinoma of the prostate: a re-
view of the literature and critical reappraisal of classification. J.urol. 124:626-631
Shimizu h, ross rK, Bernstein L, yatani r, henderson Be and Mack TM (1991): cancers 
of the prostate and breast among Japanese and white immigrants in Los Angeles 
county. Br.J.cancer 63:963-966
Siddiqui SA, Sengupta S, Slezak JM, Bergstralh eJ, Zincke h and Blute ML (2006): Impact 
of familial and hereditary prostate cancer on cancer specific survival after radical 
retropubic prostatectomy. J.urol. 176:1118-1121
Sigurdsson S, Thorlacius S, Tomasson J, Tryggvadottir L, Benediktsdottir K, eyfjord Je and 
Jonsson e (1997): BrcA2 mutation in Icelandic prostate cancer patients. J.Mol.
Med. 75:758-761
Siltanen S, Syrjäkoski K, fagerholm r, Ikonen T, Lipman P, Mallott J, holli K, Tammela TL, 
Järvinen hJ, Mecklin JP, Aittomäki K, Blomqvist c, Bailey-wilson Je, nevalinna 
h, Aaltonen LA, Schleutker J, vahteristo P (2008): ArLTS1 germline variants and 
the risk for breast, prostate and colorectal cancer. eur J hum Genet. 16: 983-91
Simard J, dumont M, Soucy P and Labrie f (2002):  Perspective: prostate cancer susceptibil-
ity genes. endocrinology 143:2029-2040
Slater eP, Langer P, niemczyk e, Strauch K, Butler J, habbe n, neoptolemos J, Greenhalf w 
and Bartsch dK (2010): PALB2 mutations in european familial pancreatic cancer 
families. clin.Genet. epub ahead of print. 
Spangler e, Zeigler-Johnson cM, Malkowicz SB, wein AJ and rebbeck Tr (2005): Associa-
tion of prostate cancer family history with histopathological and clinical characteris-
tics of prostate tumors. Int.J.cancer 113:471-474
Stamey TA, yang n, hay Ar, Mcneal Je, freiha fS and redwine e (1987): Prostate-spe-
cific antigen as a serum marker for adenocarcinoma of the prostate. n.engl.J.Med. 
317:909-916
Stanford JL and ostrander eA (2001): familial prostate cancer. epidemiol.rev. 23:19-23
Profiling of High-risk Prostate Cancer Families in Finland – 87
Stratton Mr, campbell PJ and futreal PA (2009): The cancer genome. nature 458:719-
724
Suuriniemi M, Agalliu I, Schaid dJ, Johanneson B, Mcdonnell SK, Iwasaki L, Stanford JL 
and ostrander eA (2007): confirmation of a positive association between prostate 
cancer risk and a locus at chromosome 8q24. cancer epidemiol.Biomarkers Prev. 
16:809-814
Tavtigian Sv, Simard J, Teng dh, Abtin v, Baumgard M, Beck A, camp nJ, carillo Ar, 
chen y, dayananth P, desrochers M, dumont M, farnham JM, frank d, frye 
c, Ghaffari S, Gupte JS, hu r, Iliev d, Janecki T, Kort en, Laity Ke, Leavitt A, 
Leblanc G, McArthur-Morrison J, Pederson A, Penn B, Peterson KT, reid Je, ri-
chards S, Schroeder M, Smith r, Snyder Sc, Swedlund B, Swensen J, Thomas A, 
Tranchant M, woodland AM, Labrie f, Skolnick Mh, neuhausen S, rommens J 
and cannon-Albright LA (2001): A candidate prostate cancer susceptibility gene at 
chromosome 17p. nat.Genet. 27:172-180
Teahan o, Beaven c, waxman J and Keun hc (2010): Metabolic signatures of malignant 
progression in prostate epithelial cells. Int J Biochem cell Biol. epub ahead of 
print. 
Teppo L, Pukkala e and Lehtonen M (1994): data quality and quality control of a popula-
tion-based cancer registry. experience in finland. Acta oncol. 33:365-369
Thiessen eu (1974): concerning a familial association between breast cancer and both pro-
static and uterine malignancies. cancer 34:1102-1107
Thomas c. duncan (2004) Statistical methods in genetic epidemiology. oxford university 
Press. 
Thomas G, Jacobs KB, yeager M, Kraft P, wacholder S, orr n, yu K, chatterjee n, welch 
r, hutchinson A, crenshaw A, cancel-Tassin G, Staats BJ, wang Z, Gonzalez-Bos-
quet J, fang J, deng X, Berndt SI, calle ee, feigelson hS, Thun MJ, rodriguez 
c, Albanes d, virtamo J, weinstein S, Schumacher fr, Giovannucci e, willett 
wc, cussenot o, valeri A, Andriole GL, crawford ed, Tucker M, Gerhard dS, 
fraumeni Jf Jr, hoover r, hayes rB, hunter dJ, chanock SJ (2008) Multiple 
loci identifies in a genome-wide association study of prostate cancer. nat Genet. 
40:310-315
Tischkowitz M, Xia B, Sabbaghian n, reis-filho JS, hamel n, Li G, van Beers eh, Li L, 
Khalil T, Quenneville LA, omeroglu A, Poll A, Lepage P, wong n, nederlof PM, 
Ashworth A, Tonin Pn, narod SA, Livingston dM and foulkes wd (2007):Analy-
sis of PALB2/fAncn-associated breast cancer families. Proc.natl.Acad.Sci.u.S.A. 
104:6788-6793
Tulinius h, egilsson v, olafsdottir Gh and Sigvaldason h (1992): risk of prostate, ovar-
ian, and endometrial cancer among relatives of women with breast cancer. BMJ 
305:855-857
Tulinius h, olafsdottir Gh, Sigvaldason h, Arason A, Barkardottir rB, egilsson v, og-
mundsdottir hM, Tryggvadottir L, Gudlaugsdottir S and eyfjord Je (2002): The 
effect of a single BrcA2 mutation on cancer in Iceland. J.Med.Genet. 39:457-462
valeri A, Azzouzi r, drelon e, delannoy A, Mangin P, fournier G, Berthon P and cussenot 
o (2000): early-onset hereditary prostate cancer is not associated with specific clini-
cal and biological features. Prostate 45:66-71
valeri A, Briollais L, Azzouzi r, fournier G, Mangin P, Berthon P, cussenot o and demenais 
f (2003): Segregation analysis of prostate cancer in france: evidence for autosomal 
dominant inheritance and residual brother-brother dependence. Ann.hum.Genet. 
67:125-137
88 – Sanna Pakkanen
van den Brandt PA, Zeegers MP, Bode P and Goldbohm rA (2003): Toenail selenium levels 
and the subsequent risk of prostate cancer: a prospective cohort study. cancer epi-
demiol.Biomarkers Prev. 12:866-871
verhage BA, Aben KK, witjes JA, Straatman h, Schalken JA and Kiemeney LA (2004): Site-
specific familial aggregation of prostate cancer. Int.J.cancer 109:611-617
verhage BA, Baffoe-Bonnie AB, Baglietto L, Smith dS, Bailey-wilson Je, Beaty Th, cata-
lona wJ and Kiemeney LA (2001): Autosomal dominant inheritance of prostate 
cancer: a confirmatory study. urology 57:97-101
verkasalo PK, Kaprio J, Koskenvuo M and Pukkala e (1999): Genetic predisposition, envi-
ronment and cancer incidence: a nationwide twin study in finland, 1976-1995. Int.
J.cancer 83:743-749
wang L, Mcdonnell SK, Slusser JP, hebbring SJ, cunningham JM, Jacobsen SJ, cerhan Jr, 
Blute ML, Schaid dJ and Thibodeau Sn (2007): Two common chromosome 8q24 
variants are associated with increased risk for prostate cancer. cancer res. 67:2944-
2950
whittemore AS, wu Ah, Kolonel Ln, John eM, Gallagher rP, howe Gr, west dw, Teh 
cZ and Stamey T (1995): family history and prostate cancer risk in black, white, 
and Asian men in the united States and canada. Am.J.epidemiol. 141:732-740
wooster r, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, collins n, Gregory S, Gumbs 
c and Micklem G (1995): Identification of the breast cancer susceptibility gene 
BrcA2. nature 378:789-792
Xia B, dorsman Jc, Ameziane n, de vries y, rooimans MA, Sheng Q, Pals G, errami 
A, Gluckman e, Llera J, wang w, Livingston dM, Joenje h and de winter JP 
(2007): fanconi anemia is associated with a defect in the BrcA2 partner PALB2. 
nat.Genet. 39:159-161
Xia B, Sheng Q, nakanishi K, ohashi A, wu J, christ n, Liu X, Jasin M, couch fJ and Liv-
ingston dM (2006): control of BrcA2 cellular and clinical functions by a nuclear 
partner, PALB2. Mol.cell 22:719-729
Xu J, dimitrov L, chang BL, Adams TS, Turner Ar, Meyers dA, eeles rA, easton df, 
foulkes wd, Simard J, Giles GG, hopper JL, Mahle L, Moller P, Bishop T, evans 
c, edwards S, Meitz J, Bullock S, hope Q, hsieh cL, halpern J, Balise rn, oak-
ley-Girvan I, whittemore AS, ewing cM, Gielzak M, Isaacs Sd, walsh Pc, wiley 
Ke, Isaacs wB, Thibodeau Sn, Mcdonnell SK, cunningham JM, Zarfas Ke, heb-
bring S, Schaid dJ, friedrichsen dM, deutsch K, Kolb S, Badzioch M, Jarvik GP, 
Janer M, hood L, ostrander eA, Stanford JL, Lange eM, Beebe-dimmer JL, Mo-
hai ce, cooney KA, Ikonen T, Baffoe-Bonnie A, fredriksson h, Matikainen MP, 
Tammela TL, Bailey-wilson J, Schleutker J, Maier c, herkommer K, hoegel JJ, 
vogel w, Paiss T, wiklund f, emanuelsson M, Stenman e, Jonsson BA, Gronberg 
h, camp nJ, farnham J, cannon-Albright LA, Seminara d and AcTAne consor-
tium. (2005): A combined genomewide linkage scan of 1,233 families for prostate 
cancer-susceptibility genes conducted by the international consortium for prostate 
cancer genetics. Am.J.hum.Genet. 77:219-229
Xu J, Zheng SL, Isaacs Sd, wiley Ke, wiklund f, Sun J, Kader AK, Li G, Purcell Ld, Kim 
ST, hsu fc, Stattin P, hugosson J, Adolfsson J, walsh Pc, Trent JM, duggan d, 
carpten J, Gronberg h and Isaacs wB (2010): Inherited genetic variant predisposes 
to aggressive but not indolent prostate cancer. Proc.natl.Acad.Sci.u.S.A. 107:2136-
2140
Profiling of High-risk Prostate Cancer Families in Finland – 89
Xu J, Zheng SL, Komiya A, Mychaleckyj Jc, Isaacs Sd, hu JJ, Sterling d, Lange eM, 
hawkins GA, Turner A, ewing cM, faith dA, Johnson Jr, Suzuki h, Bujnovszky 
P, wiley Ke, deMarzo AM, Bova GS, chang B, hall Mc, Mccullough dL, Partin 
Aw, Kassabian vS, carpten Jd, Bailey-wilson Je, Trent JM, ohar J, Bleecker er, 
walsh Pc, Isaacs wB and Meyers dA (2002): Germline mutations and sequence 
variants of the macrophage scavenger receptor 1 gene are associated with prostate 
cancer risk. nat.Genet. 32:321-325
yoshizawa K, willett wc, Morris SJ, Stampfer MJ, Spiegelman d, rimm eB and Giovan-
nucci e (1998): Study of prediagnostic selenium level in toenails and the risk of 
advanced prostate cancer. J.natl.cancer Inst. 90:1219-1224
ORIGINAL INVESTIGATION
Segregation analysis of 1,546 prostate cancer families in Finland
shows recessive inheritance
Sanna Pakkanen Æ Agnes B. Baffoe-Bonnie Æ Mika P. Matikainen Æ
Pasi A. Koivisto Æ Teuvo L. J. Tammela Æ Snehal Deshmukh Æ Liang Ou Æ
Joan E. Bailey-Wilson Æ Johanna Schleutker
Received: 7 August 2006 / Accepted: 25 November 2006
 Springer-Verlag 2006
Abstract Prostate cancer (PCa) is the most frequently
diagnosed cancer in men worldwide and is likely to be
caused by a number of genes with different modes of
inheritance, population frequencies and penetrance.
The objective of this study was to assess the familial
aggregation of PCa in a sample of 1,546 nuclear fami-
lies ascertained through an affected father and diag-
nosed during 1988–1993, from the unique, founder
population-based resource of the Finnish Cancer
Registry. Segregation analysis was performed for two
cohorts of 557 early-onset and 989 late-onset families
evaluating residual paternal effects and assuming that
age at diagnosis followed a logistic distribution after
log-transformation. The results did not support an
autosomal dominant inheritance as has been reported
in many of the hospital-based prostatectomy series.
Instead, it confirmed the existence of hereditary PCa in
the Finnish population under a complex model that
included a major susceptibility locus with Mendelian
recessive inheritance and a significant paternal regres-
sive coefficient that is indicative of a polygenic/multi-
factorial component. The strengths of our study are the
homogenous Finnish population, large epidemiological
population-based data, histologically confirmed cancer
diagnosis done before the PSA-era in Finland and
registry based approach. Our results support the evi-
dence that the inheritance of PCa is controlled by
major genes and are in line with the previous linkage
studies. Moreover, this is the first time a recessive
inheritance is suggested to fit PCa in all data even when
divided to early and late-onset cohorts.
Introduction
Prostate cancer (PCa) is the most frequently diagnosed
cancer among men in the western world (World Health
Organization 2003). In Finland, where the incidence of
PCa has been rising in the last decade, it is estimated
that in the year 2006, there will be 5,485 newly diag-
nosed PCa cases with the age-adjusted incidence rate
of 115.4/100,000 inhabitants (Finnish Cancer Registry
2006).
Familial clustering of PCa was observed as early as
the 1950s (Gianferrari et al. 1956), and in about 10% of
all cases there is a clear positive family history of the
disease. Carter et al. (1992) reported that for 40–50%
of PCa cases, familial clustering was associated with
multiple affected relatives, especially in families of
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early-onset probands. Hereditary prostate cancer
(HPC), which accounts for 5–10% of all PCa, is an
etiologically complex disease with several genes
implicated in determining risk (Gro¨nberg et al. 1997).
In a large Nordic consortium study of twins, Lichten-
stein et al. (2000) reported an unusually high herita-
bility of 42% for PCa. The clinical phenotype of PCa is
complex and heterogeneous, and the arrival of the
prostate specific antigen (PSA) era has further com-
plicated the genetic analysis of PCa by allowing the
early diagnosis of disease that might remain latent or
clinically unimportant. The International Consortium
for Prostate Cancer Genetics (ICPCG), which seeks to
improve the mapping of PCa genes, has emphasized
that one of the major difficulties in studying PCa is
genetic heterogeneity, possibly due to multiple,
incompletely penetrant PCa-susceptibility genes (Xu
et al. (2005). Using parametric (dominant and reces-
sive) and nonparametric analyses on 1,233 families, Xu
et al. (2005) identified five distinct chromosomal re-
gions with ‘‘suggestive’’ linkage (LOD score > 1.86) to
PCa, namely 5q12, 8p21, 15q11, 17q21, and 22q12.
Subsets of the analyzed group of families characterized
by large numbers of early-onset (£65 years) PCa,
which are more likely to segregate highly penetrant
mutations, provided stronger evidence of linkage in
several regions (including the 22q12 locus, with a LOD
score of 3.57). Additional PCa susceptibility loci re-
ported to date (Schaid 2004) also include the three
cloned genes: HPC1/RNASEL, HPC2/ELAC2 and
MSR1 (Rebbeck et al. 2000; Tavtigian et al. 2001;
Carpten et al. 2002; Xu et al. 2002).
The Finnish population of 5 million inhabitants
represents a genetically isolated population with a
unique gene pool useful for the study of genetic sus-
ceptibility to cancer and other complex diseases (de la
Chapelle 1993; Peltonen 1997). Reliable population
data are obtainable from various linked registries and
the population-based Finnish Cancer Registry (FCR)
covers virtually all histologically confirmed cancer
diagnoses over almost 50 years. In addition, church and
parish records enable the identification of familial
relationships for individuals over several centuries. In
Finland, HPC1/RNASEL, HPC2/ELAC2 and MSR1
loci explain only a small fraction of PCa cases (Ro¨k-
man et al. 2001, 2002; Seppa¨la¨ et al. 2003). Instead,
three additional major susceptibility loci have been
mapped in Finnish families including the HPCX
(Xq27–28), 3p25–26 and 11q14 regions (Xu et al. 1998;
Schleutker et al. 2003). Even so, a large proportion of
Finnish HPC remains unexplained.
The purpose of this study was to assess the nature of
familial aggregation of PCa in a sample of 1,546
Finnish nuclear families using regressive models as
employed in complex segregation analysis. Segregation
analysis is a statistical method for testing compatibility
with Mendelian expectations by estimating the
parameters of a given model of inheritance from family
data. Previous segregation analyses in diverse popula-
tions have suggested that familial aggregation of PCa
follows autosomal dominance, multifactorial, recessive
or X-linked inheritance, but remain inconclusive. Six
reports suggest a dominant inheritance mode (Carter
et al. 1992; Gro¨nberg et al. 1997; Schaid et al. 1998;
Verhage et al. 2001; Conlon et al. 2003; Valeri et al.
2003). Cui (2001) reported a mixture of models
including autosomal dominant inheritance in younger
onset families with recessive or X-linked inheritance in
older-onset families. A multifactorial model has been
suggested by Gong et al. (2002). Families of Icelandic
breast cancer probands with PCa-affected men yielded
a codominant model (Baffoe-Bonnie et al. 2002). To
account for the possibility of different modes of
inheritance in families of early-onset probands
(<61 years) versus late-onset families (‡61 years), we
performed segregation analyses on these two separate
cohorts and also analyzed the complete, combined
dataset to determine the most parsimonious model for
explanation of the familial aggregation of the disease in
Finland.
Subjects and methods
Data sources
The nation-wide population based Finnish Cancer
Registry (FCR) was founded in 1952 and reporting of
cancer to the FCR was made obligatory in 1961.
Currently physicians, hospitals and pathology labo-
ratories send their reports to the registry indepen-
dently. In addition, the FCR receives information
from every death certificate in which cancer is men-
tioned, registering over 99% of all solid tumors
diagnosed in Finland (Teppo et al. 1994). The FCR
files can be linked to the registry of deaths and of
immigrants issued by the Population Register Center
in Finland. Population registration in Finland has
traditions dating back to the sixteenth century and is
considered to be of excellent quality. Since 1964 a
centralized, nation-wide, computer-based population
registry has been maintained by the National Popu-
lation Registry Center and is based on unique per-
sonal identifiers, which are now used as main keys in
every major person registry including the Finnish
Cancer Registry.
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Probands and relatives
We chose the pre-PSA time period between 1 Jan-
uary 1988 and 31 December 1993 and identified 9,142
men with newly diagnosed PCa nationwide from the
Finnish Cancer Registry. Two non-overlapping
cohorts were identified with 557 early-onset probands
(diagnosed at <61 years of age) and 989 late-onset
probands (diagnosed at ‡61 years of age). The cut-off
of 61 years was selected so that the cohort of
early-onset PCa would be informative, i.e., has en-
ough cases. Although all cut-offs are arbitrary, ours
is in line with the one used by previous PSA
screening trial in Finland (Ma¨kinen et al. 2002).
Details of the collection of population-based PCa
families and the analyses for other cancers among
first-degree relatives have been published elsewhere
(Matikainen et al. 2001). Briefly, information on the
birthplaces of probands was obtained from the Cen-
tral Population Registry. The local registries (par-
ishes and local authorities) of the communities where
probands were born were contacted to obtain the
names and birth dates of their parents, siblings,
spouses and children. Family members were suc-
cessfully traced for 94% of the probands, giving a
total of 10,650 first-degree relatives out of the 11,427
identified. Descriptive statistics of these two non-
overlapping cohorts and after combining them are
shown in Table 1.
Segregation analysis
To test specifically for Mendelian inheritance of PCa in
these Finnish pedigrees, maximum likelihood segre-
gation analyses were performed on the age at diagnosis
expressed as a censored trait using the REGTL module
of the Statistical Analysis for Genetic Epidemiology
program (SAGE 3.1. 1997). Under model 1 of this
program, employing class A regressive models (Bon-
ney 1986), the ‘‘type’’ or ‘‘ousiotype’’ (Cannings et al.
1978) influences age at diagnosis of PCa through the
location and scale parameters of the logistic distribu-
tion, but does not influence susceptibility. Specifically,
some constant proportion (c) of the male population is
assumed to be at a risk of PCa. The PCa phenotype is
defined as a dichotomous variable (Y), where Y = 1 if
affected and Y = 0 if unaffected (censored). Parame-
ters estimated in the analysis include: qA, the frequency
of the putative high-risk allele ‘A’, bi baseline param-
eters, where i represents an individual’s type (AA, AB,
BB); ai the age coefficients and ci the susceptibilities
(Elston and George 1989). The logistic function
describing the probability that an individual is affected
by age ‘‘a’’ is given as ci[1/(1 + e
–F], where
U ¼ bi þ ai(a) þ dFðYF) ð1Þ
The coefficient dF reflects familial influence on risk
corresponding to having an affected father.
Table 1 Descriptive statistics for prostate cancer cohorts in Finland
Description Cohort-1 Cohort-2 Combined cohorts
Probands 557 989 1,546
Non-probands 3,631 7,019 10,650
Affected non-probands 51 109 160
Number of affected 608 1,098 1,706
Individuals in cohort 4,188 8,008 12,196
Number of males 2,418 (57.7%) 4,664 (58.2%) 7,082 (58.1%)
Number of females 1,770 (42.3%) 3,344 (46.9%) 5,114 (41.9%)
Number of fathers 390 673 1,063
Number of brothers 846 1,840 2,686
Number of sons 625 1,162 1,787
Number of mothers 388 681 1,069
Number of sisters 794 1,642 2,436
Number of daughters 588 1,021 1,609
Mean age of probands (years) 56.6 ± 3.4 74.4 ± 7.4 68.2 ± 10.7
Range of age at diagnosis of probands (years) 41.8 – 60.9 61 – 96 41.8 – 96
Mean age of affected non-probands (years) 69.6 ± 8.0 71.9 ± 7.8 71.2 ± 7.9
Range of age at diagnosis of affected non-probands (years) 48.3–85.5 48.1–88.7 48.1–88.7
Unaffected men aged ‡48 (years) 909 (18.3%) 2,141 (23.0%) 3,050 (21.4%)
Mean age of unaffected men (years) 65.2 ± 9.8 67.5 ± 12.3 66.6 ± 11.4
Range of ages of unaffected men (years) 48–85.5 48–104.3 48–104.3
Pedigree sizes (average, range) 8.9 (3–23) 9.4 (3–25) 9.2 (3–25)
Percent of pedigrees with ‡10 and ‡20 persons 28% (0.7%) 37.6% (0.5%) 34.2% (0.6%)
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Positive values of dF mean that the individual with
an affected father is more likely to have an earlier age
at diagnosis, while negative values mean that the
individual with an affected father is more likely to have
a later age at diagnosis. Nonzero values of dF indicate
the effects of polygenic and/or unmeasured shared-
familial environmental risk factors on PCa risk.
Age at diagnosis for prostate cancer phenotype is
assumed to follow a logistic distribution described by
two parameters a and b, with the probability distribu-
tion function according to Elston and George (1989)
f ðageÞ ¼ [aebiþaðageÞ]=(1 þ ebiþaðageÞ)2 ð2Þ
This symmetric distribution is similar to a normal
distribution and has a mean –b/a, and variance, p2/3a2,
where p has a value of 3.1416. Based on the logistic
distribution, the cumulative distribution function
(CDF) is given by
FðageÞ ¼ [aebiþaðageÞ]=[1 þ ebiþaðageÞ]: ð3Þ
The CDF represents the probability that a suscep-
tible person will be affected by a given age. Age-spe-
cific penetrances were calculated for each genotype as
P(Yjgenotype i; age) ¼ [ebiþaðageÞ]=[1 þ ebiþaðageÞ]:
ð4Þ
If the observed sex-specific ages at diagnosis do not
follow a logistic distribution, this model may still be
appropriate after transformation. A transformation
equation equivalent to: aG1 · ln (age) was considered
here, where aG1 is the geometric mean age at diag-
nosis for prostate cancer, computed from the observed
ages at diagnosis among the 160 affected non-probands
with PCa, 51 for the early-onset and 109 for the late-
onset cohorts (Table 1).
Tests for genetic contribution to disease risk were
implemented by postulating three types of individuals
(AA, AB, BB) with three corresponding transmission
parameters (sAA, sAB, sBB) describing the probability
that a parent of a given type transmits the disease
producing factor ‘A’ to his/her offspring (Elston and
Stewart 1971; Elston and Yelverton 1975; Elston 1981).
Under the hypothesis of genetic transmission, these s
parameters are constrained to the Mendelian values of
sAA = 1.0, sAB = 0.5, sBB = 0.0. Five sub-models of
disease transmission were tested against a general
model, where the transmission probabilities are esti-
mated but with the restriction of homogeneity of trait
distribution across generations to identify the best
model for these data (Elston 1981). The ‘‘no major
gene’’ model assumes that baseline risk is not influ-
enced by ‘‘type’’ therefore all persons would come
from a single distribution of age-specific risk for PCa.
Single-locus Mendelian models assume that a major
locus with two alleles should act in codominant, dom-
inant or recessive fashion. The dominant and recessive
models are special cases of the codominant model,
where each genotype has a distinct age at diagnosis
distribution. An environmental model with potentially
distinct types of individuals was also tested, but here
the transmission probability was held constant for all
individuals.
We present results from the maximum likelihood
segregation analyses performed on the log-transformed
age at diagnosis of PCa expressed as a censored trait
using the REGTL program (SAGE 3.1. 1997). Log-
transformation of ages at diagnosis and ages at exam-
ination for all individuals with non-zero ages led to a
final model that estimated genotypic baseline param-
eters (bi) and age coefficient (ai) and lifetime suscep-
tibility for PCa for males along with the frequency
(qA) of the high-risk allele A.
Hypothesis testing
The likelihood ratio test (LRT) was used to test each
sub-model against the general model, and was
computed as minus twice the natural log likelihood
[–2ln(L)] of the general model subtracted from that for
a restricted sub-model. This difference is asymptoti-
cally distributed as a v2 distribution with degrees of
freedom equal to the difference in the number of
independent parameters estimated in the two models.
Another method to compare models uses Akaike’s
information criteria (AIC), defined as: AIC = –2ln(L)
+ 2(number of parameters estimated). The most
parsimonious model has the minimum AIC value
(Akaike 1974). To correct for ascertainment bias, the
likelihood of each pedigree was conditioned on the
proband’s affection status, using his age at diagnosis as
recorded in the Cancer Registry (Cannings and
Thompson 1977; Elston and Sobel 1979).
Results
Cohort-1 with 557 early-onset PCa families
As shown in Table 2, the no major gene model gave
a very poor fit to the data in the early-onset PCa
cohort and was thus rejected against the general
unrestricted model in which all parameters were
estimated based on the likelihood ratio test (LRT)
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(model 1 vs. model 6, v2 = 18.36, P < 0.005 for 6df).
The dominant (P < 0.0014), codominant (P < 0.036)
and environmental (P < 0.0082) models were all re-
jected compared to the general model. The final
general model reported is almost identical to the
recessive Mendelian model (model 4 vs. model 6,
v2 = 1.54, P < 0.83 for 4df). The AIC, which takes
into account the number of parameters estimated
also, confirmed that the recessive model was the
most parsimonious model. The estimated frequency
±SE (standard error) for the high-risk allele qA was
0.054 (±0.01) for the recessive model. Figure 1 pre-
sents the predicted cumulative distribution function
curves for log-transformed ages at diagnosis for the
early-onset families under the recessive model. High-
risk homozygous carriers of the putative risk allele
AA have predicted age-specific cumulative proba-
bilities greater than the heterozygous AB and BB
non-carriers. The predicted mean age at diagnosis
(i.e., 50% cumulative risk in Fig. 1) for the AA
individuals is 60 and 64.6 years for the non-carriers.
The susceptibility parameter c was estimated at 1.0
for all male carriers of the risk allele, suggesting that
100% of the male population if they lived to infinity
and did not die of competing causes, would express
PCa if they were homozygous carriers of the allele
A. Under this Mendelian recessive model, the
cumulative probability that a male in Finland would
be affected by PCa by age 70 was 0.92 for carriers
and 0.79 for non-carriers, thus implying that if car-
riers and non-carriers did not die from competing
causes, the estimated risk of being diagnosed with
PCa at age 70 years for the homozygote carriers of
the deleterious allele (q = 0.054), would be 2.7 per
1,000 among a hypothetical cohort of 100,000 men.
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Fig. 1 Predicted cumulative risks for recessive AA (carriers) and
AB/BB (non-carriers) with an affected father: 557 early-onset
Finnish prostate cancer families
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Cohort-2 with 989 late-onset PCa families
Table 3 shows the parameter estimates from the seg-
regation analysis for the 989 families ascertained
through late-onset probands diagnosed at ‡61 years of
age. Compared to the unrestricted general model, the
no major gene, the Mendelian dominant and environ-
mental models did not fit the data and were rejected at
P < 0.001. The Mendelian codominant model was also
rejected by the LRT with a v2 of 12.64 and a P value of
0.006. The recessive model was the most parsimonious
model according to the LRT (model 4 vs. model 6,
v2 = 6.82, P < 0.15 for 4df), and it also had the lowest
AIC = 1,331.10. Under this recessive model, inheri-
tance of a putative high-risk allele A with an allele
frequency (±SE) of 0.086 (±0.006) had predicted mean
ages of onset of 65.6 years for men with the AA
genotype and 72.2 years for AB/BB males, respec-
tively. The lifetime risk of being diagnosed with PCa
under this model was 5.0 per 1,000 among a hypo-
thetical cohort of 100,000 men.
Figure 2 shows the predicted cumulative distribu-
tion function curves for log-transformed ages at diag-
nosis for this late-onset cohort in which the AA
genotype has a distinctly different mean age at diag-
nosis of PCa.
Combined Cohort-1 and Cohort-2 with 1,546 PCa
families
From Table 4, the combined cohorts with 1,546 pro-
bands gave parameter estimates very similar to those
obtained from Cohort-2 with 989 probands. All other
models except the Mendelian recessive model were
significantly rejected when compared with the unre-
stricted general model. The recessive model was the
most parsimonious model according to the LRT
(model 4 vs. model 6, v2 = 8.78, P < 0.07 for 4df), and
it also had the lowest AIC = 1,795.12. Under this
recessive model, inheritance of a putative high-risk
allele A with an allele frequency (±SE) of 0.0903
(±0.005) had predicted mean ages of onset of
63.6 years for men with the AA genotype and
71.0 years for AB/BB genotype males, respectively.
Figure 3 shows that under the recessive model, the
predicted cumulative risks for PCa are distinctly dif-
ferent for the AA compared to the AB/BB genotypes.
The estimated mean age at diagnosis for the male
homozygous carriers of the putative, high-risk allele A
is 63.6 and it is 71.0 years for AB/BB genotype males.
With a cumulative risk of 0.80 for homozygote carriers
of the A allele at age 70 years, the estimated risk of
being diagnosed with PCa in the absence of competing T
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causes of death was 6.5 per 1,000 among a hypothetical
cohort of 100,000 men.
All of these models (in each cohort and in the
combined cohorts) included a residual paternal
regressive coefficient, since inclusion of this coefficient
significantly improved the fit of these models. The
impact of genotype alone versus residual effect of
having an affected father can be measured by com-
puting the log odds of various combinations.
In effect, among men of the same age, born in the
same cohort, and having the same affected father
status, the log odds for being a homozygous carrier of
the high risk allele A is computed as the difference
between the genotypic baseline coefficients of the
homozygous carriers and of the heterozygote and
homozygous non-carriers. Using the parameters of
the recessive model in the combined cohort as an
example:
(bAA þ aa0 þ dF(YF))  (bAB=BB þ aa0 þ dF(YF))
¼ bAA  bAB=BB
¼ 63:34  (  71:23) ¼ 7:89:
The odds of PCa in homozygous carriers of the A
allele compared to the AB/BB non-carriers is 2,670, i.e.,
the exp (7.89). The log-odds due to an affected father
between two individuals with the same genotype is 3.90
and the corresponding odds ratio is 49.40. The increase
in log odds for a homozygote for the high-risk allele A
with an affected father compared to the heterozygote
carrier of the same age born in the same cohort but
having an affected father would therefore be (bAA–bAB/
BB) + dF(YF)) = 7.89 + 3.90 = 11.79 leading to high
odds ratio.
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Fig. 2 Predicted cumulative risks for recessive AA (carriers) and
AB/BB (non-carriers) of high-risk allele A with an affected
father for 989 late-onset Finnish prostate cancer families
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Discussion
In the present segregation analysis of our 1,546 popu-
lation-based PCa families in Finland with ages at
diagnosis of probands ranging between 41.8 and
96 years, a Mendelian recessive model with significant
paternal regressive coefficient was shown to fit the
homogeneous Finnish population best when the fami-
lies were not separated into early- and late-onset co-
horts. Recessive models with significant paternal
regressive coefficients were also the most parsimonious
models in both the 557 families of the early-onset co-
hort and in the 989 late-onset families. Under Hardy–
Weinberg equilibrium, the estimated allele frequency
of 0.09 for the combined cohort implies that 0.81% of
the population in Finland would carry this rare puta-
tive high-risk allele. However, being a gender limited
disease the susceptibility parameter c of 1.0 obtained in
the analysis suggested that 100% of the homozygous
carrier male population at risk would develop PCa if
they lived to infinity and did not die of competing
causes.
Our results suggest that individuals carrying the risk
allele get PCa at younger ages (<66 years) compared to
non-carriers, whether they belong to the 557 early-
onset or 989 late-onset groups or when the two cohorts
are combined. Homozygous carriers of the risk allele
(AA genotype) in the three groups above have a mean
age at diagnosis of 60.1, 65.6 and 63.6 years, respec-
tively, given that only about 6 years separate the ages
at diagnosis of the homozygotes for the risk allele in
the early-onset from the late-onset cohorts. Since the
residual paternal effect was positive, those with af-
fected fathers were at a higher risk for earlier onset
PCa with polygenic and/or unmeasured shared-familial
environmental risk factors compared to those with
unaffected fathers. These findings are quite different
from the previously reported evidence for the segre-
gation of a rare autosomal dominant gene with high
penetrance among different populations that included
some series of prostatectomy patient families (Carter
et al. 1992; Gro¨nberg et al. 1997; Schaid et al. 1998;
Verhage et al. 2001; Conlon et al. 2003; Valeri et al.
2003). Likewise a Swedish study by Gro¨nberg et al.
(1997) that was carried out on a population-based
sample of 2,857 families selected through an affected
father diagnosed with PCa in 1959–1963 and identified
from the nationwide Cancer Registry, revealed that the
observed clustering of PCa was best explained by a
high risk allele inherited in a dominant mode, with a
high population frequency (1.67%) and a moderate
lifetime penetrance (63%). Similarly, the segregation
analysis by Valeri et al. (2003) of families identified
through 691 PCa patients recruited from three hospi-
tals reported evidence for autosomal dominant gene
inheritance of a high risk allele (frequency of 0.03%)
with brother–brother dependence.
Our analyses suggest that there are likely to be
multiple loci behind PCa and similar results have also
been reported previously. A segregation study per-
formed in Australia on 1,476 population-based pedi-
grees whose probands were diagnosed with PCa before
the age of 70 in 1994–1997 suggested that a two-locus
model fitted better than single-locus models and in-
cluded a dominantly inherited risk that was greater at
younger ages and a recessively inherited or X-linked
increased risk which was greater at older ages (Cui
et al. 2001). In a study of 1,719 first degree relatives in
American and Canadian families by Gong et al. (2002),
it was also observed that the good fit of the multifac-
torial model suggests that multiple genes, each having
low penetrance, may be responsible for most inherited
PCa susceptibility, and that the contribution of rare
highly penetrant mutations might be small. In a seg-
regation analysis of 389 Icelandic pedigrees that in-
cluded both breast and prostate cancer, Baffoe-Bonnie
et al. (2002), reported that the most parsimonious
model was a Mendelian codominant model.
Previously, a recessive mode of inheritance has been
reported in only a few studies. Cui et al. (2001) sug-
gested that recessively inherited or X-linked inheri-
tance increased risk at older ages, which was also seen
in our linkage analyses of the HPCX locus (Xu et al.
1998; Schleutker et al. 2003). For an adult onset, sex-
limited cancer such as PCa, recessive inheritance with
incomplete penetrance and sporadic cases is consistent
with X-linked PCa, which we previously mapped to the
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Fig. 3 Predicted cumulative risks for recessive AA (carriers) and
AB/BB (non-carriers) of the putative high-risk allele A with an
affected father for the 1,546 combined Finnish prostate cancer
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Xq27–28 region using Finnish families characterized by
‘‘no-male-to-male transmission’’ (NMM). A follow-up
linkage disequilibrium study utilizing familial/sporadic
PCa cases and appropriate healthy controls identified
an associated haplotype in the HPCX region (Baffoe-
Bonnie et al. 2005). The results of this segregation
analysis study are therefore consistent with the X-
linked PCa transmission described previously
(Schleutker et al. 2000). It has also been shown that
there is a presence of residual brother–brother
dependence (Valeri et al. 2003). In the study, by Narod
et al. (1995) the prevalence of PCa was increased in
those men with any first-degree relative affected. Most
of the increase in relative risk was contributed by af-
fected brothers, thus alluding to recessive or X-linked
inheritance of the disease. In the study, by Monroe
et al. (1995) an excess risk of PCa in men with affected
brothers compared to those with affected fathers was
also observed, consistent with the hypothesis of an X-
linked, or recessive model of inheritance. Moreover,
the prostate cancer risk was higher in probands’
brothers than in probands’ fathers in the Mayo Clinic
Study (Schaid et al. 1998). These observations can be
interpreted as evidence of recessive or X-linked effects
in the risk of PCa.
Probands in the four American studies (Carter et al.
1992; Schaid et al. 1998; Verhage et al. 2001; Conlon
et al. 2003) were part of a radical prostatectomy series
for primary clinically localized PCa, and thus corre-
sponded to a subgroup of patients not representative of
all prostate cancer cases. This, as conceded by Schaid
et al. (1998), could limit the power to assess hetero-
geneity of transmission across different age groups and
represent a selection bias due to phenotypic charac-
teristics. The particular strength of our study is the
large population-based data composed of a homoge-
nous Finnish population with registry-based ap-
proaches that provide unbiased information of
malignancies in families. Prostate cancer was histo-
logically confirmed in all cases in our families, and did
not rely on PSA screening. The homogeneity of the
Finnish population increases our chances of identifying
loci, which may be less, pronounced in ethnically more
diverse populations. Thus, linkage and association
analyses of HPC conducted on Finnish families have
found loci that are different from those reported in
studies from other countries and populations
(Schleutker et al. 2003; Seppa¨la¨ et al. 2003a, b). Also,
the present study was based on all prostate cancer
cases in a population in a certain time window, not just
known prostate cancer families, where genetic com-
ponents may contribute to other cancer types and also
be biased by specific family collection criteria.
The International Consortium for Prostate Cancer
Genetics (ICPCG) recently announced that even
though evidence of the existence of major PCa-sus-
ceptibility genes has been provided by multiple segre-
gation analyses, genome-wide screens have not yielded
conclusive chromosomal regions due to major diffi-
culties that include genetic heterogeneity (Xu et al.
2005). The ICPCG employed parametric (dominant
and recessive) and nonparametric analyses of 1,233
families world wide to identify several regions ‘‘indic-
ative’’ of linkage. The main subsets of families likely to
segregate highly penetrant mutations include families
with large numbers of affected individuals or early age
at diagnosis, leading to stronger evidence of linkage in
several regions. Linkage and the association analysis of
HPC conducted on Finnish families have found loci
that are different from those reported in studies from
other countries and populations (Schleutker et al. 2003;
Seppa¨la¨ et al. 2003a, b). We therefore believe that the
results of these segregation analyses will be applied to
defining a new model(s) for improving linkage analyses
of the multiplex PCa families collected in Finland.
In conclusion, our findings suggest that the inheri-
tance of PCa in the Finnish population is best ex-
plained by a Mendelian recessive model with a
significant paternal regressive coefficient that is indic-
ative of a polygenic multifactorial component. The
rising incidence of PCa in Finland is possibly due to a
combination of factors that include socio-cultural and
lifestyle changes, environmental factors and the on-
going PSA screening (Finnish Cancer Registry, Ma¨ki-
nen et al. 2003).
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Abstract
Background: Clinical features of familial prostate cancer
(PCa) and other malignancies associated with PCa are
poorly described. Using a large family-based data regis-
try of histologically confirmed cancers with a 40-year
follow-up, we sought to determine incidence of cancer
in Finnish PCa families, separately for clinically aggres-
sive and clinically nonaggressive PCa.
Methods: We calculated standardized incidence ratios
(SIR) for 5,523 members of 202 families by dividing
the number of observed cancers (altogether 497 cases)
by the number of expected cancers. The number of ex-
pected cancers is based on the national cancer incidence
rates.
Results: SIR for overall cancer risk, excluding PCa, for
male relatives in clinically nonaggressive families was
0.7 [95% confidence interval (95% CI), 0.6-0.8] and in
clinically aggressive families 0.8 (95% CI, 0.6-1.0). The
respective SIRs for women were 1.0 (95% CI, 0.8-1.1)
and 1.1 (95% CI, 0.8-1.3). The incidence of lung cancer
among men was significantly lower than in the general
population. The SIR for gastric cancer among women
was 1.9 in both clinically nonaggressive and clinically
aggressive families. In clinically aggressive families,
there was borderline significant excess of cancer of
the gallbladder in men and liver cancer in women.
Conclusions: The incidence of non-PCa cancers is not
increased in clinically aggressive or clinically nonag-
gressive PCa families except for stomach cancer
among women. (Cancer Epidemiol Biomarkers Prev
2009;18(11):3049–56)
Introduction
Prostate cancer (PCa) is the most frequently diagnosed
malignancy among men in the Western world.6 Largely
due to the earlier diagnosis provided by the prostate-
specific antigen (PSA) test, introduced in the 1990s, the
incidence of PCa is no longer increasing. The highest in-
cidence (115/100,000) of PCa in Finland was observed in
2005. In 2007, there were 4,188 newly diagnosed PCa
cases in Finland with an age-adjusted incidence rate of
85.7/100,000.7 Similar patterns of decline in PCa inci-
dence have been observed in most Western industrialized
countries (1).
The etiology of PCa has remained poorly understood.
Ethnicity, age, and family history are considered major
risk factors for PCa. The familial aggregation of PCa has
been observed as early as the 1950s (2). Men with a posi-
tive family history of PCa have a 2- to 10-fold higher risk of
getting PCa compared with those with no family history.
The risk of PCa is highest in families with multiple PCa
cases and in those with a low age of cancer diagnosis (3, 4).
Extensive efforts have been made to find genetic causes
for PCa susceptibility. By linkage analysis, several chro-
mosomal regions have been associated to PCa (5). Fine
mapping of promising loci has identified three highly
penetrant candidate genes ELAC2, RNASEL, and MSRI
(6-8). However, mutations in these genes seem to be ex-
tremely rare, especially in the Finnish population (9-11).
Several low penetrant polymorphisms have been found
to be associated with PCa; however, recent studies sug-
gest that the detected associations vary in different popu-
lations and ethnic groups (12-14), indicating genetic
heterogeneity among people with PCa.
Based on the first reports on familial aggregation
of PCa, hereditary PCa was considered to be site-specific
(15). Hereditary PCa has been associated with a number
of cancers, including gastric, breast, central nervous sys-
tem, colon, multiple myeloma, gallbladder, non–Hodgkins
lymphoma, skin melanoma, and kidney cancer (15-17).
In population-based study associations between PCa
and other cancers, such as gastric, colon, rectal, kidney,
breast, ovarian, bladder, thyroid, and brain cancers,
melanoma and non–Hodgkin lymphoma, have been
reported, but the findings have been inconsistent between
studies and only a few of these neoplasms have been
reported even twice (4, 18-23). Studies of families with
hereditary breast cancer, however, have reported that
6 http://www.who.int/
7 http://www.cancerregistry.fi/
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male carriers of BRCA2 mutations are at increased risk
for PCa (24-26).
Being a genetically heterogeneous disease, analysis of
PCa families with incidences of similar cancer types
could be highly informative in genetic linkage and asso-
ciation analysis toward the identification of PCa predis-
position genes. The use of clinically defined phenotypes
could simplify locus-heterogeneity problems that con-
found the search for PCa susceptibility genes (27, 28).
Further, alternative phenotypes, such as tumor aggres-
siveness, may be a solution for overcoming the apparent
heterogeneity that has hindered the identification of PCa
genes. The odds of finding clinically relevant mutations
should be hypotentially greater among clinically aggres-
sive PCa families (29).
We have done the first complete epidemiologic evalua-
tion of cancer risks in Finnish families with two or more
cases of PCa across the generations studied. The Finnish
genetic population structure is relatively homogenous
due to a small founder population some 100 generations
ago that has expanded into 5.3 million people today, with
immigration contributing little to the genetic variation (30).
Moreover, unbiased epidemiologic data on familial cancer
clustering can be accessed throughnation-wide population
and cancer registries. The aim of this study was to assess
whether primary non-PCa tumors are associated with
Finnish families having two or more PCa cases.
Materials and Methods
Families. A detailed description of the Finnish PCa
family data has been previously described (31). Since
then, additional families from 1999 to 2008 have been
found and integrated into the database using the same
methods. In the present study, we used data from 202
families with two or more first-degree relatives with
PCa. Genealogic information on family members was
confirmed from records kept by the Finnish Population
Register Centre, and medical information regarding can-
cer incidence was obtained from hospital records and the
Finnish Cancer Registry. Known cancer syndromes were
excluded by pedigree analysis. Previously, BRCA1 and
BRCA2 Finnish founder mutations and multiple other
genes, including CDH1, CHEK2, MLH1, NBS1, and FH
have been screened and found to have only a minor role
in predisposition to PCa (32-37).
The genealogic data of 202 families were collected
through church and parish registries and the Finnish Pop-
ulation Register Centre. Complete pedigrees were con-
structed for each family. We traced back the parents of
the index person, the earliest person being born at the
end of 19th century and then traced all their descendants,
through parish registries, until death or until further off-
spring were considered unlikely (female age, 55 y; male
age, 70 y). The 844 persons (13%) who had died before
the beginning of follow-up (1967) were excluded.
Statistical Methods. Because PCa is a common disease,
it is likely that even when strict hereditary cancer family
criteria, the so-called Carter criteria (3), is followed, a fam-
ily with sporadic disease aggregation can become classi-
fied as a hereditary PCa family. To avoid this, we
analyzed the clinical characteristics of the PCa cases in
each of the families. All familial PCa cases were obtained
from hospital records, including age of diagnosis, primary
PSA value, WHO grade, Gleason score, and tumor-node-
metastasis stage at diagnosis. In addition, the proportion
of PCa cases in the family was calculated by dividing the
number of PCa cases with the number of males in the
family. Hierarchical cluster analysis by the agglomerative
method and average distance was used to classify fami-
lies with clinically aggressive disease into a separate co-
hort. Diagnostic age, primary PSA and the proportion
of PCa cases in the family were standardized to equalize
variables. As the incidences of PCa in these families were
diagnosed between 1962 and 2006, Gleason grading was
introduced in 1990s, Gleason grading was available for
only 204 patients. In addition, because the criteria for
Gleason grading have changed remarkably from 1990 to
2000, this variable was excluded from our analyses, rely-
ing instead on WHO grading.
The mean number of affected men with PCa was 2.9
per family (range, 2-8). The mean year of PCa diagnosis
was 1992 (SD, 9.3; range 1962-2006), and the mean age of
onset of PCa was 68 y (SD, 9.0; range, 43-98). The primary
PSA median value was 16.0 [Quartile deviation (QD), 17;
range, 0.8-11000]. The histopathologic WHO grade was 1
for 25%, 2 for 43%, and 3 for 9% (missing 23%).
Primary PSA values were available for 420 patients. To
avoid the effect of outliers in hierarchical cluster analysis,
the value of primary PSA was downgraded to a value of
101 for the analysis if it was initially measured to be over
100. We assumed that these extreme PSA values over 100
are uninformative. Cluster analysis was done for all vari-
ables collected (except Gleason score) and in different
combinations. Primary PSA showed significant depen-
dence on WHO grading, tumor size, and metastasis
(PKruskall-Wallis < 0.0005 for all except WHO grading
PMann-Whitney < 0.0005). Overall, the analyses showed that
primary PSA alone was sufficient to well group the fam-
ilies compared with the use of all the variables or different
combinations of the variables.
Using the collected clinical data, patients were sorted
into one of two groups, group 1 (clinically nonaggressive
PCa) or group 2 (clinically aggressive PCa). Fifty-nine of
the 202 families were classified as a family with clinically
aggressive PCa and 143 as nonaggressive PCa. The clini-
cally aggressive PCa men had a primary PSA median val-
ue of 230 (QD, 280; range, 76-11,000) compared with 13.3
(QD, 16; range, 1.0-70) of the clinically nonaggressive
men. When using the downgraded PSA values in clinical-
ly aggressive families the median value was 101 (QD, 101;
range, 80-101) and 13.1 (QD, 16.2; range, 0.8-70) in clini-
cally nonaggressive families, respectively. In addition,
71% of the clinically aggressive PCa men had metastases
at the time of diagnosis as this was only 10% in clinically
nonaggressive PCa men. Eighty-three percent of the clin-
ically aggressive PCa men had extraprostatic tumor
growth compared with only 34% in clinically nonaggres-
sive PCa men. Consequently, with clinically aggressive
disease, a histologically poorly differentiated and/or
more advanced disease is meant showing in either a high
tumor grade or stage (38, 39).
Follow-up analysis for cancer incidence among family
members was done using medical information obtained
by personal identity code–based automatic record linkage
from the Finnish Cancer Registry. The follow-up period
was from January 1, 1967 to December 31, 2004. However,
for index patients, the follow-up started from their first
PCa diagnosis. For the parents of the index patient, the
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follow-up started from the birth of the index. For the
other cohort members, the follow-up started from their
date of birth, if this was later than January 1, 1967. If
the person had emigrated or deceased before December
31, 2004, the calculation of person-years ended at that
earlier date.
When calculating family data and trying to avoid the
bias inherent in defining a PCa-family, the index person
should be the first PCa male from any given family re-
cruited into the study. However, due to the large amount
of variability in this information or because the informa-
tion was simply not available, we calculated familial SIRs
in two ways. In the single-index data method (method 1),
the follow-up to the date of PCa diagnosis was excluded
for one PCa case, but all other family members were fol-
lowed-up from the beginning. In the multiple index data
method (method 2), all known PCa males were consid-
ered as index persons and follow-up data before PCa di-
agnosis was excluded from the analysis. The standardized
incidence ratios (SIR) calculated by these two methods
provide the lowest and highest possible estimate of the
true relative risk for PCa and for overall cancer risk.
The number of people analyzed using single index data
were 5,523 (169,700 person-years) and 5,504 (161,500
person-years) in the multiple index data (Table 1).
Expected numbers of malignancies is based on person-
years at risk, gender, age, and calendar-period of the spe-
cific incidence rates in the general population. SIRs were
calculated by dividing the observed numbers of malig-
nancies by the expected numbers. Exact 95% confidence
Table 1. Number of relatives of PCa patients in Finland with clinically nonaggressive and aggressive PCa, and
person-years at follow-up during 1967 to 2004, by gender
Relative status Males Relative
status
Females
Method 1 Method 2 Method 1 and 2*
No P-years No P-years No P-years
CNA PCa families
Index person 143 869 352 2,062
Father 61 711 32 370 Mother 81 1,429
Brother 429 13,116 266 7,984 Sister 288 8,555
Son 1,185 39,195 1,135 37,956 Daughter 1,067 36,594
Spouse 184 4,054 184 4,054 Spouse 464 12,346
Total 2,002 57,945 1,969 52,426 Total 1,900 58,924
CA PCa families
Index person 59 315 160 894
Father 21 287 13 138 Mother 29 488
Brother 160 4,737 90 2,500 Sister 115 3,539
Son 525 19,510 500 18,610 Daughter 434 16,088
Spouse 79 1,908 79 1,908 Spouse 199 5,977
Total 844 26,757 842 24,050 Total 777 26,092
NOTE: The numbers for males are given separately for method 1 (single index PCa) and method 2 (multiple index PCa).
Abbreviations: P-years, person-years; CNA, clinically nonaggressive; CA, clinically aggressive.
*Both methods give the same number of family members who produce person-years at follow-up for females.
Table 2. Risk of cancer among men in PCa families separately with clinically nonaggressive and aggressive PCa
Cancer site CNA PCa families CA PCa families
Obs Exp SIR 95% CI Obs Exp SIR 95% CI
All sites 364 210.8 1.7 1.6-1.9 188 97.0 1.9 1.7-2.2
Prostate 247 44.7 5.5 4.9-6.3 126 21.7 5.8 4.8-6.9
Other 117 166.1 0.7 0.6-0.8 60 75.3 0.8 0.6-1.0
Lip 3 2.8 1.1 0.2-3.2 3 1.2 2.6 0.5-7.6
Stomach 7 13.5 0.5 0.2-1.1 3 5.7 0.5 0.1-1.5
Small intestine 0 1.1 0.0 0.0-3.4 2 0.3 5.9 0.7-21.2
Colon 6 11.7 0.5 0.19-1.1 3 3.0 1.0 0.2-2.9
Rectum 2 8.3 0.2 0.03-0.9 5 3.8 1.3 0.4-3.1
Liver 2 2.9 0.7 0.08-2.5 1 1.4 0.7 0.02-4.1
Gallbladder 1 1.6 0.6 0.02-4.4 3 0.7 4.1 0.8-11.8
Pancreas 9 7.4 1.2 0.6-2.3 1 3.4 0.3 0.01-1.6
Larynx 2 2.9 0.7 0.08-2.5 2 1.3 1.6 0.2-5.6
Lung 16 42.6 0.4 0.2-0.6 10 18.5 0.5 0.3-1.0
Skin melanoma 9 5.5 1.6 0.7-3.1 2 2.7 0.7 0.09-2.7
Kidney 7 7.9 0.9 0.4-1.8 6 3.6 1.7 0.6-3.6
Bladder 15 11.1 1.4 0.8-2.2 5 5.1 1.0 0.3-2.3
Nervous system 5 6.4 0.8 0.3-1.8 2 3.0 0.7 0.08-2.4
Hodgkin lymphoma 4 1.7 2.4 0.6-6.0 0 0.8 0.0 0.0-4.7
Non–Hodgkin lymphoma 3 7.2 0.4 0.09-1.2 3 3.6 0.9 0.2-2.5
Leukemia 2 5.5 0.4 0.04-1.3 3 2.5 1.2 0.2-3.5
NOTE: Observed and expected numbers of cases and SIRs with 95% CIs. Only the first index PCa cases excluded from the observation period (method 1);
the other PCa cases counted as observed cases.
Abbreviations: Obs, observed; exp, expected.
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intervals (CI) were defined, assuming that the numbers
of the observed cases followed a Poisson distribution.
The SIRs were calculated separately for clinically aggres-
sive and clinically nonaggressive families using method 1
and 2, respectively, as described above.
Cancers belonging to hereditary cancer syndromes
tend to have an earlier age of onset compared with spo-
radic cancers cases in a population; for example, the mean
age of onset of breast cancer for BRCA1 carriers is 35 y
(40), so for breast cancer, we looked at the cancer risk
for women under the age of 40 y.
Results
Clinically Nonaggressive PCa Families. There were
497 malignancies among 3,902 members of the clinically
nonaggressive PCa families. Using analysis method 1,
364 malignancies were observed among males, 211 cases
were expected, yielding a SIR of 1.7 (95% CI, 1.6-1.9;
Tables 2 and 3). Using analysis method 2, the number
of observed malignancies was 151, whereas 180 cases
were expected, yielding a SIR of 0.8 (95% CI, 0.7-1.0).
The difference in values is mainly due to the different
numbers of PCa cases in analysis. Among females, there
were 133 observed malignancies compared with 140 ex-
pected cases (SIR, 1.0; 95% CI, 0.8-1.1; Table 4). Increased
risk for gastric cancer among women in clinically nonag-
gressive PCa families was statistically significantly (SIR,
1.9; 95% CI, 1.0-3.2; Table 4). Among men, there was less
lung cancer than expected (for method 1: SIR, 0.4; 95% CI,
0.2-0.6; and for method 2: SIR, 0.5; 95% CI, 0.4-1.1; Tables 2
and 3).
Table 3. Risk of cancer among men in PCa families separately with clinically nonaggressive and aggressive PCa
Cancer site CNA PCa families CA PCa families
Obs Exp SIR 95% CI Obs Exp SIR 95% CI
All sites 151 179.7 0.8 0.7-1.0 83 79.3 1.1 0.8-1.3
Prostate 45 40.0 1.1 0.8-1.5 27 18.9 1.4 1.0-2.1
Other 106 149.7 0.7 0.6-0.9 56 60.4 0.9 0.7-1.2
Lip 2 2.3 0.9 0.1-3.2 2 0.8 2.4 0.3-8.7
Esophagus 1 2.3 0.4 0.01-2.4 0 1.0 0.0 0.0-3.7
Stomach 5 11.1 0.5 0.1-1.1 2 4.4 0.5 0.06-1.6
Small intestine 0 0.6 0.0 0.0-5.9 2 0.3 6.9 0.8-24.9
Colon 6 8.7 0.7 0.3-1.5 3 3.9 0.8 0.2-2.2
Rectum 2 7.0 0.3 0.03-1.0 4 3.1 1.3 0.4-3.3
Liver 3 2.4 1.2 0.3-3.6 1 1.1 0.9 0.02-5.0
Gallbladder 1 1.4 0.7 0.02-4.0 3 0.6 5.1 1.0-14.9
Pancreas 9 6.3 1.4 0.7-2.7 1 2.7 0.4 0.01-2.0
Larynx 1 2.3 0.4 0.01-2.4 2 0.9 2.1 0.3-7.7
Lung 16 35.1 0.5 0.4-1.1 9 13.3 0.7 0.3-1.3
Skin melanoma 7 4.8 1.5 0.6-3.0 2 2.3 0.9 0.1-3.1
Kidney 7 6.6 1.1 0.4-2.2 6 2.9 2.1 0.6-4.5
Bladder 14 8.6 1.6 0.9-2.7 4 5.0 0.8 0.2-2.1
Nervous system 5 5.5 0.9 0.3-2.1 2 2.6 0.8 0.09-2.8
Hodgkin lymphoma 4 1.5 2.7 0.7-6.8 0 0.7 0.0 0.0-5.4
Non–Hodgkin lymphoma 2 6.2 0.3 0.04-1.2 3 3.0 1.0 0.2-2.9
Leukemia 2 4.7 0.4 0.1-1.5 2 2.0 1.0 0.1-3.5
NOTE: Observed and expected numbers of cases and SIRs with 95% CIs. All index PCa cases excluded from the observation period (method 2).
Table 4. Risk of cancer among women in PCa families separately with clinically nonaggressive and aggressive PCa
Cancer site CNA PCa families CA PCa families
Obs Exp SIR 95% CI Obs Exp SIR 95% CI
All sites 133 139.9 1.0 0.8-1.1 72 68.6 1.1 0.8-1.3
Esophagus 0 1.4 0.0 0.0-2.7 2 0.6 3.1 0.4-11.1
Stomach 13 6.9 1.9 1.0-3.2 6 3.2 1.9 0.7-4.0
Colon 8 8.1 1.0 0.4-2.0 2 3.9 0.5 0.06-1.9
Rectum 5 4.8 1.0 0.3-2.4 3 2.3 1.3 0.3-3.7
Liver 1 1.3 0.8 0.02-4.3 3 0.6 4.8 1.0-14.0
Gallbladder 2 2.4 0.9 0.1-3.0 3 1.1 2.7 0.6-7.9
Pancreas 6 4.8 1.2 0.5-2.7 2 2.3 0.9 0.1-3.1
Lung 6 5.5 1.1 0.4-2.4 1 2.8 0.4 0.01-2.0
Skin melanoma 3 3.9 0.8 0.2-2.2 4 2.0 2.0 0.6-5.2
Breast 42 40.8 1.0 0.7-1.4 22 21.0 1.1 0.7-1.6
Cervix uteri 3 3.4 0.9 0.2-2.6 1 1.5 0.7 0.02-3.6
Corpus uteri 7 8.4 0.8 0.3-1.7 2 4.1 0.5 0.06-1.7
Ovary 5 6.6 0.8 0.2-1.8 4 3.1 1.3 0.3-3.3
Kidney 3 3.8 0.8 0.2-2.3 3 1.8 1.6 0.3-4.8
Bladder 3 2.2 1.4 0.3-4.0 1 1.0 1.0 0.02-5.4
Nervous system 4 6.0 0.7 0.2-1.7 5 2.9 1.7 0.6-4.0
Thyroid gland 3 3.8 0.8 0.2-2.3 2 1.8 1.1 0.1-4.0
Non–Hodgkin lymphoma 6 4.6 1.3 0.5-2.9 0 2.3 0.0 0.0-1.6
Multiple myeloma 1 1.8 0.6 0.01-3.1 3 0.9 3.5 0.7-10.1
Leukemia 3 3.2 0.9 0.2-2.7 0 1.5 0.0 0.0-2.5
NOTE: Observed and expected numbers of cases and SIRs with 95% CIs.
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Clinically Aggressive PCa Families. We analyzed
1,621 members of 59 clinically aggressive PCa families
using analysis method 1. We observed 188 malignancies
(52,849 person-years) among males, 97 malignancies
were expected, yielding a SIR of 1.9 (95% CI, 1.7-2.2).
Using analysis method 2 to analyze 1,619 members with
50,143 person-years, we observed 83 malignancies, 79
malignancies were expected, yielding a SIR of 1.1 (95%
CI, 0.8-1.3). Among females, there were 72 observed can-
cer cases compared with 68.6 expected cases (SIR, 1.1;
95% CI, 0.8-1.3; Tables 1-4). Analyzing males and fe-
males separately, males had more small intestine (ob-
served, 2; SIR, 5.9; 95% CI, 0.7-21.2; method 1:
observed, 2: SIR, 6.9; 95% CI, 0.8-24.9) and gallbladder
cancer (observed, 3; SIR, 4.1; 95% CI, 0.8-11.8; method 1:
observed, 3; SIR, 5.1; 95%, CI 1.0-14.9), whereas females
had more liver cancer (observed, 3; SIR, 4.8; 95% CI, 1.0-
14.0) and multiple myeloma (observed, 3; SIR, 3.5; 95%
CI, 0.7-10.1; Table 4). Women under 40 years had slightly
increased risk of breast cancer (observed, 4; SIR, 3.1; 95%
CI, 0.8-7.9) and ovarian cancer (observed, 3; SIR, 3.9;
95% CI, 0.8-11.4).
The 479 cancer cases observed during the follow-up
were in 425 individuals. Sixty individuals had two ma-
lignancies, and six individuals had three. Forty-one had
PCa as one of the cancers. Other common cancers found
included urinary bladder (9), kidney (4), pancreas (4),
gastric (3), and rectal (3). In Fig. 1, we present an exam-
ple of a family (257) with individuals having multiple
malignancies, including two men with three malignan-
cies and a woman with two malignancies. Table 5 lists
families with individuals having both PCa and gastric
cancer, and Fig. 1 shows a selected sample of a family
with gastric cancer (143). Family 62 is an example of a
clinically aggressive family showing both gallbladder
and small intestine cancers.
Figure 1. A pedigree of a PCa family with three individuals with multiple malignancies (family 257), with an aggregation of gastric
cancer (family 143), and of a clinically aggressive PCa family with gallbladder and small intestine cancer (family 62). The age in
years at the time of diagnosis is shown under the symbol for each relative.▪, PCa (male); , other cancer (male); , cancer (female).
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Discussion
The incidence of non-PCa cancers other than women's
gastric cancer was not higher than in the reference popu-
lation. Out of the numerous associations tested in our
study, only the risks of liver cancer in women and gall-
bladder cancer in men were increased in clinically aggres-
sive PCa families. There was no statistically significant
difference in risk of any cancer type studied between clin-
ically aggressive and clinically nonaggressive families.
Unlike this study, to date, there are only a few studies
on the overall cancer risk in PCa families where: (a)
all cancers of the relatives have been identified, (b) family
pedigrees have been genealogically confirmed, and
(c) family material is population based and data are
registry-based. In a study by Isaacs et al. (15), PCa was
suggested to be relatively site specific and only central
nervous system tumors were statistically increased. In
2000, Grönberg et al. (17) published a study on 62 hered-
itary PCa families, which found a significant aggregation
of PCa together with breast and/or gastric cancer, sug-
gesting a common germ line mutation in a cancer suscep-
tibility gene. Valeri et al. (41) reported a significant
increase in breast cancer risk. Conflicting results were
published in 2005, in an American study on 1,238 Utah
hereditary prostate cancer cases, supporting the existence
of heritable PCa syndromes that included other malignan-
cies. The Utah hereditary prostate cancer families had in-
creased risk for colon, breast, rectum, gallbladder, and
kidney cancers and also had increased risk to multiple
myeloma, non–Hodgkin lymphoma, and melanoma
(16). Of above-mentioned studies, only the study by Alb-
right et al. (16) was done in a population-based manner.
However, only 55% to 60% of the Utah Cancer Registry
records can be linked to an individual in the Utah Popu-
lation Data Base genealogy (16).
The different results in the studies done here can be
explained in part by the difficulty in identifying heredi-
tary prostate cancer pedigree populations and all malig-
nancies among relatives. In addition, differences in
cancer aggregation and clinical phenotype among the
studied populations could reflect different genetic back-
grounds and heterogeneity of germ line mutations among
the different analyzed populations.
In accordance with findings of others, we observed an
increase in gastric cancers among female members of the
PCa families (42, 43). In a previous population-based
Finnish study (18), an increased risk for gastric cancer
was only seen among male relatives of early onset PCa
patients, whereas in the present analysis, the risk for gas-
tric cancer was increased among female family members.
In the study by Grönberg et al. (17), a gender difference
was seen in the SIR for gastric cancer; male gastric
cancer SIR was 3.7 (1.9-6.2) and female was 1.4 (0.3-4.0).
E-cadherin (CDH1) had been suggested as a potential
gene explaining prostate and gastric cancer association
(32), but subsequent studies did not confirm the hypoth-
esis (43). Our findings on the association of familial PCa
and gastric cancer support the need for further studies to
find a candidate gene.
Our results are to certain extent congruent with the
study by Albright et al. (16) showing an increased risk
of gallbladder cancer, breast cancers, and multiple myelo-
ma with familial PCa. We also found weak suggestions of
increased incidence for liver and small intestine cancers
that have not been published previously in any family
data. The risk for liver cancer has been found to be elevated
among the relatives of PCa patients in population-based
settings but not in PCa families (16, 23).
Malignancies in many hereditary cancer syndromes
often have an early age of onset and/or a clinically ag-
gressive form of the disease compared with sporadic
malignancies of the same cancer type. Due to the hetero-
geneity of PCa, subgrouping patients based on clinical
characteristics will enhance detection of clinically rele-
vant genes and mutations. In comparing clinicopatholog-
ic features and progression-free survival among sporadic
and familial PCa cases, Roehl et al. (44) observed no clear
Table 5. Individual family data of detected cancers in the PCa families selected on the basis of PCa and stomach
cancer aggregation
Family size* No. of
PCa cases
Mean age at
PCa diagnosis
Sites of other cancers in the family (ages at diagnosis)
49 3 64.8 Stomach (61, 65, 72), salivary gland (67), pancreas (80), lung (58), breast (61)
31 2 71.7 Stomach (58), vulva (59), skin melanoma (53), leukemia (67),
24 3 74.3 Stomach (75), ovary (58), breast (70), leukemia (81)
22 2 69.7 Stomach (59), breast (56), lung (43), ovary (82), connective tissue (56)
18 2 76.4 Stomach (61), breast (55), multiple myeloma (40)
28 3 67.3 Stomach (44, 79), duodenum (53), colon (86), rectum (69), extra
hepatica bile ducts (81)
51 4 67.5 Stomach (69, 76), lip (70), colon (61), lung (66), breast (54),
corpus uteri (69), non–Hodgkin lymphoma (72)
17 3 72.9 Stomach (34), breast (53), thyroid gland (55)
19 2 73.1 Stomach (42), rectum (66), breast (53), corpus uteri (71),
urinary bladder (52, 65), leukemia (84),
12 2 73.8 Stomach (81), colon (82), lung (69), breast (73), non–Hodgkin lymphoma (58)
20 4 76.5 Stomach (85), kidney (69)
23 3 73.2 Stomach (81), breast (60, 63), ovary (48), urinary bladder (75),
22 3 59.8 Stomach (72), lip (46), corpus uteri (30, 50), urinary bladder (71)
35 2 65.5 Stomach (46), skin melanoma (52)
21 4 73.8 Stomach (83)
52 2 68.7 Stomach (64), pancreas (69), lung (63), breast (51), corpus uteri (36),
non–Hodgkin lymphoma (33), leukemia (12)
41 2 73.2 Stomach (66), skin melanoma (63)
15 2 74.0 Stomach (73), breast (53)
25 3 55.0 Stomach (61)
*Number of family members who produced person-years at follow-up.
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differences, but sibling pairs had a trend toward less fa-
vorable tumor features and progression-free survival.
In our analysis of clinically aggressive PCa families,
females under the age of 40 years had (nonsignificantly)
increased risk for breast cancer and ovarian cancer, sup-
porting the epidemiologic findings of coaggregation of
prostate and breast cancers (45, 46). Reported associations
of PCa and breast cancer may be partially explained by the
presence of recognized cancer predisposition genes;
BRCA2 has been implicated in PCa cancer predisposition
in some populations (47-49). Significant elevations in PCa
risk were found for BRCA2mutation carriers (24, 50) in the
relatively homogenous Icelandic population. Likewise, in a
report from the Breast Cancer Consortium, the risk for PCa
in BRCA2mutation carriers was RR = 4.65 (51). Although it
seems that known Finnish BRCA1/2 founder mutations do
not associate with PCa predisposition among Finnish PCa
patients (33), an increased risk for PCa in Finnish breast
cancer families carrying BRCA2 mutations has been ob-
served (52). Other negative findings for an association be-
tween BRCA2 mutations and susceptibility to hereditary
PCa in high-risk families have been reported (53). Most
likely, mutations in BRCA1/2 pathway genes can causema-
lignancies at multiple cancer sites (51). Likewise, several
studies of cancer clusters within families have reported
cooccurrence of PCa with breast, ovarian and endometrial
cancers suggesting a single gene or a limited number of
genes could be responsible for association with cancers in
hormonal tissue (44, 54, 55).
From our data, male members of PCa families have sig-
nificantly less lung cancer than men in the general popu-
lation. One possible explanation is that to get PCa, you
have to live to a relatively healthy life-style and old age
(the average age of onset is 71 years in Finland). A study
by Pukkala et al. (56) revealed that PCa is most common
among the males in the highest social class. It is therefore
possible that families with PCa are a selected group of
people from higher social class with healthier life-style
such as lower prevalence of smoking.
The strengths of this study are that it is based on a large
family-based data registry (202 families) with total of
5,523 family members with confirmed genealogy within
the homogenous Finnish population with a follow-up
time of almost 40 years. All malignancies in all family
members are verified from the Finnish Cancer Registry
with unique linked personal identity codes. Cancer diag-
noses were also confirmed from medical records. When
calculating SIRs, we compared the observed cases of
malignancies to the expected cases in the whole Finnish
population and standardized these values with gender,
10-year calendar periods, and age. To our knowledge, this
is the first study where clinical data of all PCa cases within
families has been collected, enabling separation of families
into two groups based on the clinical aggressiveness of the
cancers.
In summary, members of the studied 202 Finnish PCa
families had no general elevation in non-PCa malignan-
cies. However, females in both clinically nonaggressive
and clinically aggressive families had elevated incidence
of stomach cancer, indicating that the risk of developing
other cancers seems not to be related to the clinical
characteristics of familial-PCa cases. The profile of related
cancers and risk genes for hereditary PCa families may
differ between populations; therefore, further studies of
PCa in other populations are warranted.
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Abstract
Background: PALB2 1592delT mutation is associated with increased breast cancer and suggestive
prostate cancer (PRCA) risk in Finland. In this study we wanted to assess if any other PALB2 variants
associate to increased PRCA risk and clinically describe patients with formerly found PALB2
1592delT mutation.
Methods: Finnish families with two or more PRCA cases (n = 178) and unselected cases (n = 285)
with complete clinical data were initially screened for variants in the coding region and splice sites
of PALB2. Potentially interesting variants were verified in additional set of unselected cases (n =
463).
Results: From our clinically defined sample set we identified total of six variants in PALB2. No novel
variants among Finnish PRCA cases were found. Clinical characteristics of the variant carriers,
including the previously described family carrying PALB2 1592delT, revealed a trend towards
aggressive disease, which also applied to a few non-familial cases. Hypersensitivity to mitomycin C
(MMC) of lymphoblasts from individuals from the family with 1592delT revealed haploinsufficiency
among carriers with altered genotype.
Conclusions: Though any of the detected PALB2 variants do not associate to PRCA in population
level in Finland it cannot be ruled out that some of these variants contribute to cancer susceptibility
at individual level.
Introduction
Prostate cancer (PRCA) is the most frequently diagnosed
cancer among men in the Western world [1]. The inci-
dence of PRCA has been increasing throughout the last
decade, partly due to the earlier diagnosis provided by the
prostate specific antigen (PSA) test, introduced in the
1990s. In Finland, the highest incidence of 115/100 000
was observed in 2005. In 2007 there were 4188 newly-
diagnosed PRCA cases with the age-adjusted incidence
rate of 85.9/100,000 [2]. Similar high increase and now
decline have been observed in most Western industrial-
ized countries [3].
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behind PRCA susceptibility [4]. Early linkage studies and
more recent genome-wide association analyses have
revealed multiple susceptibility loci for PRCA [5-7]. How-
ever, both causal variants and genes of the associated loci
in are still not known and the identified PRCA risk vari-
ants only account for a fraction of the overall genetic var-
iance for PRCA risk [8-10].
DNA repair pathway genes have an undisputed role in
cancer progression and inherited mutations in them have
been strongly associated with different cancers. BRCA1
and BRCA2 are both tumor suppressor genes involved in
DNA repair and mutations in these genes predominantly
predispose carriers to breast and ovarian cancers [11].
Potential links to PRCA have been studied for both of
these genes and mutations in BRCA2 lead to an increased
risk for the disease in multiple studies [12,13]. In an Ice-
landic study, mutations in BRCA2 (999del5, Icelandic
founder mutation) are associated with a poorly differenti-
ated, advanced type of PRCA [14]. These results are also
consistent with results from a recent study in the UK,
where a significantly higher Gleason score was observed
among BRCA2 mutation carriers than with non-carriers.
These findings suggest that BRCA2 is a high-risk PRCA sus-
ceptibility gene and mutational analysis could be used as
a prognostic marker for aggressive PRCA [15]. However,
Finnish BRCA1/2 founder mutations do not associate
with PRCA predisposition among Finnish PRCA patients
[16]. This does not exclude the possibility of these genes
to be involved in PRCA susceptibility but no studies have
been published where the whole genes would have been
sequenced in large data sets. Nevertheless an increased
risk for PRCA in Finnish breast cancer families carrying
BRCA2 mutations has been observed [17]. Moreover,
mutations of CHEK2, a gene acting in the same DNA
repair route as BRCA1/2, have been shown to have a sig-
nificant role in PRCA susceptibility in Finland [18].
PALB2 is a BRCA2 binding protein and the BRCA2-PALB2
interaction is essential for BRCA2-mediated DNA repair
[19]. Recently it was shown that proper PALB2 function is
necessary for the homologous recombination repair via
interaction with BRCA1, revealing that PALB2 is actually a
linker between BRCA1 and BRCA2 [20]. In the Finnish
study by Erkko and colleagues a novel PALB2 founder
mutation (c.1592delT) was identified among Finnish
breast cancer families (OR 11.3, CI 1.8-57.8) increasing
the risk to breast cancer 4-fold [21]. In the same study the
c.1592delT mutation was observed also from a patient
with familial PRCA (1/164) but none of 475 unselected
cases were carriers of the mutation. No statistically signif-
icant association with PRCA and c.1592delT was detected
and no other variants were screened for in PRCA patients.
Here, to investigate the role of possible other PALB2 vari-
ants, we screened all PALB2 exons(exons 1-13) in a cohort
of 938 Finnish PRCA patients including both familial and
unselected cases.
Material and methods
Patients and controls
A population-based cohort was collected from 1999 to
2005 from patients diagnosed with PRCA in the Pirkan-
maa Hospital District that serves a population of a half a
million inhabitants. The mean age at diagnosis for the
760 unselected patients was 62 (range 43-77), The
median primary PSA and Gleason score were 8.9 and 6.4,
respectively. The controls (n = 760) consisted of DNA
samples from anonymous male blood donors obtained
from the Finnish Red Cross.
A detailed description of the collection of the PRCA fami-
lies has been previously described elsewhere [22]. In this
study, we analysed 178 families (youngest affected male
from each family) with two or more affected first-degree
relatives. The average number of affected family members
was three. Familial cancer data was attained from the
Finnish Cancer Registry and detailed clinical information,
including Gleason score, WHO grade, PSA at the time of
diagnosis, TNM stage and primary treatment from hospi-
tal records.
To examine the association between the variants and the
disease aggressiveness a subgroup of 380 with clinically
aggressive disease was analyzed. Consequently clinically
aggressive disease patients were selected according to
Gleason score over seven and an age at diagnosis less than
61 years.
Mutation analysis of PALB2
All familial samples had been previously screened for the
11 Finnish BRCA1 and seven BRCA2 founder mutations
[16]. DNA samples from each family (n = 178), 285 unse-
lected cases and 470 control samples were initially used
for direct sequencing of the entire coding region and
splice sites of PALB2. Unselected cases for screening the
whole gene were early onset cases with Gleason score over
seven. Additional analyses were carried out on four vari-
ants that showed a trend for association (PALB2
c.1592delT, 1674A>G, 2993G>A and 3300T>G). Unse-
lected cases for additional analysis included 95 early
onsets, aggressive cases and 368 non-aggressive cases with
average age at diagnosis 67 years (range 63-77). Control
samples in both primary and additional analysis were
anonymous male blood donors from the Finnish Red
Cross.
Mutation detection was performed through resequencing
using the ABI PRISM BigDye Terminator Cycle Sequenc-
ing Ready Reaction kit with the ABI 3130xl sequencerPage 2 of 6
(page number not for citation purposes)
Journal of Negative Results in BioMedicine 2009, 8:12 http://www.jnrbm.com/content/8/1/12(Applied Biosystems). Primers and the naming of
sequence variants were produced to correspond to the
GenBank reference sequences for PALB2 (NM_024675.3).
Primer sequences are available on request. Variants were
identified using Sequencher software 4.7 (Gene Codes
Corporation, Ann Arbor, Mi). Loss of heterozygosity
(LOH) analysis was carried out on two available tumor
samples from the family with the segregating PALB2
1592delT. Selected sections of formalin fixed paraffin
embedded tumors were obtained according to pathologist
declaration. After tumor deparaffinization, DNA was
extracted using a standard proteinase K protocol.
Sequence from the tumor samples was compared to the
patients' DNA sample from their peripheral blood.
DNA damage response in PALB2 deficient cell line
Peripheral blood leucocytes from two cancerous individu-
als carrying PALB2 1592delT mutation were immortalized
with Epstein-Barr virus (EBV) and sensitized to DNA
crosslinking agent mitomycin C (MMC). Cells were
treated with 0 nM, 1 nM, 5 nM, 10 nM and 50 nM MMC
for 96 h and their viability was assayed by CellTiter-Blue®
Cell Viability Assay (Promega Corporation, Madison, WI,
USA).
Statistical analyses
To validate significance of variants, the odds ratios and
95% confidence intervals were calculated and association
analyses were made using the Fisher's exact test. Analyses
were done using SPSS 12.0 statistical software. Pairwise
linkage disequilibrium between three most frequently
detected variants (1674A>G, 2993G>A and 3300T>G) in
PALB2 were analysed with Haploview 4.1. To define the
haplotypes of cases familial and unselected cases were
combined.
Results and Discussion
Mutation analysis
Prompted by the previous observation that the Finnish
truncating founder mutation, PALB2 c.1592delT, was
identified segregating in one family with four PRCA cases
[21], we wanted to study the contribution of other possi-
ble PALB2 mutations. Probands from 178 Finnish HPC
(hereditary prostate cancer) families and 285 unselected
cases were screened for the entire coding region of PALB2.
Total of six variants were detected in the coding regions
and the exon-intron boundaries of PALB2 (Table 1). All
the variants have been previously described and only the
truncating mutation (c.1592delT) has been shown to
have functional consequences on DNA damage response.
Association of four detected variants (c.1592delT,
1674A>G, 2993G>A and 3300T>G) were assessed in
more detail in a larger set of unselected cases and controls.
The truncating c.1592delT mutation was detected in two
sporadic cases in addition to the previously described
family 310 and in one control sample [21]. Interestingly,
family 310 has now been found to have also stomach and
skin cancer, in addition to earlier described breast cancer,
as indicated in Figure 1 and Table 2. Three of the detected
variants, 1674A>G in exon 4, 2993G>A in exon 9 and
3300T>G in exon 12, co-existed in six patients out of 178
familial samples (OR 1.52 CI 95% 0.6-3.9), 20/748 unse-
lected cases (OR 1.20 CI 95% 0.6-2.3) and in 17/760 of
the controls. To assess question whether these three vari-
ants have a stronger joint effect that would strengthen the
trend seen with singletons a haplotype analysis was per-
formed. The strongest linkage was between 1674A>G and
2993G>A (D'= 0.975; r2 = 0.14, LOD 34.7) when 1886
case chromosomes and 1714 control chromosomes were
analysed. Although these two variants appeared to have a
frequency in PRCA cases that is higher than the Finnish
population control frequency, their combined haplotype
gave no improved results, i.e. none of the haplotype com-
binations showed significant association with the disease.
Variant 2993G>A is now reported for the first time in the
Finnish population since it did not come up in the study
of Finnish breast cancer patients [21]. As reported by Rah-
man and colleagues [23] the 2993G>A variant is possibly
Family 310 segregating the PALB mutationigure 
Family 310 segregating the PALB mutation. Minus-
symbol signifies a person that has been screened for the 
PALB2 1592delT mutation, but found negative. Clinical infor-
mation on this family is found in Table 2. Index person is 
marked with a black triangle, black square denotes persons 
with prostate cancer, grey circle indicates breast cancer 
cases and black square with white and grey corners signifies 
patient with prostate, stomach and skin cancers.Page 3 of 6
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intolerant from tolerant) analysis.
We found that the 2993G>A variant exhibits a borderline
significant odds ratios in a subgroup of 380 unselected
cases with a Gleason score over seven and an age at diag-
nosis less than 61 years (20/380; OR 1.9; 95% CI 1.0-3.5).
Edwards and colleagues [24] have presented similar age
related observation with BRCA2 mutations in prostate
cancer. They reported protein truncating mutations in
BRCA2 to associate with PRCA diagnosed at or before age
of 55. Our subgroup analysis also revealed that the variant
1674A>G has an OR of 1.4 (86/380; 95% CI 1.0-1.9) in a
group of 368 patients with an average age at diagnosis of
67 years. However, the 1674A>G variant is commonly
found in the Finnish population and well tolerated
according to SIFT analysis, indicating no clear contribu-
tion to cancer formation. Similarly, the Val932 Met
(2794G>A) change in exon 8 is well tolerated and has no
effect on protein function [23].
In order to obtain information about loss of heterozygos-
ity in the tumors from c.1592delT mutation positive
patients, two available paraffin-embedded tumors were
analysed. Repeated PCR-analysis did not reveal existence
of LOH, which argues against the role as tumor suppressor
gene. However the sample size is very small and therefore
more tumor samples from PALB2-associated tumors
needs to be characterized to be able to reliable assess
PALB2 function in tumor formation. To date there is only
one report indicating LOH in PALB2 related tumors.
Unfortunately also this study lacks a statistical power to
make an appropriate conclusion about the role of PALB2
in tumorigenesis [25].
DNA damage response in PALB2 deficient cell line
Previously, MMC sensitivity test to c.1592delT mutation
has been done in a reporter cell line [21]. To test whether
the previously described PALB2 c.1592delT mutation has
functional consequences also in a heterozygous form, as
present in all our patients, we predisposed two lymphob-
last cell lines with c.1592delT and a wild type carrying
control cell line to DNA cross linking agent MMC (Figure
2). c.1592delT mutation carriers were patients (15 and
24) from family 310 earlier described by Erkko et al. [21].
In both cell lines MMC-induced growth inhibition was
observed suggesting PALB2 haploinsufficiency. It is also
possible that dominant-negative effect is affecting in
tumor formation in these patients.
Geographical and ethnical differences in the PRCA sus-
ceptibility alleles have been previously reported in the
Table 1: Observed PALB2 variants among the Finnish familial and unselected prostate cancer cases.
Exon/Intron Nt change Amino acid Change Carrier Frequency (OR; 95% CI)
Familial Unselected Controls
PALB2
Ex 4 1592delT Leu531>Fs>Stop 1/178 (0.6%) (4.3; 0.3-68.8) 2/748 (0.3%) (2.0; 0.2-22.2) 1/760 (0.2%)
Ex 4 1674A>G Gln559Agr 36/178 (20.2%) (1.2; 0.8-1.8) 153/748(20.5%) (1.2; 0.9-1.5) 134/760(18.0%)
Ex 8 2794G>A Val932 Met 4/178 (2.2%) (1.0; 0.3-3.4) 7/285(2.5%) (1.2; 0.4-3.1) 10/470 (2.1%)
Ex 9 2993G>A Gly998Glu 8/178 (4.5%) (1.6; 0.7-3.5) 35/748 (4.9%) (1.6; 0.9-2.8) 22/760 (2.9%)
Ex 12 3300T>G Thr1100Thr 6/178 (3.4%) (0.8; 0.3-2.0) 30/748 (3.9%) (1.0: 0.6-1.7) 30/760 (3.9%)
5'UTR G>A - 8/178 (4.5%) (1.8; 0.7-4.4) 14/285 (4.9%) (2.0; 0.9-4.3) 12/470 (2.6%)
Table 2: Clinical characteristics of family 310. The patient number refers to the number in the pedigree in Figure 1.
Patient Cancer Histology Age at 
diagnosis
Reason for 
diagnosis
First 
treatment
Primary 
PSA value
WHO 
grading
Gleason 
grading
TNM 
grading
IHC
6 Prostate Adenocarcinoma 83 NA NA NA NA NA NA
11 Prostate Adenocarcinoma 68 Symptoms Orchiectomy NA III Na T3NXMX
13 Stomach Adenocarcinoma 70 Symptoms Gastrectomy NA NA Na T4N0 M0
13 Skin Carcinoma 
epidermoides
75 NA Resection NA NA Na NA
13 Prostate Adenocarcinoma 76 Elevated PSA Orchiectomy 47 III 2+3 = 5 T2NXMX
15 Prostate Adenocarcinoma 69 Elevated PSA Brakytherapy 7.7 I 2+3 = 5 T1cNXMX
17 Breast Ductal carcinoma 52 Screening 
mammography
Mammary 
resection
NA I Na T1N0 M0 ER+, PR+
24 Breast Ductal carcinoma 49 Mammography Mammary 
resection
NA I Na T1N0 M0 NA
IHC = immunohistochemistry, NA = not availablePage 4 of 6
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therefore, variation in the PALB2 mutation spectrum in
different populations would not be surprising. In the
present study and in the study by Erkko et al. [21], the
number of mutations found in PALB2 is relatively small
among both Finnish breast and PRCA patients, with nine
and six variants detected, respectively, compared to the
British breast cancer family study by Rahman and col-
leagues [23] where a total of 50 variants and five
frameshift mutations were reported. Recently, Tischkow-
itz and colleagues [26] reported a study of 95 US PRCA
patients from Michigan, all diagnosed at < 55 years of age.
Eleven variants in PALB2 were found, but none of them
were truncating and no association with the disease was
observed. When comparing our patients to those very
early-onset patients studied by Tischkowitz and col-
leagues [26] there is a clear difference in the mean age of
onset between the two datasets. On the other hand, no
variants were found in the 14 Ashkenazi-Jewish and 21
French-Canadian PRCA cases with family history of can-
cer [27]. In Finland, the smaller number of variation
found likely reflects the known genetic homogeneity and
founder effect of the population [28].
Our findings indicate that no other deleterious PALB2 var-
iants, except 1592delT mutation, contribute even margin-
ally to PRCA risk in Finland. However, it remains possible
that other genes from the BRCA1-PALB2-BRCA2 pathway
have PRCA-predisposing alleles
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